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In 1872 the first official publication on Huntington‘s disease (HD) appeared in
The Medical and Surgical Reporter1. In his essay ‘On chorea’, George Huntington
described a hereditary form of chorea which he noted while at work as a general
practitioner in Long Island, USA. This disease became known as Huntington‘s
Chorea, and was renamed into Huntington‘s disease in the eighties of the last cen-
tury.
Manifest versus premanifest
Huntington‘s disease is a progressive neurodegenerative disease with an autoso-
mal dominant mode of inheritance. The pathology leads to a triad of progressive
clinical symptoms: motor, cognitive and psychiatric. In 1983 the genetic defect
was mapped to chromosome 4, and one decade later the Huntington‘s Disease Re-
search Group succeeded in generating an exact location for the HD gene2. With
the availability of genetic testing it became possible to identify gene carriers who
are still without clinical symptoms and signs, but who will inevitably progress into
manifest disease. These so-called premanifest gene carriers play an important role
in the understanding of the earliest damage caused by HD. Studying and mapping
these early changes has become an important goal in the search for a cure for the
disease.
Knowledge of the earliest conversion from healthy to disease may help to identify
the fields that degenerate first, even before the appearance of overt clinical symp-
toms. This knowledge about the earliest pathophysiological, metabolic or func-
tional changes could lead to the development of pharmacological agents targeting
these specific fields. Currently, pharmacological research is focused on discovering
disease modifying and/or disease slowing compounds, to prolong and improve the
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quality of life for patients suffering from HD3. Identifying markers for the transition
from premanifest to manifest is important for the timing of the start of therapeutic
agents in individual patients. In the view of drug side-effects and health care costs
it is of importance to start drug treatment at the right moment.
A key challenge in HD research is its heterogenic presentation among patients.
Even when belonging to the same family, no prediction can be made about an in-
dividuals initial symptoms, age at onset, clinical presentation or disease duration.
To date, no single symptom or sign has been identified as generalised marker of
definite onset of disease. Most likely early changes on pathophysiological measures
of the brain in combination with changes on several clinical functional measures
will help to more precisely pinpoint the onset in the individual person3.
Clinical features
HD symptoms can be separated in three domains: motor, behavioural and cogni-
tive. The most characteristic and debilitating motor symptoms are the choreatic,
or dance-like, movements. Starting as subtle twitches in arms, legs, face or trunk,
and often (consciously or unconsciously) masked by other normal movements, they
progress in severity throughout the whole body over several years, severely debilitat-
ing patients in their daily activities4 5. Other motor impairments include, amongst
others, bradykinesia and dystonia5 6. Although the clinical diagnosis is often based
on the appearance of the first overt motor abnormalities (together with a positive
family history and genetic test) subtle motor abnormalities have been detected in
premanifest subjects also. Here, chorea, defective oculomotor functioning, bradyki-
nesia and dystonia have been shown to differentiate premanifest gene carriers from
healthy control subjects7 8 9.
Behavioural changes are also well recognized in HD gene carriers, sometimes more
so by partners and family members than by the patients themselves. Among the
most common psychiatric symptoms associated with HD are depression, apathy
and aggression or irritability, resulting in progressive personality changes10 11. Par-
ticularly, symptoms such as depression, anxiety and obsessive-compulsive behaviour
can already be seen in premanifest subjects12.
he third main area of decline in HD is cognition. HD patients become progres-
sively more disabled on several areas of cognitive functioning, eventually leading
up to full blown dementia. HD belongs to the group of subcortical dementias, and
patients often exhibit a frontal syndrome and the associated disabilities reflect the
neuropathological damage to fronto-subcortical connections13. Typically, execu-
tive dysfunctioning (i.e. difficulties with planned behaviour, attentional impairment
and disinhibition) is one of the first cognitive symptoms to appear, together with
marked reductions in psychomotor and mental processing speed14 15 16. This is
opposed to the picture of cognitive decline that we see in dementias of the cortical
type, such as Alzheimers disease (AD), where severe memory loss, aphasia and
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agnosia are most pronounced early on in the disease process13. In HD, memory
deficits are also common, but less prominent than in AD15. Language is relatively
spared until the latest stages of the disease, but will eventually also deteriorate,
alongside other cognitive functions. A robust finding, which has even been found
in individuals in the premanifest phase, is defective recognition of negative emo-
tions17. But subtle changes in psychomotor speed, executive functioning and
memory have also been detected before clinical disease onset18 19 20. However,
variability in observed premanifest cognitive changes is large and no agreement is
reached yet from the studies performed.
Nowadays, consensus is starting to form among scientists and clinicians that
changes in any of the three main HD domains can already be detected in the
premanifest phase, before the motor symptoms are severe enough to warrant a
clinical diagnosis. The area of cognition is one of the largest research fields in
HD literature, evident by the large body of articles on cognition in both manifest
and premanifest HD21. Next to psychiatric disturbances, cognition is also one of
the symptoms most debilitating for patients in daily life, even more so than the
unwanted movements6 14.
Genetics
HD is caused by an expanded and unstable trinucleotide (CAG) repeat in the
huntingtin gene, leading to an expanded polyglutamine stretch in the huntingtin
protein22. CAG repeats from 36 repeats on are associated with HD, but only
repeats from 39 on are considered fully penetrant, where individuals will develop
symptoms and signs of the disease within their lifetime. Repeats from 36 to 39 are
regarded as a grey area, where the disease may or may not manifest23 24. Abnormal
CAG repeat lengths have been found to be inversely related to age at onset, and
they can account for up to 70% of the variability in age at onset. The remaining
variability is likely influenced by both other genetic influences and environmental
factors6.
In most cases, clinical manifestation of the disease occurs in mid-life (between 30
and 50 years of age) and inevitably leads to death in approximately 15 to 30 years.
To date, no cure is available for HD, and patients receive symptomatic treatment
only3 25.
Neuropathology
ven though the exact neuropathology of HD is not yet completely known, the earli-
est and most pronounced neuropathology is found in the striatal parts of the basal
ganglia (e.g. caudate nucleus and putamen) and progresses throughout the course
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of the disease23 26. Subsequently, neuronal loss and atrophy spread throughout the
cerebral cortex, affecting both grey and white matter27 28. In the later stages of
the disease the entire brain is affected to a greater or lesser extent, resulting in up
to 25% brain weight loss in the most advanced stages23.
Magnetic Resonance Imaging (MRI) studies have indicated that brain abnormal-
ities in HD develop long before overt clinical symptoms and signs appear. Both
structural29 30 and functional31 32 brain changes have been found in premanifest
gene carriers up to 20 years from their estimated disease onset33.
Motoric influence on cognitive tests
That cognitive test performance is influenced by affective disorders, such as de-
pression, is well recognized in the literature34, for example in Parkinsons disease
(PD)35. Therefore, depression score is often taken into account when differences
in cognitive functioning between groups are studied. However, the influence of
motor disturbances on cognition has not received much attention, even though it
probably has a negative impact on cognitive outcome, because almost all cognitive
test require some form of motoric response (e.g. speaking, drawing, writing).
With HD primarily being a movement disorder, and together with the subtle motor
changes already recognized in premanifest HD gene carriers7, the influence of mo-
tor impairments on cognitive functioning in HD must not be neglected when doing
cognitive research. However, in very few studies on cognition in HD the influence
of motor impairment is accounted for.
Aims of this thesis
The main aim of this thesis was to gain more insight into the course of cognitive
functioning in HD, especially in the premanifest phase. Furthermore, we aimed
to minimize the influence of HD specific motor disturbances on cognitive scores,
by taking the motoric influence into account making use of several different ap-
proaches.
We studied the cognitive construct of attentional control in both premanifest
and manifest HD gene carriers using the Sustained Attention to Response Task
(SART), a cognitive test of attention and inhibition with minimal motor demands.
Moreover, the P300, an event related potential independent from motor influence,
was recorded simultaneously with the SART, to more accurately measure cogni-
tive processes free from motor influences. We investigated possible differences in
attentional control and P300 characteristics between premanifest, manifest and
control subjects cross-sectionally (chapter 2). Furthermore, we studied potential
change in attentional control and P300 in our groups over a three-year follow-up
Introduction and aims | 5
period (chapter 3). In chapter 4 we studied longitudinal change in premanifest
gene carriers on several cognitive tests over a seven-year follow-up period. We
further investigated the natural progression of cognition by studying both manifest
and premanifest subjects over a ten-year period, and compared their longitudinal
change on three cognitive and one motor domain to control subjects in chapter
5. In chapter 6 we explored whether differences exist in the cognitive and global
profiles of two different HD motor phenotypes; predominant hypokinetic-rigid HD
and choreatic HD. In chapter 7 we present the results of a longitudinal study
where we investigated the possible negative influence of motor functioning on cog-
nition by creating an extra ‘high motor low cognition’ conditions for existing tests
of executive functioning. We subtracted these motor conditions from the original
test scores to be able to isolate more ‘pure’ cognitive functioning. To conclude, a
general discussion and future perspectives are presented in chapter 8.
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Abstract
Objective Evidence for the extent and nature of attentional impairment in pre-
manifest and manifest Huntington‘s disease (HD) is inconsistent. Understanding
such impairments may help to better understand early functional changes in HD
and could have consequences concerning care for HD patients. We investigated
attentional control in both early and premanifest HD.
Method We studied 17 early HD subjects (mean age: 51 yrs), 12 premanifest HD
subjects (mean age: 43 yrs), and 15 healthy controls (mean age: 51 yrs), using the
Sustained Attention to Response Task (SART), a simple Go/No-go test reflecting
attentional and inhibitory processes through reaction time (RT) and error rates.
Simultaneously recorded EEG yielded P300 amplitudes and latencies.
Results The early HD group made more Go errors (p<0.001) and reacted slower
(p<0.005) than the other groups. The RT pattern during the SART was remark-
ably different for early HD subjects compared to the other two groups (p<0.005),
apparent as significant post-error slowing. P300 data showed that for early HD
the No-go amplitude was lower than for the other two groups (p<0.05).
Conclusions Subjects with early HD showed a reduced capacity to effectively con-
trol attention. They proved unable to resume the task directly after having made
an error, and need more time to return to pre-error performance levels. No atten-
tional control deficits were found for the premanifest HD group.
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INTRODUCTION
Huntington‘s disease (HD) is an autosomal dominant neurological disorder char-
acterized by progressive motor, cognitive and behavioural abnormalities. While
the clinical diagnosis is based on the presence of motor signs, deficits in the other
functional domains are widespread1 2. The discovery of the HD gene3 allows gene-
carriers to be identified in the premanifest phase of the disease, i.e., before symp-
toms and signs appear. Deficits in cognition such as psychomotor slowing, memory
decline and executive dysfunctioning have been reported in both manifest and pre-
manifest individuals4, but inconsistently5.
Attentional processing may well be abnormal in HD, but results are conflicting:
some authors reported attentional and inhibitory deficits in both patients and pre-
manifest gene carriers6 7, while others did not8. The conflict may be due to the
complex nature of the widely applied neuropsychological tests such as the symbol
digit modalities test, the Stroop colour-word task and the trial making test. These
assess attention and inhibition, they also tap into psychomotor speed, implicit
learning, and visuomotor integration.
Studies of attentional processing showed deficits in focused attention9 10, shifting
attention11 12, and inhibition, with sometimes reduced inhibition12 and sometimes
increased inhibitory control13. Due to such methodological differences it is difficult
to come to a conclusion about overall attentional processing in HD. Moreover, at-
tention and inhibition are functionally very closely related and rely heavily on each
other, i.e. attention often is a prerequisite of correct inhibition. This interdepen-
dence lead us to investigate attention and inhibition together in the context of
attentional control, a construct overarching the two terms14 15.
The Sustained Attention to Response Test
The Sustained Attention to Response Test (SART) is a test of attention con-
trol assessing both attentional and inhibitory processes16 17 18. Participants are
requested to press a button when a number (1-9) appears on a screen except when
that number is a 3. The need to withhold responses only to rare stimuli means
that the task relies heavily on attentional control. Pressing a button is simple in
terms of motor control, important in HD, as motor disturbances can interfere with
the determination of cognitive deficits. The SART demonstrated deficiencies in
attention, in disorders such as traumatic brain injury19, schizophrenia20, attention
deficit hyperactivity disorder21 and narcolepsy22.
The P300
There is a growing need in HD research for sensitive, objective and quantifiable
assessments. Electroencephalography (EEG) has the advantages of low cost, non-
invasiveness and high temporal resolution. Event-related potentials (ERP) are
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EEG-based potentials reflecting the neurophysiologic substrate of mental processes
such as stimulus identification, processing and response initiation23. We focused
on the P300 peak, which is most commonly evoked by rare stimuli interspersed in
a series of frequent ones. Although the exact neural origin is not entirely clear,
the P300 is often linked with processes of attention24 25 26. Some authors have
suggested P300 amplitude to reflect the amount of attentional resources allocated
to the stimulus, while the latency is linked to the stimulus evaluation time, or more
general, speed of cognitive processing of the stimulus27. In previous work P300
latency was increased and its amplitude decreased in manifest HD compared to
healthy controls in a visual search task28 and a visual Go/No-go task29. However,
no P300 abnormalities were found in premanifest HD or those at risk in auditory
odd-ball paradigms30 31.
The P300 can be elicited by Go/No-go tasks such as the SART. Studies in healthy
individuals found that simultaneous SART and EEG assessment resulted in good
indexes for attentional and inhibitory processes32. Only one previous study has
used the combination of SART and P300 in premanifest HD33, but found no dif-
ferences in P300 characteristics between the premanifest HD group and controls.
They concluded that possibly their premanifest group was not yet close enough to
disease onset and that with progressive basal ganglia degeneration closer to onset
differences would have emerged. Indeed, magnetic resonance imaging measure-
ments of grey and white matter structures showed changes before the appearance
of overt clinical signs of HD34 35.
We hypothesized that both premanifest and manifest (early) HD groups show
impaired attentional control in comparison with control subjects as measured by
a heightened error rate on the SART. Furthermore, we aim to further strengthen
this hypothesis by showing altered P300 characteristics (i.e. lowered amplitude and
increased latency) in both HD groups in accordance with deviant SART results.
Due to the motor disturbances in HD we expected the SART reaction times for
the early HD group to be longer.
METHODS
Subjects
Thirteen subjects with premanifest HD (PMHD), 18 with early manifest HD (MHD)
and 17 age-matched healthy controls, relatives that were tested as gene-negative,
were included, all above the age of 18 years. Participants were recruited from
the outpatient neurologic clinic of the Leiden University Medical Centre and had
been genetically tested for HD. Gene carriers were considered premanifest when
they had 5 points or less on the total motor subscale of the Unified Huntingto‘s
Disease Rating Scale (UHDRS)36. The manifest group consisted of early HD sub-
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jects (Shoulson-Fahn stages 1 and 2)37. Disease burden was calculated using the
formula ‘age(CAG-35.5)’38. Exclusion criteria were major psychiatric disorders,
neurological co-morbidity, a score of ≤ 25 on the Mini-Mental State Examination
and medication with known effects on the EEG (e.g. neuroleptics). The study was
approved by the local Medical Ethical committee and all participants gave written
informed consent.
All participants underwent neurological, SART and EEG assessments. Depression
was measured using the short version of the Problem Behaviour Assessment for
HD39. The motor part of the UHDRS was administered by a clinician (SvdB)
blinded for genetic status.
One PMHD, one MHD, and one control subject were excluded because of exces-
sive muscle artefacts on the EEG. One additional control was excluded because
of epileptiform abnormalities on the EEG. Data of 12 PMHD, 17 MHD and 15
controls were analyzed.
Sustained Attention to Response Task
For the SART, subjects were seated in a comfortable chair one meter from a com-
puter screen, with a computer keyboard placed in easy access of the dominant
hand. Numbers from 1 to 9 were shown 25 times on a computer screen. Subjects
were asked to respond to the appearance of every number by pressing the spacebar
(‘Go’ trials), except when the number 3 was shown (’No-go’ trials). When the
number 3 was displayed, participants were instructed to withhold their response.
Reaction time (RT) was recorded whenever the spacebar was pressed. To ensure
accurate measurement of RT a cathode ray screen was used together with a pur-
pose built hardware device that allowed precise measurement of the build-up time
of the screen information and hence of RT in relation to the visual stimulus. Sub-
jects were instructed that accuracy and speed were equally important. Before the
start of the test subjects performed a practice run consisting of 25 numbers from
1 to 9 in random order. Stimuli were shown for 250 milliseconds followed by a
blank screen for 900 milliseconds (detailed description of the task see16). Outcome
measures for the SART were RT and error rates. Overall RT refers to mean RT
over all trials performed. The mean RT for correct Go trials and incorrect No-go
trials were also computed. Error rate data consisted of overall error rate (the total
number of errors as a percentage of the total number of trials performed), error
rate Go (total of Go errors as percentage of total number of trials) and error rate
No-go (total of No-go errors as a percentage of total number of trials).
ERP recording and analysis
All EEGs (Nihon Kohden 2110 EEG apparatus) were recorded between 12.00 and
14.30 hrs, except for one control subjects tested late in the morning. Twenty-
one Ag/AgCl electrodes were placed according to the 10/20 convention. ECG,
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respiration and horizontal eye movement leads were also recorded. The EEG was
band-pass filtered from 0.16-70 Hz before display and analysis. Sample frequency
was 200 Hz and A-D precision 12 bits. For the P300 analysis we used the midline
sites Fz (frontal), Cz (central) and Pz (parietal) with linked mastoids as reference.
The computer controlling the SART paradigm wrote synchronization signals to
the EEG machine, allowing averaging to take place offline after controlling for
signal quality. Data were averaged over epochs of 1200 ms, starting 200 ms
before stimulus onset. Individual trials with eye blink artefacts or suspected muscle
artefacts (peak amplitudes more than 75 µV) were excluded from P300 analysis.
The P300 component was defined as the maximum positivity between 350 and
650 ms. This time-frame was based on visual inspection of the averaged ERPs.
ERP analysis, including peak detection, was performed automatically using an in-
house developed program written in MATLAB (The MathWorks, Natick, USA).
Peak amplitudes were measured relative to a 200 ms baseline before stimulus onset.
Outcome measures consisted of amplitude and latency data. The mean amplitudes
and latencies for all trials, all Go trials and all No-go trials were calculated averaging
the data from the midline electrodes.
Statistical analysis
SPSS for Windows version 17.0 was used for data analysis. Analyses of demo-
graphic variables were performed using parametric and non-parametric tests where
appropriate. Group differences for mean SART RT and error rate and P300 am-
plitude and latency data were calculated using univariate analysis of covariance
(ANCOVA) with age as a covariate. Upon visual inspection of the RT patterns for
the four trials preceding and the four trials following a No-go trial different pat-
terns were observed. To investigate possible group differences in these patterns a
secondary analysis was performed. For this purpose the difference (delta) between
the mean RT just before and just after both correct and incorrect No-go trials was
calculated for each subject. The delta scores for the three groups were analyzed
again using ANCOVA with age as covariate. The Bonferroni method was used to
correct for multiple testing. The level of significance was set at p ≤ 0.05. P-values
> 0.05 < 0.1 were reported as trend significant.
RESULTS
Clinical characteristics
There were no differences between groups for sex, age, IQ and level of educa-
tion (Table 1). Disease burden differed significantly between PMHD and MHD
(p<0.0001). Two subjects (one premanifest, one early HD subject) were rated
as mildly depressed; depression did however not differ between groups (data not
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shown in table).




Age 51 (10) 43 (10) 50 (11)
CAG 20 (3) 42 (2) 44 (3)




Intelligence Quotient (IQ) 107 (8) 105 (8) 101 (12)
Disease burden 251 (75) 404 (81)
Note. Descriptive statistics are presented as mean (standard deviation), except for a which is
total number. IQ was measured by the National Adult Reading Test (Dutch version). Disease
burden is age(CAG-35.5). bPearson Chi Square Test.
SART
Table 2 shows SART error rate and RT data. The overall error rate (i.e. all errors
made, not differentiated for type) differed significantly between groups (p<0.05)
(Table 2). The MHD group made significantly more errors of all types than both
PMHD and controls (p<0.05). Further analysis revealed that only for Go-errors
(i.e., subjects did not press the spacebar when they ought to) there was a group dif-
ference (p<0.001). Surprisingly, the number of No-go errors (pressing the spacebar
when the number ‘3 appears’) did not differ between groups. Concerning mean RT
(i.e. mean RT for all pressed trials, not differentiated for correct or erroneous tri-
als) there was a group difference (p<0.005), where the overall RT was significantly
longer for MHD than for PMHD (p<0.005) and controls (p<0.001).
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(a) Go
Note. P300 waves for the three groups during SART Go trials, averaged over the midline
electrodes. Time point 0 denotes the point of stimulus presentation.
(b) No-go
Note. P300 waves for the three groups during SART No-go trials, averaged over the midline
electrodes. Time point 0 denotes the point of stimulus presentation.
Figure 1: P300 waves per group (averaged)
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P300
The number of epochs used for P300 analyses were not different between groups.
P300 amplitudes were larger for No-go trials than Go trials (Table 2; Figures
1a/1b.). Overall P300 amplitude proved only trend significant between groups
(p<0.06). Amplitude in No-go trials differed significantly between groups, with
lower amplitude in MHD than in the other groups (p<0.05). For mean latency only
a trend towards significant group differences for Go trials was observed (p<0.06).
Note. The reaction time for the four trials preceding and the four trials following No-go trails.
Data are separated for RT patterns surrounding correct responses (i.e. not pressing at No-go
stimulus) and incorrect responses (i.e. pressing at No-go stimulus), averaged per group.
Figure 2: RT patterns for trials before and after correct and incorrect No-go trial
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Reaction time patterns before and after correct and incorrect
No-go
Almost all Go errors (not pressing on 1-9) occurred directly following a No-go error
(incorrectly pressing on 3), with MHD making significantly more of these errors
than the PMHD group (p<0.05). The RT patterns for the four trials preceding and
following both correct and incorrect No-go trials are shown in Figure 2. Analysis
of covariance on the difference between the RT of the last trial before and the
first trial after both correct and incorrect No-go responses revealed a significant
result for incorrect No-go trials only (p<0.01). MHD had a significantly slower
response to the first Go trial following an incorrect No-go trial compared to controls
(p<0.005) and PMHD (p<0.05). P300 amplitude did not differ significantly for




















Table 2: Main and post-hoc effects for SART error rate and mean reaction time data and P3 mean amplitude and
latency data
Controls PMHD MHD p-value p-value p-value p-value







Error rate 4.3 (1.8) 3.9 (2.5) 6.3 (2.8) 0.021 0.027 ns 0.014
Error rate No-go 27.7 (11.9) 25.8 (13.8) 32.9 (15.9) ns ns ns ns
Error rate Go 1.4 (0.98) 1.2 (1.3) 3.0 (1.4) <0.001 0.001 ns 0.001
Mean RT 381 (34) 388 (48) 462 (77) 0.001 <0.001 ns 0.004
P300
Amplitude 8.7 (2.8) 8.3 (4.4) 5.9 (3.2) 0.058 ns ns ns
Amplitude Go 7.9 (2.8) 7.8 (4.6) 5.4 (3.1) ns ns ns ns
Amplitude No-go 16.3 (4.9) 1.61 (4.5) 1.20 (5.6) 0.046 0.023 ns 0.064
Latency 414 (37) 401 (37) 439 (57) ns ns ns ns
Latency Go 408 (30) 405 (43) 445 (62) 0.059 ns ns ns
Latency No-go 430 (38) 424 (47) 447 (50) ns ns ns ns
Note. Data are mean (standard deviation). RT = Reaction time in milliseconds. Errors are percentage of errors out of total number of
stimuli. Amplitude is µV. Latency is milliseconds. ns = not significant.
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DISCUSSION
The main finding of this study was that attentional control is deficient in MHD,
evident primarily through a heightened error rate on the SART. This behavioural
deficit was corroborated by abnormalities of P300 characteristics.
SART error rate
As expected, MHD made more errors of any type than the other groups, indicative
of defective attentional mechanisms. Unexpectedly, this was not caused by a high
rate of No-go errors, but by significantly more Go errors. The only study using
the SART in HD did not report about the type of errors made33. Even though
they used different Go/No-go paradigms other studies also report on attentional
deficits in manifest HD as measured by more Go errors for manifest HD compared
to controls, but all have concomitantly also found more No-go errors, contrary
to our findings10 40. Our findings are partly in line with studies using the SART
in other brain disorders with known attentional deficits. Schizophrenic patients
have also been found to largely make Go errors and not No-go errors20. However,
patients with traumatic brain injury made significantly more errors of both types,
with stronger evidence for No-go than Go errors16 21. So, our findings cannot be
easily attributed to attentional deficits alone as earlier findings in other studies were
not replicated. Therefore they were further investigated in reaction time pattern
analyses.
Reaction time patterns surrounding No-go errors
As the SART is likely to provoke No-go errors, due to the repetitive nature of
the task and the rarity of No-go stimuli, we further investigated the significant
amount of Go errors made by the early HD group. Examination of these Go errors
in MHD revealed that most were made directly following a No-go error. Analysis
of the reaction time patterns for trials directly preceding and following a correct
No-go trial (correctly withholding response to a three) revealed identical patterns
for the three groups, although the MHD group reacted significantly slower than
the PMHD or control groups. Prior to correct responses to a No-go trial RT
was relatively stable for all three groups. Directly after such a correctly withheld
response, RT was noticeably shorter. This speeding most likely represents action
anticipation that is evoked by the repetitive nature of the SART. This primes the
motor response; after having correctly withheld the response at the No-go trial,
the response to the next Go trial is more quickly accessed, resulting in a quicker
response41. Although the MHD group reacted slower, the general pattern was the
same as for the other groups. This suggests that the cause of slowing is due to
motor disturbances and not to different cognitive processing.
Interestingly, a different pattern emerged concerning incorrect No-go responses, i.e.
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when participants incorrectly pressed the space bar in response to a three. For all
three groups the trials directly preceding such a No-go error showed a shortened
RT. We hypothesize that this pre-error speeding could mean that the task was
performed fairly automatically, with less attentional control, eventually resulting in
an error16. Remarkably, this pre-error speeding was more prominent in MHD than
in the other two groups. This could indicate that subjects with MHD can sustain
attention less well than the other groups. After such a No-go error RT returned
to the pre-error level almost immediately for the PMHD and control groups, but
not for the MHD group, showing a dramatic post-error slowing.
One proposition for this is that a No-go error induces MHD subjects to slow down
in response time in the hope of making fewer errors. This is an unconscious
cognitive strategy known as ‘speed-accuracy trade-off’ (SAT): low speed allows
high accuracy42. That healthy controls performing the SART use this SAT strategy
has also been put forward by Helton and colleagues17. At first glance one would
then expect that subjects who choose ‘accuracy over speed’ would make fewer
errors, but this was not the case. A more likely explanation is that there is an
intrinsic deficit of attentional control in MHD. This is seen in the obvious drop
in RT trials preceding an error. This could possibly reflect a drop in attentional
control, in turn causing the No-go error. The post-error RT pattern shows that the
PMHD and control groups are able to return to the task immediately and perform
on pre-error level. The pattern of the MHD subjects however reflects a difficulty in
recovery; it takes this group several trials to return to pre-error performance. This
difficulty could be due to the realization of having made an error, i.e., the response
evaluation, causes confusion; the subsequent quick return to a Go trial adds to this
confusion, leading to a slower return to pre-error performance. Alternatively, this
post-error slowing does not reflect cognitive confusion, but could be indicative of
an inability to switch from a No-go to a Go response, and thus from inhibiting the
response to activating it. Together with the fact that directly following a No-go
error significantly more Go errors are made in the MHD group than in the other
two groups we speculate that attentional and inhibitory deficits are the probable
causes of inadequate attentional control in MHD. Adding to this theory of impaired
attentional control we found, on further analysis, that in the trial directly following
a No-go error trial, the early group made significantly more go-errors (8%) than
both the premanifest (0.5%) and control groups (3%). Similar results in a task-
switch and stop-signal task in MHD have been reported12. Post-error slowing was
interpreted in that study as task-switch cost and a deficit in the ‘inhibition of the
just-performed response’ respectively. The authors attributed these phenomena to
deficient inhibition. These explanations are not mutually exclusive in that early
HD subjects can use the speed-accuracy trade-off strategy to avoid making further
errors, but that their cognitive abilities are deficient and they cannot use this
strategy successfully.
Even though constructs such as attention and inhibition are not directly measurable
and can only be derived from secondary measurements, we hypothesize that the
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RT pattern around No-go errors in the MHD group seems to reflect a cognitive
rather than a motor process as subjects with early HD are able to respond in
the same manner as PMHD and controls in correctly withheld No-go trials, albeit
slower. This similar pattern for all groups demonstrates that it is not a No-go trial
per se that elicits a deviant reaction from early subjects. The problem seems to lie
purely in the fact that an error was made.
P300 amplitude and latency
As stated before P300 amplitude is hypothesized to reflect the amount of atten-
tional capacity that is being allocated to a stimulus27. If so, then P300 amplitude
would be lower for incorrectly performed No-go trials. This was indeed the case for
the MHD group, confirming a lowered attentional control during presentation of
No-go stimuli. Our findings correspond well to those of Beste et al. and Jurgens
et al.29 33. Münte et al.28 also reported lowered P300 amplitude, however not in
the context of a Go/No-go task.
P300 latency is thought to be linked to the speed of attentional processing27. In
accordance with Münte et al.28, P300 latency was significantly longer in MHD
compared to the other groups for Go trials. This implies a low speed of attentional
processing during Go trials is lessened for MHD. Together with a lowered atten-
tion during No-go trials this strengthens our hypothesis that the disturbed pattern
observed surrounding No-go errors is of a cognitive rather than a motor nature.
Premanifest HD results
PMHD did not exhibit any attentional or inhibitory deficits. Explanations for this
are that no attentional control deficits are yet present or that subtle changes in
attentional control capacity are already present in PMHD, but that they are still too
subtle to be measured with this method. Possibly these deficits gradually worsen
and are better picked up in subjects closer to expected onset. This interpretation
seems plausible as both SART and P300 data did show a nonsignificant trend
towards worse performance in the premanifest group. The only reverse pattern
concerned SART error rate, where PMHD subjects made fewer errors than controls.
We hypothesize that this reflects a high motivation. Clinical experience suggests
that PMHD subjects are highly motivated to perform to their best on the tests, as
they may wish to prove that there they are still in the premanifest phase.
Practical implications and limitations
Patients with HD may experience more distress from the decline of their cognitive
functions rather than the presence of motor disturbances. The results from this
study indicate that patients with HD experience difficulties with recovering after
an error and maintaining attentional control for a longer period, which adds to the
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knowledge about cognition in HD and could have implication for daily care.
A limitation to the present study is the relative small number of subjects in the
PMHD group and therefore having less statistical power. This could have obscured
possible subtle differences from controls.
We conclude that there is an attentional control deficit in MHD. MHD subjects
are cognitively not able to directly resume task requirements after having made an
error and that they need more time to return to pre-error performance level. No
attentional control deficits were found for the PMHD group.
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Abstract
Background Earlier research has found cross-sectional attentional control deficits
in manifest Huntington‘s disease (HD) using neuropsychological testing combined
with simultaneous P300 registration. In the current pilot-study we investigate
attentional control in premanifest and manifest HD over a three-year follow-up
period.
Method Five manifest HD (MHD), 9 premanifest HD (PMHD) and 12 control
subjects were included. Sustained Attention to Response Test (SART) and P300
registration resulted in number of errors, reaction time (RT), and P300 amplitude
and latency. RT change patterns surrounding No-go trials were also investigated.
Within-subject differences were tested using paired-samples t-tests and between-
group results with ANCOVA on delta scores (follow-up - baseline scores).
Results MHD made more errors and were slower than controls and PMHD. Lon-
gitudinally, MHD showed an overall RT increase and a specific slowing on trials
preceding a correct No-go trial. The latter was also seen in PMHD. P300 latency
prolongation was found for controls on No-go and for MHD on Go trials. Directly
preceding a correct No-go, MHD became significantly slower over time than con-
trols and PMHD.
Conclusions Over three-years MHD subjects became slower on the SART and
showed a prolongation of P300 latency on specific SART trials. Specific slowing
of performance over time was also seen in PMHD, suggestive of compensatory
mechanisms in this group.
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INTRODUCTION
Huntington‘s disease (HD) is a neurodegenerative disease caused by a gene muta-
tion located on chromosome 41. Its clinical manifestation is heterogeneous, with
symptoms and signs occurring in three domains: motor, psychiatry and cognition2.
Attentional deficits in HD patients have been widely demonstrated3 4 5. In preman-
ifest HD subjects, i.e. gene carriers without overt clinical symptoms, differences
in attentional processing compared to controls have also been found6, but with
inconsistent results7 8. Reports on longitudinal change in attentional functioning in
premanifest HD are few9 10 11, and again contradictory results have been found12 13.
A practical test to investigate attentional processing is the Sustained Attention
to Response Task (SART)14, a simple Go/No-go task with little motor involve-
ment. The P300, an event-related potential (ERP) that can be deduced from the
EEG, is proposed to be an electrophysiological substrate of attentional and in-
hibitory processes15 16. In combination, these two assessments have demonstrated
ability to detect lapses in attention17.
Hart and colleagues18 combined the SART with a simultaneous P300 registration
to investigate attentional functioning in both a manifest and a premanifest HD
group cross-sectionally. They demonstrated that attentional control was deficient
in manifest HD subjects, apparent in the inability to directly resume task require-
ments after having made an error. The manifest subjects showed higher error rates
corroborated by abnormalities in the P300 signal. While the attentional control
deficit in manifest HD was evident, the performance of the premanifest HD group
did not differ from that of controls, and no P300 abnormalities were found.
Recent MRI studies reported early brain changes involving grey and white mat-
ter19 20 in premanifest gene carriers even far from expected disease onset. This
raises the possibility that these changes can also be measured with functional as-
sessments, such as P300. Indeed, differences in ERPs between premanifest HD
subjects and controls have been found21. A majority of these studies have found
reduced neurophysiologic measures in the absence of abnormal clinical performance
in the premanifest groups. This coincides with findings in MRI studies where patho-
logical changes in premanifest HD gene carriers are seen before onset of clinical
symptoms20.
To date, one longitudinal study has been performed using electrophysiological as-
sessment in HD. Here, somatosensory evoked potentials were studied in a group of
manifest HD subjects. The amplitude of these potentials demonstrated progressive
decline over the two year follow-up period22. To our knowledge, no longitudinal
electrophysiological research has been performed in premanifest HD subjects yet.
The current pilot-study aimed to investigate attentional deficits in premanifest
and manifest HD subjects longitudinally. Observed early brain changes in preman-
30 | Chapter 3
ifest HD literature lead us to expect possible longitudinal change for SART error
scores and P300 characteristics over the three year interval in this group. For the
manifest group we expected to find abnormalities similar to those found earlier by
Hart and colleagues: longer reaction time, more errors, and a lower No-go P300
amplitude than controls and premanifest HD subjects. Furthermore, due to the




Five manifest (MHD), 10 premanifest (PMHD), and 13 control subjects partici-
pated in this pilot-study and were tested with a three-year interval using the same
tests. All subjects completed the baseline and follow-up visit, with a mean follow-
up time of 36.7 months. One PMHD and one control subject were excluded from
longitudinal analyses due to excessive muscle artefacts visible during the ERP reg-
istration. Eventually, data of 5 MHD, 9 PMHD and 12 control subjects were
analyzed. None of the PMHD subjects converted to manifest HD over the study
period. All subjects were grouped at visit 1 and were subsequently analyzed in this
group at follow-up.
All participants were recruited from our outpatient neurology clinic. The controls
were gene-negative relatives. Genecarriers were considered premanifest if they had
a CAG expansion of >39 and a total motor score (TMS) of 5 on the Unified
Huntington‘s Disease Rating Scale (UHDRS)23. Disease burden was calculated
using the formula ‘age(CAG-35.5)’24. Exclusion criteria for all subjects were ma-
jor psychiatric disorder, neurological co-morbidity, a score of ≤25 on the Mini
Mental State Examination (MMSE)25 and medication with known effects on the
P300 (e.g. neuroleptics). The study was approved by the local medical ethical
committee and all participants gave written informed consent (according to the
declaration of Helsinki). Subjects underwent neurological examination including
the complete UHDRS, P300 and SART assessment on both baseline (visit 1) and
follow-up visit (visit 2). The MMSE was used to measure global cognitive function-
ing. Depression was measured with the depression part of the Problem Behaviours
Assessment short version26, where depressive feelings are scored by severity and
frequency (score range 0-16). The neurological assessment was performed at both
visits by clinicians specialized in HD, blinded for genetic status.
Sustained Attention to Response Test
The SART was administered during both visits under the same conditions. Subjects
were seated in a comfortable chair one meter from a computer screen, with a
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computer keyboard placed in easy access of the dominant hand. Numbers from
1 to 9 were each shown 25 times on a computer screen. Subjects were asked
to respond to every number by pressing a spacebar (‘Go’ trials), except when
the number 3 was shown (‘No-go’ trials). In the case of a No-go trial subjects
were instructed to withhold their response. Accuracy and speed were instructed
to be equally important. Before the test subjects were allowed to practice with
25 random trials. The numbers were shown for 250 milliseconds followed by a
blank screen for 900 milliseconds14. Reaction time (RT) was recorded whenever
the spacebar was pressed. To ensure accurate measurement of RT a cathode ray
screen was used together with a purpose built hardware device that allowed precise
measurement of the build-up time of the screen information and hence of RT in
relation to the visual stimulus18.
Outcome measures for the SART were reaction time (RT) and number of errors.
‘Overall RT’ refers to mean RT over all trials performed. Errors are divided into
total number of errors, and errors on Go and No-go trials. For error processing
analyses the mean RT of the trials directly preceding and directly following both
correct and incorrect No-go trials were used (‘3’ is the No-go item in the SART). A
delta score was also computed, which comprised the difference between the mean
RT on the trials directly preceding and directly following both correct and incorrect
(i.e. an incorrect response to a three) No-go trials.
ERP recording and analysis
Twenty-one Ag/AgCl electrodes were placed according to the 10/20 convention.
ECG, respiration and horizontal eye movement leads were also recorded. The EEG
was band-pass filtered from 0.16-70 Hz before display and analysis. Sample fre-
quency was 200 Hz and A-D precision 12 bits. For the P300 analysis we used the
midline sites Fz (frontal), Cz (central) and Pz (parietal) with linked mastoids as
reference. The computer controlling the SART paradigm wrote synchronization
signals to the EEG machine, allowing averaging to take place offline after control-
ling for signal quality. Data were averaged over epochs of 1200 ms, starting 200
ms before stimulus onset. Individual trials with eye blink artefacts or suspected
muscle artefacts were excluded from P300 analysis. The P300 component was de-
fined as the maximum positivity between 350 and 650 ms. ERP analysis, including
peak detection, was performed automatically using an in-house developed program
written in MATLAB (The MathWorks, Natick, USA). Peak amplitudes were mea-
sured relative to a 200 ms baseline before stimulus onset. P300 outcome measures
consisted of amplitude and latency data. The mean amplitudes and latencies for
all trials, all Go trials and all No-go trials were calculated18.
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Statistical analysis
Data analysis was done using IBM SPSS statistics for Windows, version 20.0.
Demographic variables were compared between groups using ANOVA (continuous
variables) and Pearson’s χ2 (categorical variables). Classification of the groups at
baseline was used for all analyses. ANCOVA was done for cross-sectional SART
and P300 analyses, where separate analyses were performed for baseline and follow-
up visits. For SART error scores, the age and mean RT at time of visit were
used as covariates. Age was chosen because of the known effect of aging on
neuropsychological testing. With the inclusion of RT as covariate we assume to
test more pure cognitive performance while controlling for possible differences in
RT. For the RT, P300 and error processing analyses, age at time of visit was
selected as covariate. Again, age has been proven to have an altering effect on
both RT and P300 characteristics. For longitudinal analyses of between group
effects, delta scores (follow-up visit score-baseline visit score) were calculated and
analyses of covariance were performed on these scores. Age at baseline was used
as covariate, except for the analyses of SART error scores where age and mean RT
at baseline were selected. Significant main results were further investigated using
Bonferroni post-hoc tests. Within subjects effects were investigated using paired
samples t-tests. Effect sizes are reported as partial eta squared values. The level of
statistical significance was set at p≤0.05. For both cross-sectional as longitudinal
analyses Bonferroni correction was applied to correct for multiple testing.
RESULTS
Demographic data
Demographic and clinical data of baseline and follow-up visits are shown in Table
1. The groups were similar in terms of age, gender, education, and total functional,
depression and MMSE scores on both visits. MHD subjects had a higher disease
burden than PMHD subjects (F (1, 12) = 12.41, p = 0.004). The TMS of the
MHD group was higher than the TMS of the PMHD (F (2, 23) = 8.89, p = 0.002)
and control group (visit 1: F (2, 23) = 8.89, p = 0.003, and visit 2: F (2, 23) =
8.89, p < 0.001) on both visits.
Cross-sectional data
Cross-sectional data of the SART and P300 are shown in Table 2. MHD subjects
made more total (F (2, 21) = 4.07, p = 0.03, η2p = 0.280) and No-go errors (F (2,
21) = 5.18, p = 0.02, η2p = 0.330) on both visit 1, and visit 2 (F (2, 21) = 7.30, p
= 0.004, η2p = 0.410, and F (2, 21) = 8.80, p = 0.002, η
2
p = 0.456, respectively)
compared to PMHD subjects and controls. Additionally, the MHD group reacted
slower on visit 2 (F (2, 22) = 9.51, p = 0.001, η2p = 0.464) compared to PMHD
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subjects and controls.
Concerning the P300 characteristics MHD subjects showed a longer overall (visit
1 F (2, 22) = 3.68, p = 0.04, η2p = 0.250), Go (visit 1 F (2, 22) = 3.53, p =
0.047, η2p = 0.243 and visit 2 F (2, 22) = 4.14, p=0.03, η
2
p = 0.273) and No-go
(visit 1 F (2, 22) = 4.64, p = 0.02, η2p = 0.297) latency than PMHD and control
subjects. Also, the MHD group demonstrated a lower No-go amplitude than the

















Age (years) baseline 40.3 (10.0) 45.4 (10.7) 48.2 (9.7)
follow-up 43.4 (9.7) 48.4 (10.7) 51.3 (9.7)
Gender, m/fa baseline 3/6 2/3 5/7
Education (years) baseline 12.3 (2.6) 14.4 (2.9) 11.9 (2.7)
CAG repeat length baseline 41.3 (1.5) 44.4 (3.1) 20.0 (2.9)
Disease burden baseline 232.2 (73.3) 382.5 (82.5)
follow-up 250.7 (75.8) 409.2 (90.7)
Total motor score baseline 1.6 (2.5) 6.4 (1.3) 2.0 (2.2)
(range 0-124) follow-up 2.2 (1.5) 14.8 (7.7) 3.0 (3.4)
Total functional capacity baseline 12.2 (1.1) 12.0 (1.4) 13.0 (0)
(range 0-13) follow-up 11.8 (1.6) 12.0 (1.2) 12.8 (0.6)
PBA-s depression score baseline 2.8 (2.9) 2.2 (3.3) 3.0 (3.5)
(range 0-16) follow-up 1.0 (2.1) 2.0 (2.0) 1.1 (1.6)
Score MMSE baseline 28.8 (0.8) 28.4 (0.9) 29.0 (1.0)
(range 0-30) follow-up 28.8 (1.2) 28.6 (1.5) 29.4 (0.7)
Note. Data is presented as mean (SD), a is total number.
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Longitudinal data
No between-group effects were found longitudinally for SART and P300 data.
Concerning within-subjects differences, paired samples t-tests showed a significant
mean RT increase over time on the SART for MHD participants (t(4) = -9,56, p
= 0.01, η2p = 0.938).
A prolongation of the No-go P300 latency was found for controls (t(11) = -3.56,
p = 0.004, η2p = 0.494) and of the Go latency for MHD (t(4) = -2.82, p = 0.048,
η2p = 0.570). No significant changes were observed concerning P300 amplitude.
SART error processing analyses cross-sectional data
Data for the error processing analysis are shown in Table 3. Cross-sectionally,
MHD subjects reacted slower on the trial directly following both correctly (F (2,
22) = 3.75, p = 0.04, η2p = 0.254) and incorrectly (F (2, 21) = 5.49, p = 0.01,
η2p = 0.343) withheld responses to No-go trials (appearance of the number ‘3’)
compared to controls at visit 1. MHD subjects were also slower in reacting to the
trial just preceding a correct No-go (F (2, 22) = 6.03, p = 0.007, η2p = 0.364) and
following both correct (F (2, 22), p < 0.001, η2p = 0.544) and incorrect (F (2, 22),
p < 0.001, η2p = 0.542) No-go trials, all compared to both controls and PMHD
participants at visit 2.
SART error processing analyses longitudinal data
ANCOVA on delta scores revealed between group differences for trials preceding a
correct No-go trial. RT in all groups became longer over time, but MHD subjects
became significantly more so than the other groups (F (2, 22) = 6.22, p = 0.007,
η2p = 0.361). Regarding within-subject effects paired samples t-tests showed that
both MHD (t(4) = -5.15, p = 0.007, η2p = 0.815) and PMHD (t(8) = -2.68, p =






























PMHD 7.9 (4) 6.7 (3) 0.171
Total error MHD 12.0 (8) 12.4 (4) <0.05 <0.01 0.889 0.267
Controls 8.2 (5) 9.3 (3) 0.362
PMHD 6.9 (3) 6.4 (3) 0.559
No-go error MHD 10.8 (7) 8.8 (4) <0.05 <0.01 0.417 0.140
Controls 7.1 (4) 8.3 (3) 0.234
PMHD 1.0 (2) 0.2 (0) 0.211
Go error MHD 1.2 (2) 3.6 (4) 0.596 0.421 0.170 0.587
Controls 1.1 (1) 0.9 (1) 0.732
PMHD 361.4 (32) 374.9 (33) 0.098
Mean RT MHD 422.9 (81) 481.9 (84) 0.055 <0.01 <0.01 0.174
Controls 371.2 (29) 379.9 (39) 0.435












































PMHD 380 (18) 394 (36) 0.138
Latency MHD 435 (46) 451 (58) <0.05 0.089 0.313 0.760
Controls 406 (39) 413 (39) 0.407
PMHD 391 (34) 420 (47) 0.080
Lat No-go MHD 449 (62) 474 (45) <0.05 0.081 0.453 0.850
Controls 408 (22) 432 (33) <0.001
PMHD 375 (21) 396 (36) 0.119 0.204
Latency Go MHD 430 (45) 454 (53) <0.05 <0.05 <0.05
Controls 409 (41) 406 (30) 0.646
PMHD 10.2 (5) 9.6 (4) 0.597 0.674
Amplitude MHD 7.8 (3) 8.2 (2) 0.427 0.736 0.630
Controls 9.6 (3) 8.9 (3) 0.222
PMHD 17.3 (6) 16.5 (5) 0.534
Amp No-go MHD 10.9 (3) 14.1 (6) <0.05 0.406 0.223 0.111
Controls 17.8 (4) 17.6 (5) 0.742
PMHD 9.6 (5) 9.1 (5) 0.628
Amplitude Go MHD 7.6 (3) 7.8 (2) 0.449 0.698 0.769 0.767
Controls 8.3 (3) 7.9 (3) 0.221
Note. Data is presented as mean (SD). apaired samples t-tests; bANCOVA on delta-scores. RT = reaction time in milliseconds.





























RT PMHD 336 (21) 392 (43) <0.05
before MHD 426 (92) 535 (128) 0.070 <0.01 <0.01 <0.01
Controls 409 (43) 416 (67) 0.760
RT PMHD 314 (57) 349 (37) 0.054
after MHD 381 (76) 421 (70) <0.05 <0.001 0.223 0.099
Controls 317 (18) 310 (23) 0.442
Incorrect 3
RT PMHD 338 (45) 350 (48) 0.391
before MHD 350 (39) 444 (194) 0.777 0.185 0.278 0.115
Controls 349 (35) 364 (53) 0.625
RT PMHD 414 (85) 360 (36) 0.092
after MHD 476 (104) 529 (108) <0.05 <0.001 0.435 0.118
Controls 338 (54) 363 (59) 0.414
Note. Data are mean (SD). Reaction time are milliseconds. apaired samples t-tests; bANCOVA on delta-scores, MHD=manifest
HD, PMHD=premanifest HD, RT = Reaction Time.
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DISCUSSION
In this pilot-study we present preliminary data on longitudinal SART and simul-
taneous P300 assessment in HD. To our knowledge we are the first to perform a
longitudinal ERP study in premanifest HD. We found that over a course of three
years MHD subjects showed an increase in RT on the SART, and exhibited a pro-
longation of the P300 latency on specific trials of the SART. PMHD subjects only
showed specific increase in reaction time just before having prevented a possible
error on the SART.
In the MHD group we replicated the findings of the cross-sectional study by Hart
et al.18 on the SART and P300 in HD where MHD subjects make more errors on
the SART than both other groups, and took longer to react to the trials (follow-
up visit). The increase in reaction time is not surprising, and is likely to reflect
motor slowing. This conclusion is strengthened by only specific, and not overall,
RT increase in the PMHD subjects. In the earlier study the authors hypothesized
that the observed slowing could reflect a speed-accuracy trade-off, a (conscious
or unconscious) strategy applied by MHD participants to maintain task require-
ments27. The increase in RT seen in the current MHD cohort does however not
prevent these subjects from making more mistakes than the other two groups. So,
there is no task-related benefit from the motor slowing. One explanation for this
absence of benefit could be that the employment of the speed-accuracy trade-off
has reached a maximum. If this level is reached the impairment can no longer be
compensated and task-related benefit is absent.
The MHD group also showed the most pronounced RT increase over time, which
was expected in view of the neurodegenerative nature of HD. Neurodegeneration is
also reflected in the neurophysiologic data, as demonstrated by the cross-sectionally
longer P300 latencies compared to the other groups, and the latency prolongation
over time on Go trials. The P300 latency has been linked to stimulus evaluation
time, or generalized, cognitive processing speed28, so a lengthened latency in the
MHD group could reflect reduced processing speed. Deficits in processing speed
have also been demonstrated by other authors using other paradigms29 30.
Cross-sectionally, premanifest subjects perform equally to control subjects, evi-
dent by the lack of cross-sectional results. Interestingly, in the PMHD group we
did find specific slowing over time. During follow-up this group became slower in
reacting to trials directly preceding correct No-go trials (i.e. correctly withholding
the response to the appearance of a ‘3’). This slowing was also seen in the MHD
group, but only MHD subjects produced more errors than controls. The exact
significance of such specific deterioration is difficult to explain, but as the PMHD
subjects make the same number of errors as controls and increase in RT where
controls do not, this could mean that it takes more attentional demands for PMHD
subjects to maintain task performance. As PMHD subjects can keep up with the
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demands of the SART it could mean that the RT increase is the result of some
kind of compensatory mechanism. That it reflects pure motor slowing is less likely
as in this case we would have expected increased RT on more variables.
A candidate compensatory mechanism here could be speed-accuracy trade-off, a
strategy that was used by MHD subjects in the cross-sectional study18. That
growing attentional demands could translate into increased RT is well described
in speed-accuracy trade-off literature27. Additionally, the controls did not slow
over time on these specific trials, and produced a similar amount of errors as the
PMHD subjects. This strengthens our hypothesis that some kind of compensa-
tion is utilized by the latter group. This proof of early compensation by means
of speed-accuracy trade-off in PMHD complements our earlier hypothesis that in
the current MHD cohort the maximum level of compensation (by means of speed-
accuracy trade-off) is reached and no more task-related benefits are observed.
That compensatory mechanisms are at work in PMHD has been suggested be-
fore31. In another basal ganglia disorder, Parkinsons disease (PD), compensatory
mechanisms responsible for delaying overt symptom onset have long been ac-
cepted32. Here, even several compensatory networks have been identified post-
poning the final appearance of parkinsonism33. Looking at our overall raw data
we also see that for SART errors and mean RT scores the premanifest subjects
perform better not only than the MHD, but also than the control subjects. This
could reflect overall compensation to perform at pre-disease level.
The significant post-error slowing that was found in the previous cross-sectional
study was not replicated in the present study. An explanation for this could be
that the manifest group, consisting of five subjects, was too small to make this
difference visible. Also, individual differences in such a small sample could have
large effects. This is evident in the differences in RT patterns surrounding incorrect
responses to a No-go trial, where at baseline some post-error slowing was visible
(albeit not statistically significant) for MHD and PMHD, while it was absent at
follow-up.
As our preliminary data derived from small pilot groups our conclusions should
be considered with caution. Generalization of our results is limited as, due to the
sample sizes, statistical power is low and the impact of individual fluctuations in
scores more influential.
The combination of cognitive testing (SART) with simultaneous P300 registration
is a strength of this study, in the way that the P300 is independent of motor
slowing whereby conclusions about cognitive functioning can be made more eas-
ily. Following the specific result in the PMHD group we recommend replication of
this pilot-study with larger numbers of participants in order to be better able to
understand the transition from premanifest to manifest HD.
In conclusion, this pilot-study partly replicated the findings from the cross-sectional
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study by Hart and colleagues18 that MHD subjects perform worse than both PMHD
and control subjects on tests of attentional control. MHD subjects are slower and
make more mistakes on the SART, and show longer P300 latencies. Longitudinal
change in attentional control was observed for specific trials in the PMHD subjects,
which could be suggestive of compensatory mechanisms in this phase of HD.
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Abstract
Detecting subtle clinical abnormalities in the ‘premanifest’ phase of Huntington‘s
disease (HD) is of importance in the development of instruments to monitor early
therapeutic intervention trials. The current study examined changes in motor func-
tion, cognition and behaviour over a period of seven years in premanifest carriers
of the HD gene mutation. Twenty-nine carriers without unequivocal motor signs
of HD and 43 non-carrier controls were prospectively examined four times. The
assessments consisted of the Unified Huntington‘s Disease Rating Scale (UHDRS)
and an extensive neuropsychological test battery addressing global cognitive func-
tion, memory, language and executive function. Rate of Change (RoC) analysis was
performed to measure longitudinal differences between carriers and non-carriers.
Carriers performed consistently worse on executive function (Symbol Digit Modali-
ties Test, Stroop, Trail Making Test and Wechsler Adult Intelligence Scale-Revised
arithmetic). Over the years, carriers showed a decline in memory and concen-
tration function (Wechsler Memory Scale) and in motor function (UHDRS motor
scale). Changes over time could be particularly ascribed to carriers converting to
manifest HD. These results demonstrate that standardized motor assessments and
objective memory and concentration tasks are sensitive to change over a period
of 7 years, specifically in carriers converting to manifest HD. Executive tasks also
showed subtle cognitive abnormalities in premanifest HD, but a decline over time
could not be demonstrated.
7-Year cognitive follow-up | 47
INTRODUCTION
Huntington‘s disease (HD) is a hereditary neurodegenerative disease that becomes
manifest in midlife and is characterised by motor disturbances, cognitive decline
and behavioural dysfunction. HD is caused by the abnormal expansion of a trinu-
cleotide (CAG) repeat in the gene for the protein huntingtin1. The genetic defect
leads to cerebral cell death, especially in the basal ganglia. Although the clinical
diagnosis of HD is based on the first appearance of motor signs, a positive family
history and confirmation by DNA-testing, subtle changes in motor function, cog-
nition and behaviour are known to precede manifest disease. Detecting these very
early changes is of importance in the development of instruments to monitor early
therapeutic intervention trials and to obtain more insight into the phase of clinical
disease onset.
Cross-sectional reports showed that carriers of the HD gene mutation without
manifest motor signs (further labelled as carriers) perform significantly worse than
non-carriers on certain motor scores, neuropsychological tests and behavioural as-
sessments2 3 4 5 6 7 8 9 10 11. Furthermore, some studies showed relationships between
fewer years to estimated onset of diagnosable clinical disease and worse motor and
cognitive function2 7 12 13 14.
Longitudinal follow-up is however necessary to really understand the pattern of
evolving motor, cognitive and behavioural abnormalities in the phase of HD clini-
cal onset. First of all, to find out if clinical markers that are sensitive in detecting
premanifest abnormalities show a decline over time and might be suitable as out-
come measures in future therapeutic trials. Secondly, to monitor whether carriers,
converting to manifest HD, display specific clinical changes.
To date, several longitudinal studies have been undertaken. The duration of follow-
up however has been brief in the vast majority of longitudinal studies and results
show discrepancies. In accordance with other studies we failed to demonstrate
clinical markers for premanifest HD in our previous 3-year follow-up study15 16 17.
Others did detect a significant decline over time in motor function, executive func-
tion, attention and memory18 19 20 21. The longest follow-up study to date (10
years) demonstrated that the most rapid decline on motor and cognitive domains
was found in individuals approaching clinical disease onset13.
With the present observational study we aim to give more insight in the clinical on-
set phase of the disease as the number of reports on clinical decline in premanifest
HD using long-term follow-up with a comprehensive assessment battery is limited.
The objective was to follow a premanifest HD carrier group for 7 years in order
to determine if our assessment battery detects subtle clinical changes preceding
diagnosable clinical HD. Furthermore, we examined whether the rate of decline on
motor, cognitive and behavioural measures could be related to estimated proximity
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to diagnosable clinical disease.
METHODS
Participants
In the original study, 134 participants were included (46 premanifest carriers, 88
non-carriers). They were referred to the Leiden University Medical Centre (LUMC)
Department of Clinical Genetics, for predictive testing, and consented to partic-
ipate in a three-year clinical follow-up study17. Carriers were considered to be
premanifest in the absence of unequivocal motor signs on the Unified Hunting-
ton‘s Disease Rating Scale (UHDRS)22. A neurologist who was blind to genetic
status and trained in the administration of the UHDRS performed the motor exam-
ination and filled in a score ranging from 0-3 (0= normal, 1= minor soft signs, 2=
probable HD, 3= unquestionable HD). Carriers with a rating of 3 at baseline were
diagnosed with HD and excluded from the study. One hundred six participants (33
carriers, 73 non-carriers) attended all follow-ups in the three-year period. Seven
years after the start of the original study these participants were invited to take
part in an additional follow-up. Twenty-nine carriers and 44 non-carriers consented
to continue follow-up. Four carriers and 29 non-carriers did not re-enter the study
after the original three year follow-up (Figure 1). One non-carrier was excluded for
analyses since he had a minor stroke. This seven year follow-up study, therefore,
reports on 29 carriers who were premanifest at baseline, and 43 non-carriers who
served as controls. Carriers who were rated as unquestionable HD on the UHDRS
after seven years were considered converters to manifest HD. The study was ap-
proved by the local Medical Ethical Committee. Written informed consent was
obtained from all participants.
Procedure
All participants were evaluated with the UHDRS, including motor and behavioural
assessment, and an extensive set of neuropsychological tests covering global cog-
nitive function, memory, language and executive function (Tables 2 and 3)17 22.
The number of estimated years to clinical diagnosis (EYTD) was calculated using
a CAG- and age-based predictive model designed by Langbehn et al.23.
Motor assessment
The UHDRS motor rating was filled in by a neurologist (range 0-3). A Total Mo-
tor Score (TMS) was calculated by summing all motor items of the UHDRS17.
Analysis of TMS subscales was restricted to eye movement, voluntary movement
and chorea22.
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Neuropsychological assessment
Neuropsychological tests included Mini Mental State Examination (MMSE)24;
Wechsler Adult Intelligence Scale-Revised (WAIS-R)25 subtests Information, Digit
span, Arithmetic, Picture arrangement, Block design; Wechsler Memory Scale
(WMS)26; Verbal fluency (FAS)27; Boston naming test28; Symbol Digit Modali-
ties Test (SDMT)29; Trail Making Test30, consisting of a simple (TMT-A) and a
more complex (TMT-B) version; Stroop colour-word test31. Reaction time mea-
sures were both derived from a simple reaction time paradigm and a complex
‘choice’ reaction time paradigm (go/no go paradigm)32. A psychologist adminis-
tered the cognitive tests17.
Behavioural assessment
Behavioural and mood complaints were limited to the total behavioural score
(TBS) that was obtained by adding the products of the frequency and severity
for each item from the behavioural assessment of the UHDRS, administered by a
psychologist11. Analysis of individual items from the behavioural assessment were
restricted to four frequently reported neuropsychiatric symptoms; sadness, anxiety,
aggression and irritability33.
Statistical analysis
SPSS for Windows (release 16.0) was used for data analysis. Cross-sectional group
differences at baseline and after 7 years were analysed with parametric or non-
parametric tests when appropriate. Clinical group comparisons were corrected for
age at assessment using ANCOVA. For longitudinal analyses we used the method
reported by Solomon et al. (2008) since it accounts for slight differences in follow-
up period. For each clinical score the change over the 7-year period was calculated
for each participant. This Rate of Change (further labelled as RoC) was com-
puted as follows: RoC= (score2-score1)/ (age2-age1). Differences in RoC between
carriers and non-carriers were analysed using ANCOVA with correction for age at
baseline. To assess the relationship between EYTD and RoC, Pearson correla-
tion coefficients were calculated. The level of statistical significance was set at
p≤0.01. A more liberal level of significance of 0.01<p≤0.05 was also reported
to be of marginal interest to maximize any opportunity of finding trends towards
group differences. Effect sizes are displayed as partial eta squared values (pη
2),
eta squared values (η2) and r -values.
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RESULTS
Group characteristics at study entry
The mean time interval between baseline and seven-year follow-up was 7.3 years
(range 6.3-8.5 years). The group characteristics are described in Table 1. Carriers
were younger than non-carriers (p= .015, η2= .082). No group differences emerged
for gender and education.






Male/femalea 11/18 18/25 ns
Age (years) 37.9 (9.1) 43.8 (10.4) 0.015
Education (years) 12.0 (2.9) 11.9 (2.8) ns




Note. Values in the table are means with SD or rangeb between parentheses. Independent t-tests
were used except where Pearson χ2-test was used a.
Cross-sectional results
Carriers did not differ from non-carriers with respect to the UHDRS motor rating
at baseline (p= .99, r= -0.002) or after seven years (p= .12, r= -0.192) (Table
2). Five carriers (17%) converted to unquestionable HD on the UHDRS during
follow-up. Two converters were rated as normal at baseline. Three converters
were rated as probable HD at baseline. One carrier who was rated as probable
HD at baseline was rated as normal after 7 years. Three non-carriers were rated
as probable HD at baseline and five after 7 years. None of the non-carriers was
rated as unquestionable HD. From the three carriers where motor assessment was
missing at baseline, two were rated as normal after 7 years and one carrier showed
minor soft signs.
Mean clinical scores are displayed in Table 3. At baseline, carriers showed more
complaints in aggression than non-carriers (p= .024, pη
2= .073). They also per-
formed worse on the WAIS-R arithmetic subsection (p= .031, pη
2= .065), SDMT
(p=.002, pη
2= .128), TMT-A (p= .006, pη
2= .104), TMT-B (p= .024, pη
2=
.072), Stroop word (p= .008, pη
2= .097) and Stroop interference (p=.01, pη
2=
.089). After seven years carriers additionally showed more motor abnormalities
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compared to non-carriers on the UHDRS TMS (p= .012, pη
2= .096), and on
the UHDRS eye movement (p= .026, pη
2= .076), voluntary movement (p= .029,
pη
2= .073) and chorea subsection (p= .005, pη
2= .118). Also, worse scores on
the MMSE (p= .015, pη
2= .083), WMS memory quotient (p= .001, η2= .147),
WMS concentration (p= .001, pη
2= .161), WMS logical memory (p= .025, pη
2=
.07) WMS visual reproduction (p= .042, pη
2= .059) and Stroop colour (p= .009,
pη
2= .097) emerged in carriers. Cross-sectional differences at baseline on aggres-
sion and Stroop word could not be demonstrated after seven years. Without the
five carriers who converted to manifest HD, baseline differences remained, except
for TMT-B (p= .144, pη
2= .033). In the analyses after seven years, differences
remained only on UHDRS TMS (p= .04, pη
2= .071) WMS memory quotient
(p=.007, η2= .105), WMS concentration (p=.006, pη
2= .114) and Stroop colour
(p= .027, pη
2= .075).
Table 2: Frequencies of UHDRS motor ratings in carriers and non-carriers at









UHDRS rating Baseline Seven years Baseline Seven years
Normal 19 15 29 24
Minor soft signs 3 5 9 8
Probable HD 4 4 3 5
Unquestionable HD - 5 - -
Note. Values are expressed as number. UHDRS= Unified Huntington‘s Disease Rating Scale.
Out of 29 carriers 3 motor assessments were missing at baseline. Out of 43 non-carriers two









Table 3: Mean (SD) performances on motor, behavioural and cognitive assessment at baseline and seven-year follow














UHDRS TMS 6.9 (7.8) 6.3 (5.7) .124 .037 8.0 (15.5) 2.8 (2.7) .012* .096
Eye movement 2.2 (3.3) 1.9 (2.8) .113 .039 1.8 (4.2) 0.9 (1.3) .026* .076
Voluntary mov. 2.1 (2.1) 1.9 (2.0) .135 .035 2.1 (3.9) 0.9 (1.3) .029* .073
Chorea 1.2 (2.5) 0.9 (2.1) .363 .013 2.6 (5.2) 0.5 (0.8) .005** .118
Behaviourb
UHDRS TBS 9.0 (13.4) 5.2 (7.2) .484 .007 9.6 (13.1) 8.1 (12.6) .786 .001
Sadness 1.9 (2.8) 1.3 (2.2) .989 .00 2.0 (3.2) 2.0 (3.0) .436 .009
Anxiety 1.3 (2.7) 1.0 (1.9) .702 .002 1.8 (2.8) 1.3 (2.5) .873 .00
Aggression 1.5 (3.0) 0.2 (0.8) .024* .073 1.6 (3.0) 0.8 (2.3) .558 .005
Irritability 1.4 (2.8) 1.0 (2.1) .696 .002 1.6 (2.7) 1.7 (2.7) .383 .011















Table 3: (Continued) Mean (SD) performances on motor, behavioural and cognitive assessment at baseline and














MMSE 28.2 (1.1) 28.6 (1.3) .248 .019 28.3 (1.3) 29.0 (1.2) .015* .083
W-R Information 10.4 (3.0) 10.8 (1.8) .932 .00 10.6 (2.8) 10.9 (2.0) .899 .00
W-R Digit span 8.1 (2.6) 8.9 (2.2) .076 .045 8.4 (3.0) 9.3 (2.1) .078 .044
W-R Arithmetic 10.6 (3.3) 12.3 (2.5) .031* .065 10.6 (3.4) 12.4 (2.6) .023* .073
W-R Picture arr. 8.8 (2.5) 9.2 (2.6) .217 .022 9.3 (2.7) 9.2 (3.1) .347 .013
W-R Block design 11.8 (3.0) 11.7 (2.9) .591 .004 11.6 (3.3) 11.9 (2.9) .118 .036
WMS MQa 115.2 (15.6) 122.1 (14.7) .062 .05 113.8 (19.0) 127.8 (15.3) .001** .147
WMS Concent. 7.7 (1.8) 8.4 (1.2) .107 .037 6.8 (2.1) 8.4 (1.2) .001** .161
WMS Logic. mem. 9.4 (3.1) 10.1 (3.2) .237 .02 8.2 (3.3) 10.0 (3.6) .025* .07
WMS Visual rep. 11.1 (2.3) 11.2 (2.2) .686 .002 10.2 (3.3) 11.2 (2.2) .042* .059
WMS Ass. learning 18.0 (2.2) 18.0 (2.6) .719 .002 17.2 (2.9) 17.5 (3.0) .600 .004
WMS Verbal fluency 33.7 (9.4) 34.2 (11.5) .869 .000 34.8 (14.0) 37.4 (12.0) .387 .011
Boston naming 26.6 (2.6) 26.1 (4.6) .712 .002 27.1 (2.5) 27.7 (2.0) .308 .015
SDMT 48.2 (10.8) 53.2 (10.1) .002** .128 53.3 (15.8) 58.7 (10.5) .006** .103









Table 3: (Continued) Mean (SD) performances on motor, behavioural and cognitive assessment at baseline and














TMT-A (sec)b 38.3 (14.8) 31.2 (9.4) .006** .104 33.0 (17.6) 28.4 (9.4) .035* .063
TMT-B (sec)b 59.6 (22.9) 51.4 (17.4) .024* .072 66.1 (47.1) 52.1 (23.2) .017* .079
Stroop colour 74.0 (11.7) 77.4 (10.8) .054 .053 71.5 (14.6) 77.6 (13.3) .009** .097
Stroop word 95.5 (16.5) 103.4 (14.4) .008** .097 96.1 (20.4) 101.2 (15.7) .086 .043























Note. Mean scores (SD). Raw scores are displayed except for WMS memory quotient, which is calculated with a correction for age. ANCOVA
corrected for age except for a. *p≤ .05, **p ≤.01. Effect sizes are displayed as partial eta squared (pη2) values. bHigher scores correspond
with worse performance. MMSE=Mini Mental State Examination, MQ=Memory Quotient, RT=Reaction time; simple=reaction time single
stimulus conditions; complex=reaction time complex conditions, SDMT=Symbol Digit Modalities Test (number correct), TBS=Total
Behavioural Score, TMS=Total Motor Score, TMT=Trail Making Test, UHDRS=Unified Huntington‘s Disease Rating Scale. WMS=Wechsler
Memory Scale, W-R=Wechsler Adult Intelligence Scale-Revised.
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Longitudinal results
The Rates of Change (RoC) on the motor, behavioural and cognitive tests are
displayed in Table 4. Carriers demonstrated a greater rate of decline compared to
non-carriers on the UHDRS TMS (p= 0.024, pη
2= .083) and chorea subsection
(p= .008, pη
2= .114), the WMS memory quotient (p= .015, pη
2= .084), WMS
concentration (p= .007, pη
2= .101) and WMS visual reproduction (p= .045, pη
2=
.057). Without the carriers who converted to manifest HD, the only remaining
significant decline in carriers compared to non-carriers was on WMS concentration
(p= .041, pη
2= .063).
Associations between estimated years to clinical diagnosis and
Rates of Change
Table 5 shows that proximity to estimated clinical diagnosis (EYTD) in carriers
was associated with a greater rate of decline on WAIS-R Information (p= .033, r=
.397), WMS memory quotient (p= .024, r= .426) (Figure 2), WMS concentration
(p= .034, r= .396), WMS logical memory (p= .016, r= .444), WMS visual
reproduction (p= .012, r= .461) and Reaction time complex condition (p= .046,
r= -.410). Excluding the carriers who converted to manifest HD, associations
remained between EYTD and rate of decline on WMS memory quotient (p= .045,
r= .421), WMS logical memory (p= .028, r= .448) and WMS visual reproduction
(p= .005, r= .553).
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Table 4: Mean (SD) Rate of Change (RoC) in carriers and non-carriers between












UHDRS TMS 0.217 (1.440) -0.475 (0.639) .024* .083
Eye movement -0.037 (0.401) -0.141 (0.294) .431 .011
Voluntary movement 0.012 (0.375) -0.149 (0.252) .103 .045
Chorea 0.235 (0.523) -0.052 (0.328) .008** .114
Behaviourb
UHDRS TBS 0.164 (2.178) 0.380 (1.485) .634 .003
Sadness 0.025 (0.581) 0.093 (0.313) .634 .003
Anxiety 0.079 (0.556) 0.043 (0.326) .554 .005
Aggression 0.019 (0.457) 0.084 (0.321) .388 .011
Irritability 0.039 (0.493) 0.091 (0.375) .401 .010
Neuropsychology
MMSE 0.012 (0.213) 0.057 (0.200) .319 .014
W-R Information 0.030 (0.236) 0.007 (0.129) .706 .002
W-R Digit span 0.048 (0.260) 0.057 (0.225) .994 .000
W-R Arithmetic -0.006 (0.321) 0.016 (0.296) .728 .002
W-R Picture arrangement 0.067 (0.255) 0.004 (0.314) .745 .002
W-R Block design -0.028 (0.314) 0.035 (0.228) .156 .029
WMS MQa -0.265 (1.813) 0.760 (1.593) .015* .084
WMS Concentration -0.134 (0.236) 0.004 (0.148) .007** .101
WMS Logical memory -0.170 (0.369) -0.015 (0.298) .065 .049
WMS Visual reproduction -0.129 (0.327) 0.008 (0.313) .045* .057
WMS Associative learning -0.119 (0.330) -0.046 (0.368) .656 .003
WMS Verbal fluency (FAS) 0.187 (1.181) 0.428 (1.131) .174 .027
Boston naming test 0.074 (0.193) 0.211 (0.622) .351 .013
SDMT 0.709 (1.440) 0.723 (0.780) .827 .001
TMT-A (seconds)b -0.781 (2.073) -0.375 (1.105) .446 .008
TMT-B (seconds)b 0.860 (4.552) 0.088 (2.364) .172 .027
Stroop colour -0.325 (1.478) 0.027 (0.985) .125 .034
Stroop word 0.112 (1.730) -0.369 (1.409) .300 .016
Stroop interference -0.077 (1.201) 0.071 (0.775) .470 .008
RT simple (milliseconds) 6.706 (11.411) 4.229 (7.995) .627 .004
RT complex (milliseconds) 7.893 (8.229) 8.953 (12.164) .796 .001
Note. Mean RoC (SD). ANCOVA corrected for age at baseline. *p≤.05, **p≤.01. Effect sizes
are displayed as partial eta squared (pη2) values. Positive scores indicate an improvement over
time and negative scores indicate deterioration over time, except for b where positive scores
indicate deterioration and negative scores indicate an improvement. MMSE= Mini Mental State
Examination, MQ= Memory Quotient, RoC= Rate of Change, RT= Reaction time; simple=
reaction time single stimulus conditions; complex= reaction time complex conditions, SDMT=
Symbol Digit Modalities Test (number correct), TBS= Total Behavioural Score, TMS= Total
Motor Score, TMT= Trail Making Test, UHDRS= Unified Huntington‘s Disease Rating Scale.
WMS= Wechsler Memory Scale, W-R= Wechsler Adult Intelligence Scale-Revised.
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Table 5: Correlations between estimated years to clinical diagnosis (EYTD)
and rate of Change (RoC) in carriers
r -value P-value
Motorb
UHDRS TMS -.266 .189
Eye movement -.264 .193
Voluntary movement -.218 .286
Chorea -.222 .276
Behaviourb







W-R Information .397 .033*
W-R Digit span .082 .672
W-R Arithmetic .338 .073
W-R Picture arrangement .124 .529
W-R Block design .267 .170
WMS MQa .426 .024*
WMS Concentration .396 .034*
WMS Logical memory .444 .016*
WMS Visual reproduction .461 .012*
WMS Associative learning -.002 .990
WMS Verbal fluency (FAS) .089 .645
Boston naming test .130 .501
SDMT .289 .129
TMT-A (seconds)b -.171 .376
TMT-B (seconds)b -.328 .082
Stroop colour .166 .398
Stroop word .345 .067
Stroop interference -.022 .910
RT simple (milliseconds) -.214 .315
RT complex (milliseconds) -.410 .046*
Note. Pearson correlation coefficients (r-value) with *p≤.05. Positive scores indicate an im-
provement over time and negative scores indicate deterioration over time, except for b where
positive scores indicate deterioration and negative scores indicate an improvement. MMSE=
Mini Mental State Examination, MQ= Memory Quotient, RT= Reaction time; simple= reaction
time single stimulus conditions; complex= reaction time complex conditions, SDMT= Symbol
Digit Modalities Test (number correct), TBS= Total Behavioural Score, TMS= Total Motor
Score, TMT= Trail Making Test, UHDRS= Unified Huntington‘s Disease Rating Scale. WMS=
Wechsler Memory Scale, W-R= Wechsler Adult Intelligence Scale-Revised.
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DISCUSSION
This longitudinal study with a follow-up of seven years demonstrated a significant
decline in motor functioning, memory, and concentration in premanifest carriers of
the HD gene mutation. Cognitive changes over time could be primarily ascribed
to carriers who converted to manifest HD.
Cross-sectional results at baseline were comparable to previous studies demonstrat-
ing abnormalities in carriers in executive function, specifically attention, cognitive
flexibility, psychomotor speed, and inhibitory processes, as assessed with WAIS-R
arithmetic, SDMT, TMT and Stroop5 6 34. Without the carriers who converted
to manifest HD during the study, cognitive abnormalities at baseline could still
be demonstrated. This indicates that subtle cognitive deviations, especially on
executive functions, are present, even long before the onset of HD motor signs and
may be related to early deficits in the basal-ganglia circuitry15 35. After seven years
additional cross-sectional differences emerged, with carriers showing more motor
abnormalities on the UHDRS motor section and worse performance on memory
and concentration tasks from the WMS, compared to non-carriers2 6 7 10 13.
Remarkably, we could not demonstrate a significant decline on the executive tasks
that proved sensitive for the earliest cognitive manifestations of HD at baseline.
Also, we did not find an association between estimated years to clinical diagnosis
and rate of change on these tasks. Practice effects on these type of tasks and fa-
miliarity with the test procedures might compensate for subtle cognitive deficits19.
This is important for the interpretation of longitudinal data. A follow-up study by
Paulsen et al. (2001) showed an improvement on executive tasks in individuals
at-risk for HD and a decline in converters36. This is in accordance with our finding
that differences between groups at follow-up, could be ascribed in particular to car-
riers who converted to manifest HD during the study. Indeed, previous longitudinal
studies that did demonstrate a decline on these tasks displayed a much higher rate
of carriers converting to manifest HD20 21 36 37. Duff et al. (2007) suggest that the
amount of individual practice effects in longitudinal studies might provide valuable
information on cognitive status and predict long-term cognitive outcome38.
The WMS memory quotient shows an absence of practice effects in carriers com-
pared to non-carriers, suggesting cognitive dysfunction in carriers. Indeed, we did
demonstrate a decline in memory function and concentration on the WMS com-
pared to non-carriers. These changes over time could be attributed to the carriers
who converted to manifest HD, except for the decline on the concentration subtest.
Also, when estimations of age at clinical diagnosis were used, an association with
rate of change on the WMS could be demonstrated. Memory decline in individuals
approaching clinical disease onset is confirmed by other studies7 12 13. The fact that
we could not detect cross-sectional differences between carriers and non-carriers at
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baseline on memory tasks is in line with the observation by Snowden at al. (2002)
that memory function shows a precipitous decline around the time of clinical on-
set20. Perhaps, concentration changes evolve more slowly and precede the effect
on memory tasks. It can be argued, however, that the concentration subtest of
the WMS does not reflect selective attention but rather general cognitive slowing,
since it is a timed task.
Interestingly, many longitudinal studies reported mainly on motor and executive
tasks, specifically psychomotor speed and cognitive flexibility21 36 39. This is also
reflected in the broadly used UHDRS cognitive section that is highly influenced
by motor speed. Our findings confirm the importance of these tasks in detecting
premanifest abnormalities. However we advocate the addition of memory tasks for
this purpose since memory decline may be a sign of conversion to manifest HD
and these tasks have the advantage to lack the motor component.
Behavioural changes could not be demonstrated in the current study. Complaints
about aggression on the UHDRS behavioural section at baseline disappeared in sub-
sequent years and confirm the variability in occurrence of psychiatric symptoms17.
Furthermore, as many objective, quantitative cognitive tasks are available, these
are more prominently represented in the present study design. In current studies,
more attention is paid to behavioural and mood changes using extensive batteries
of neuropsychiatric questionnaires including the Problem Behaviours Assessment
for Huntington Disease (PBA-HD)8 40. Also, in motor functioning more continuous
measures of motor function should be included in clinical studies since reliability of
the UHDRS motor assessment is somewhat limited, especially when motor signs
are very subtle41. This is reflected in the large number of non-carriers in our study
that are rated with minor soft signs or probable HD. Converters to manifest HD
in the current study mainly developed signs of chorea. We suggest that the ap-
pearance of subtle choreatic movements is an important specific feature for the
motor examiner when diagnosing unquestionable HD. In a recent study, quanti-
tative voluntary neurophysiological motor tasks proved sensitive for subtle motor
deficits in carriers more than a decade before estimated clinical onset and might
be used more commonly in premanifest HD research8.
In the evaluation of longitudinal results of the current and previous studies, many
discrepancies appear. Heterogeneity in closeness to clinical disease onset within
and between studies and differences in the studied measures are probably the
most important factors. Follow-up studies should show international uniformity
in inclusion criteria and assessment protocol. Furthermore, longitudinal studies
combining clinical and biological measures will provide more insight into the pro-
cesses underlying clinical changes and may lead to a combination of measures
suitable for objectively tracking premanifest HD. Ongoing international, multi-
centre, multidisciplinary trials are an important example in improving research
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on the subject and in realising fast recruitment of study samples with sufficient
power. PREDICT-HD6, TRACK-HD8, COHORT (http://www.huntington-study-
group.org/ClinicalReserach/ClinicalTrialsObservationalStudiesinProgress/
COHORT/tabid/83/Default.aspx) and REGISTRY (http://www.euro-hd.net/html
/registry) are longitudinal observational studies on clinical and biological markers in
the evolution of HD. Longitudinal data on these impressive studies will contribute
substantially to the knowledge on the phase of onset of HD.
Conclusion
Standardized motor assessments and objective memory and concentration tasks
prove sensitive for change, specifically in the phenoconversion phase. Executive
tasks were found to be sensitive for subtle cognitive abnormalities in premanifest
HD, a decline over time could, however, not be demonstrated on these tasks.
Strengths of the current study are the lengthy follow-up and the comprehensive
assessment battery, enabling us to detect changes over time. For the purpose of
therapeutic trials, however, suitable instruments are still needed to track changes
over shorter intervals. Extended follow-up periods appear useful only for clinical
purposes since information about clinical disease onset and progression is of crucial
importance in improving the psychosocial support for patients and their families.
Because of discrepancies between studies and the discontinuous evolvement of clin-
ical changes, uniformity in international research through multi-site collaborative
research models will improve premanifest HD research substantially and point to
a selection of specific clinical measures sensitive to change in premanifest HD.
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Abstract
Background Cognitive decline in Huntington‘s disease (HD) remains an area of
inconsistencies, especially far from disease onset.
Objective To clarify the course of cognition in premanifest HD.
Methods Twenty-six premanifest HD, 19 manifest HD, and 87 control subjects
were followed for ten years, using an extensive cognitive battery. Differences in
baseline levels and change over time, on four factors (motor speed, global cog-
nition, executive functioning (EF), and memory) were examined, using multilevel
regression analyses. Converters were additionally analysed as a separate group.
Also, the influence of motor speed and predicted years to disease onset on the
cognitive factors was studied.
Results Manifest HD subjects showed lower baseline scores compared to controls
on the motor speed (p=0.002), memory (p<0.001) and EF (p<0.001). They
additionally deteriorated over the ten-year follow-up on memory (p=0.01). Con-
verters deteriorated on EF (p=0.04). Further analyses of premanifest subjects far
from and close to predicted onset revealed lower baseline scores for the close group
on EF, as compared to controls (p=0.001). They also deteriorated on memory
(p=0.01). Motor speed substantially mediated the results of the three cognitive
factors; when added as covariate to the model several baseline and slope differ-
ences for the cognitive factors ceased to be significant.
Conclusions Memory and EF are highly sensitive for ascertaining deterioration in
premanifest HD gene carriers, especially in subjects close to onset. Lack of dete-
rioration for the subjects further away from onset suggests that both domains are
largely unaffected in those far from onset. Also, motor influence on cognition is
substantial and should be taken into account in cognitive HD research.
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INTRODUCTION
Huntington‘s disease (HD) is an autosomal dominant neurodegenerative disease
causing selective neuronal damage resulting in motor abnormalities, psychiatric dis-
turbances and cognitive decline1. Due to its genetic basis subjects at risk for HD
can be tested for presence of the HD gene2. Consequently, gene carriers without a
clinical diagnosis of disease onset, so-called premanifest carriers, can be identified
and studied. In recent years the transition from premanifest to manifest HD has
become a main area of interest. As we move forward towards clinical trials with
possible disease modifying effects it is important to better understand the course
of HD symptoms, including that of cognition.
Since the localization of the HD gene3 a large number of studies on cognition in
premanifest HD have been published. Many cross-sectional studies have reported
differences between premanifest and control subjects, with defective emotion recog-
nition and reduced psychomotor speed being the most robust findings4 5 6. Con-
cerning attention, memory and executive functioning inconclusive findings have
been reported. For example, Verny et al.7 found premanifest deficits on executive
functioning and memory tasks compared to controls, whereas Witjes-An et al.8 and
Soliveri et al.9 did not report such differences. In subjects close to their predicted
age of disease onset, memory and executive deficits have been quite consistently
found. In individuals further from predicted onset results are less robust, although
psychomotor speed reduction and impaired emotion recognition have been ob-
served10 11.
Few studies have assessed cognitive functioning in HD during follow-up periods of
more than five years12 13 14 15, despite the potentially informative nature of longer
longitudinal studies, given the slow progressive nature of HD. These studies showed
large differences in the kind and extent of the included cognitive batteries, duration
of follow-up and number of participants included. Moreover, results are heteroge-
neous. Snowden et al.12 found that colour naming on the Stroop task declines,
Jurgens et al.15 reported diminished concentration on a subtest of the Wechsler
Memory Scale, in contrast to Brandt et al.13 who found no cognitive decline over
time.
As the development and progression of cognitive impairment associated with pre-
manifest HD remains an area of uncertainty, specifically in the period far from
disease onset, longitudinal research with substantial follow-up periods and com-
prehensive test batteries is important to increase our understanding of cognitive
functioning in this critical period in HD. We assessed cognitive functioning at five
time points during ten years of follow-up, allowing us to model the course of cog-
nitive functioning and to compare the decline of (pre)manifest HD subjects with
that of healthy controls. During the follow-up period we expect the HD groups
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to decline on tasks of memory and executive functioning compared to controls.
For further analyses the premanifest group will be divided in those who converted
to manifest disease over the study period, and those who remained premanifest.
Furthermore, we will investigate the difference in cognitive change between pre-
manifest HD subjects far from predicted disease onset and those close to onset as
compared to controls, as we hypothesized that the predicted duration until disease
onset at baseline is inversely associated with the rate of decline on certain cognitive
scores. The effect of motor functioning on cognition will also be investigated.
METHODS
Subjects
At baseline 134 subjects participated (46 gene-carriers, 88 controls)8 (Figure 1),
106 completed three-year follow-up16 and 72 participants completed seven-year
follow-up15. Ten-year follow-up was completed by 68 participants (26 gene carri-
ers, 42 controls). In this study we investigated all subjects over ten-year follow-up.
Gene carriers were grouped at baseline into either premanifest HD gene carriers or
manifest HD patients using the total motor score (TMS) of the Unified Hunting-
ton‘s Disease Rating Scale (UHDRS)17: subjects with scores below 6 points were
considered to be premanifest, scores of 6 and higher were considered manifest18.
Control subjects were tested non gene-carrying relatives.
Drop-outs over the ten-year period are described in Figure 1. Of the 134 subjects
one female gene-carrier was excluded from analyses as the TMS was not ascertained
at baseline, precluding a correct assignment to one of the HD groups. One male
control was excluded as he suffered from cardiovascular disease and consequent
cognitive dysfunction. The remaining 132 subjects were included and grouped as
follows: 19 manifest HD, 26 premanifest HD (of whom 5 converted to manifest
HD over the study period), and 87 control subjects.
Predicted years to disease onset were estimated using the formula by Langbehn
et al.19. The formula (age*(CAG repeat length-35.5)) was used to calculate dis-
ease burden for the HD groups. The sadness score of the UHDRS behavioural
section was used as depression measure. The study was approved by the local
ethics committee and all participants gave written informed consent according to
the Declaration of Helsinki.
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Figure 1: Flowchart of the participants and drop-outs over 10 years of follow-up
Procedure
Following the baseline visit subjects attended follow-up visits after 18 months,
three, seven and ten-years. During baseline, three and ten-year follow-up visits
an extended cognitive battery was administered. For 18 months and seven-year
follow-up a shorter battery was applied.
All participants underwent UHDRS motor, behavioral and functional assessments
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at all visits. The motor part was administered by a trained clinician. The cog-
nitive battery included tests objectifying almost all cognitive domains. For global
functioning the Mini Mental State Examination (MMSE) and the Wechsler Adult
Intelligence Scale revised (WAIS-R) were used, the latter generating a total intelli-
gence quotient (TIQ), performance (PIQ) and verbal (VIQ) intelligence quotients.
Memory tests included the Wechsler Memory Scale (WMS) and the Dutch ver-
sion of the California Verbal Learning test, namely the ‘Verbale Leer- en Geheugen
test (VLGT)’. From the WMS a memory quotient (MQ) can be derived. The
VLGT consists of a main list to be learned (list A) and directly reproduced, and
an interference condition (list B). Subjects are tested on direct recall, short term
recall, long term recall and long term recognition. The Boston Naming (BNT)
task was used for measuring picture naming abilities. For executive functioning
the Stroop test (color, word and interference conditions), Symbol Digit Modalities
test (SDMT), letter fluency (‘f’, ‘a’, ‘s’), and Trail Making test (TMT) (A and
B) were used. A reaction time (RT) test, where participants were instructed to
react as quickly as possible by releasing a ‘rest’ button and pressing a reaction
button after hearing a tone (condition 1, 14 times) and seeing a light (condition
2, 14 times), was administered resulting in a RT score, from now on referred to
as ‘motor speed’. For detailed description of study procedures see Witjes-Ané et
al.8.
Statistical analyses
IBM SPSS for Windows 20.0 was used for data analysis. Group comparisons
for demographic variables were done using ANOVA, χ2 and Kruskal-Wallis tests
for continuous, categorical and skewed data, respectively. Data pre-processing
involved reverse coding for TMT A&B and RT and logarithm (loge) transforma-
tion of non-normally distributed scores (i.e. TMT A&B, MMSE, BNT, and the
short- and long-term recall and recognition subtests of the VLGT). For longitudinal
analyses all cognitive scores were standardized to z-scores. These z-scores were
subsequently combined into factors by averaging the component test results.
To make the data on the extensive cognitive battery more comprehensible and to
reduce Type I error caused by multiple testing (19 individual cognitive tests were
administered) we decided to perform a factor analysis to combine inter-correlated
cognitive tests into factors. Based on results from previous cognitive studies in HD,
we were interested in the progression of performance on one motor construct and
three cognitive constructs (global cognitive functioning, memory, executive func-
tioning) in our cohort. The tests that are known, according to existing cognitive
HD research, to capture these constructs were pre-selected to be entered in the
factor analysis. The correlation coefficients of the variables had to be substantially
large (correlation coefficient 0.30) to be assigned to a specific factor. Principal
components analysis (using varimax orthogonal rotation) revealed four factors: (1)
‘motor speed’ (i.e., RT z-score) (2) ‘global cognition’ (composed of WAIS TIQ,
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MMSE, verbal fluency), (3) ‘memory’ (composed of WMS MQ, VLGT list A, list
B, short- and long-term recall and recognition) and (4) ‘executive functioning’
(composed of SDMT, Stroop interference, TMT B).
Because the time points were dependent for each participant, multilevel regression
analyses (i.e. linear mixed models) were used to investigate differences in baseline
levels and slopes between groups on the four factors. Firstly, a crude model was
constructed (model 1). Secondly, a multivariate model was constructed adjusting
for age, gender, and the three categories of education (model 2). Lastly, we re-
peated the multilevel regression analyses for the three cognitive factors, in which
we additionally adjusted for motor speed, in order to study the pure effect indepen-
dent from the decline in reaction time20 (model 3). We calculated the strength
of the mediating effects of motor speed by averaging the percentage change in
beta-coefficients of the significant test results between models 2 and 3. In the
multilevel analyses we used a compound symmetry covariance structure consisting
of up to five time points (i.e. lower level) and the subjects (i.e. higher level).
The four factors were used as continuous variables, and standardized mean differ-
ences versus controls (with standard error [SE]) are presented (Figure 2). Main
analyses compared the whole premanifest HD group and the manifest HD group
to controls for differences at baseline and rate of decline (i.e. slope; time*group
interaction effects). Secondary analyses involved the premanifest HD group being
divided into those who continued to be premanifest during the study, i.e. contin-
ual premanifest HD, and those who converted to manifest HD, i.e. converters, for
comparison to controls. Additionally, the subjects whom were in the premanifest
HD group at baseline were divided into ‘close to onset’ and ‘far from onset’ using a
median-split of ‘predicted years to onset’ (median is 15.2 years), and compared to
controls to test for possible influence of closeness to predicted disease onset on the
cognitive factors. Post-hoc multilevel analysis on the separate cognitive tests were
performed to investigate which cognitive tests are responsible for significant results
in the factor analyses. Beta-coefficients in the tables can be interpreted as follows:
baseline differences refer to how many standard deviations an HD group differs
from the controls at baseline, and slope differences refer to how many standard
deviations the change in the HD groups differed from the change in the control
group over the ten-year period. All tests were two-tailed with p<0.05 denoting
statistical significance.
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Figure 2: Scores for continual premanifest HD, converters, manifest HD and controls on
the cognitive factors over 10-years of follow-up
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RESULTS
Baseline demographics
The mean (± SD) age at baseline of the whole group of HD subjects combined
was 39 (± 11) years and 64% were female (Table 1). At baseline the groups
were comparable for gender, educational level, total functional capacity (TFC),
and depression scores. premanifest HD subjects were younger than manifest HD
(p=0.03) and control (p=0.04) subjects. The manifest HD group had a higher
TMS than the controls (p<0.001). The burden of the manifest HD subjects was
higher compared to the premanifest HD subjects (p=0.008). Raw cognitive scores
are given in supplementary Table 1.
The subjects who completed the ten-year follow-up (n=68) were comparable to the
drop-outs (n=64) on age at baseline (p=0.92), gender (p=0.48) and education
(p=0.12). The drop-outs showed lower TFC (p=0.006) and higher TMS scores
(p=0.02) (data not shown).








Age, yrs 42 (11) 35 (7) 44 (14) 0.02
Gender, m/f 39 (45)/48 (55) 7 (27)/19 (73) 9 (47)/10 (53) 0.23
CAG repeat length 20 (4) 43 (3) 44 (3) <0.001
Higher education 27 (31) 9 (35) 4 (21) 0.12
Depression score 0 (0; 1) 0 (0; 2) 0 (0;1) 0.06
TMS 6 (7) 3 (2) 18 (8) <0.001
TFC 13 (13;13) 13 (13;13) 13 (13;13) 0.06
Disease burdena 259 (89) 332 (79) 0.008
Predicted onsetb, yrs 16 (8)
Note. Data are mean (SD) for continuous variables, number (%) for gender and education and
median (interquartile range) for TFC and depression score. ANOVA was used for comparisons of
age, CAG and TMS variables χ2-tests for gender and education variables and Kruskal-Wallis tests
for depression score and total functional capacity variable. TFC = total functional capacity, TMS
= total motor score. aBased on formula ‘(CAG-35.5)*age)’ by Penney et al. (1997). bBased on
survival analysis formula by Langbehn et al. (2004).
Baseline differences and change over time for premanifest HD
and manifest HD on the four factors
The baseline differences and change over the ten-year follow-up period for the pre-
manifest HD and manifest HD groups compared with the controls are presented
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in Table 2. The analyses adjusted for age, gender and education showed lower
baseline scores for the manifest HD group on the motor speed factor (Table 2B).
The scores were on average 0.72 SD (SE=0.22; p=0.002) lower than the scores of
the controls. For the executive functioning and memory factors the same pattern
was found; for executive functioning factor the scores were 0.79 SD (SE=0.17;
p<0.001) lower and for the memory factor 0.61 SD (SE=0.17; p<0.001) lower.
Only for the latter factor both HD groups showed a difference in change over time
compared to that of controls. The manifest HD group deteriorated with on average
0.61 SD (SE=0.24; p=0.01) over ten-year follow-up. The premanifest HD group
deteriorated with 0.32 SD (SE=0.15; p=0.04). Post-hoc analysis to investigate
which individual cognitive tests caused significant factor results revealed that for
the memory factor both short and long term memory on the VLGT and the WMS
MQ showed lower baseline scores for the manifest subjects compared to the controls
(SD between 0.79 and 0.69, p-values between 0.001 and <0.001) (Supplementary
Table 2A). Concerning change over time the premanifest subjects deteriorated on
long term recognition of the VLGT (0.48 SD [SE=0.23, p=0.04]), and the man-
ifest subjects deteriorated in the WMS MQ (0.70 SD [SE=0.23; p=0.003]). The
significant baseline difference on the executive functioning factor was driven by
worse baseline scores for the SDMT (0.85 SD [SE=0.20; p<0.001]) and TMT-B
(0.77 SD [SE=0.20; p<0.001]).
To partition out the influence of motor functioning on cognition motor speed was
added as an additional covariate to the multilevel regression analyses on the cog-
nitive factors (Table 2C). Now, only the manifest HD group showed lower baseline
scores compared to controls on the executive functioning (-0.73 SD (SE=0.17);
p<0.001) and memory (-0.62 (SE=0.17); p<0.001) factors. The adjustment for
motor speed resulted in a reduction in size of the statistically significant beta-
coefficients by on average 20.2%. This indicates a substantial mediating effect of
the reduction in motor speed over time on the cognitive factors. Supplementary
Table 2B shows the data of the individual cognitive tests adjusted for age, gender,
education and the motor factor. Here, post-hoc analyses revealed that the memory
factor was driven by significant baseline differences for the manifest group com-
pared to the controls on both the direct and the short and long term recall of the
VLGT (SD between 0.76 and 1.08; p-values between 0.01 and <0.001) and the
WMS MQ (0.75 SD [SE=0.21; p<0.001). The executive functioning factor was
driven by worse baseline scores for the manifest group on both the SDMT (0.82
SD [SE=0.20; p<0.001]) and the TMT-B (0.74 SD [SE=0.21; p<0.001]).
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Table 2: Changes over 10-year follow-up in cognitive and motor factors










Baseline difference Ref. -0.16 (SE 0.20) -0.80 (SE 0.24)** 0.004
Slope difference Ref. -0.13 (SE 0.18) 0.27 (SE 0.34) 0.51
Global Cognition
Baseline difference Ref. 0.00 (SE 0.15) -0.39 (SE 0.17) 0.08
Slope difference Ref. -0.03 (SE 0.13) -0.49 (SE 0.21) 0.07
Executive functioning
Baseline difference Ref. -0.12 (SE 0.18) -0.95 (SE 0.20)*** <0.001
Slope difference Ref. 0.12 (SE 0.10) -0.26 (SE 0.16) 0.08
Memory
Baseline difference Ref. -0.03 (SE 0.15) -0.68 (SE 0.18)*** 0.001
Slope difference Ref. -0.34 (SE 0.15)* -0.60 (SE 0.24)* 0.01
2b. Adjusted age, gender, education
Motor
Baseline difference Ref. -0.08 (SE 0.20) -0.72 (SE 0.22)** 0.007
Slope difference Ref. -0.13 (SE 0.18) 0.25 (SE 0.34) 0.55
Global Cognition
Baseline difference Ref. 0.04 (SE 0.14) -0.32 (SE 0.16) 0.12
Slope difference Ref. -0.03 (SE 0.13) -0.51 (SE 0.21) 0.05
Executive functioning
Baseline difference Ref. -0.27 (SE 0.16) -0.79 (SE 0.17)*** <0.001
Slope difference Ref. 0.11 (SE 0.10) -0.28 (SE 0.16) 0.08
Memory
Baseline difference Ref. -0.08 (SE 0.15) -0.61 (SE 0.17)*** 0.002
Slope difference Ref. -0.32 (SE 0.15)* -0.61 (SE 0.24)* 0.007
2c. Adjusted age, gender, education, motor speed
Global Cognition
Baseline difference Ref. 0.03 (SE 0.14) -0.28 (SE 0.16) 0.21
Slope difference Ref. 0.06 (SE 0.14) -0.49 (SE 0.25) 0.11
Executive functioning
Baseline difference Ref. -0.25 (SE 0.15) -0.73 (SE 0.17)*** <0.001
Slope difference Ref. 0.11 (SE 0.10) -0.21 (SE 0.19) 0.24
Memory
Baseline difference Ref. -0.12 (SE 0.15) -0.62 (SE 0.17)*** 0.002
Slope difference Ref. -0.17 (SE 0.15) -0.44 (SE 0.28) 0.20
Note. Data are standardized mean differences versus controls (standard errors). In all multilevel
regression analyses a compound symmetry covariance matrix (CS) was used. * p<0.05, ** <0.01,
























3A. Continual premanifest subjects and converters
compared to control subjects
3B. Premanifest subjects close to and far from
predicted disease onset compared to control subjects
Motora
Baseline diff. Ref. 0.03 (SE 0.22) -0.16 (SE 0.39) 0.90 Ref. 0.15 (SE 0.26) -0.16 (SE 0.26) 0.63
Slope diff. Ref. -0.08 (SE 0.19) -0.36 (SE 0.41) 0.64 Ref. 0.04 (SE 0.22) -0.42 (SE 0.27) 0.25
Global Cognitiona
Baseline diff. Ref. 0.08 (SE 0.16) -0.04 (SE 0.28) 0.86 Ref. 0.11 (SE 0.19) -0.01 (SE 0.19) 0.83
Slope diff. Ref. 0.06 (SE 0.14) -0.36 (SE 0.25) 0.30 Ref. 0.07 (SE 0.16) -0.14 (SE 0.17) 0.60
Executive functioninga
Baseline diff. Ref. -0.29 (SE 0.17) -0.14 (SE 0.30) 0.22 Ref. 0.11 (SE 0.19) -0.64 (SE 0.19)**0.003
Slope diff. Ref. 0.27 (SE 0.10)* -0.59 (SE 0.19)**<0.001 Ref. 0.04 (SE 0.12) 0.18 (SE 0.14) 0.40
Memorya
Baseline diff. Ref. -0.15 (SE 0.16) 0.06 (SE 0.28) 0.62 Ref. -0.13 (SE 0.19) -0.08 (SE 0.19) 0.75
Slope diff. Ref. -0.21 (SE 0.16) -0.83 (SE 0.30) 0.02 Ref. -0.16 (SE 0.19) -0.53 (SE 0.21)* 0.04































3A. Continual premanifest subjects and converters
compared to control subjects
3B. Premanifest subjects close to and far from
predicted disease onset compared to control subjects
Global Cognitionb
Baseline diff. Ref. 0.06 (SE 0.16) -0.07 (SE 0.28) 0.90 Ref. 0.08 (SE 0.19) -0.03 (SE 0.19) 0.90
Slope diff. Ref. 0.12 (SE 0.14) -0.24 (SE 0.30) 0.47 Ref. 0.08 (SE 0.16) 0.03 (SE 0.20) 0.88
Executive functioningb
Baseline diff. Ref. -0.27 (SE 0.17) -0.16 (SE 0.29) 0.25 Ref. 0.08 (SE 0.19) -0.60 (SE 0.19)**0.004
Slope diff. Ref. 0.21 (SE 0.11) -0.46 (SE 0.22)* 0.01 Ref. 0.01 (SE 0.12) 0.25 (SE 0.15) 0.25
Memoryb
Baseline diff. Ref. -0.19 (SE 0.16) -0.04 (SE 0.28) 0.51 Ref. -0.14 (SE 0.19) -0.17 (SE 0.19) 0.57
Slope diff. Ref. -0.15 (SE 0.16) -0.31 (SE 0.33) 0.47 Ref. -0.13 (SE 0.18) -0.25 (SE 0.22) 0.45
Note. Data are standardized mean differences versus controls (standard errors). In all multilevel regression analyses a compound symmetry
covariance matrix (CS) was used. * p<0.05, ** <0.01, *** <0.001 indicate significant differences compared to the control group in post-hoc
tests. a is adjusted for age, gender, education; b is adjusted for age, gender, education, motor speed.
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Baseline differences and change over time for continual pre-
manifest HD and converters on the four factors
Next we analysed converters (n=5) separated from the continual subjects preman-
ifest HD (n=21). The baseline and slope data for the analysis with the converters
separated from the original premanifest HD group are shown in Table 3A. Figure
2 depicts data for all four groups. The analysis adjusted for age, gender and edu-
cation showed a deterioration over time on the executive functioning factor for the
converter group (-0.59 SD (SE=0.19); p=0.002) as compared to controls, while
the continual premanifest HD group improved with on average 0.27 SD (SE=0.10;
p=0.01) compared to controls. The converters group also deteriorated over time
on the memory factor, with 0.83 SD (SE=0.30; p=0.006).
Post-hoc analysis on the individual cognitive tests adjusted for age, gender and
education (Supplementary Table 3A) showed the significant slope difference for
memory factor was caused by significant deterioration for the converter group
compared to the controls on the WMS MQ of 0.88 SD (SE=0.27; p=0.001). The
executive functioning factor was driven by the SDMT, where the converters dete-
riorated with on average 0.70 SD (SE=0.26, p=0.008).
With the introduction of motor speed as additional covariate the deterioration
for the converter group, now 0.46 SD (SE=0.22, p=0.04), remained (Supplemen-
tary table 3B). The improvement of the continual premanifest HD group of now
0.21 SD (SE=0.11, p=0.052) was only borderline significant. Post-hoc analyses
on component tests of the executive functioning factor revealed that the deterio-
ration for the converter group was solely caused by lower scores for this group on
the SDMT, of on average 0.64 SD (SE=0.30, p=0.04).
Baseline differences and change over time for subjects close to
and far from predicted disease onset compared controls on the
four factors
Table 3B presents the baseline and slope differences of the motor speed and cog-
nitive factors for the premanifest HD group divided into close to and far from
predicted disease onset. For the executive functioning factor, analysis adjusted
for age, gender and education showed lower baseline scores for the close to onset
group of 0.64 SD (SE=0.19; p=0.001) compared to controls. The ‘close’ group
also showed a deterioration over the ten-year follow-up of 0.53 SD (SE=0.21;
p=0.01) on the memory factor compared to controls. Investigation of the indi-
vidual cognitive tests making up the factors revealed that the significant slope
difference for the memory factor was based on the ‘close’ group deteriorating with
on average 0.61 SD (SE=0.19); p=0.001) compared to controls over the ten-
year follow-up (Supplementary Table 4A). Significant baseline differences on the
executive functioning factor were the result of lower baseline scores of 0.77 SD
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(SE=0.23; p=0.001) for the ‘close’ group compared to the control group on the
SDMT.
When motor speed was added to the analyses on the cognitive factors results
showed that lower baseline scores for the close to onset group on the executive
functioning factor persisted. The scores were on average 0.60 SD (SE=0.19;
p=0.002) lower as compared to control subjects. Again, this result was mainly
based on the ‘close’ group scoring 0.73 SD (SE=0.22; p=0.001) lower on the
SDMT compared to the controls (Supplementary Table 4B).
DISCUSSION
The present study reports on ten-year follow-up of cognitive functioning in preman-
ifest and manifest HD. We found that manifest HD subjects scored significantly
worse than controls on the factors of motor, executive functioning and memory.
Over the ten-year follow-up they also showed deterioration on the memory factor,
while change over time on the other factors was comparable to that of controls.
Additionally, the premanifest subjects who converted to manifest disease were the
only group to show significant deterioration over the ten-year follow-up period
compared to the control subjects on the executive functioning factor and to lesser
extent on the memory factor, whereas the premanifest participants who remained
without clinical diagnosis showed no such change.
That the manifest HD group had lower mean baseline scores on the motor speed,
executive and memory factors is not surprising as deficits in these areas of func-
tioning are well established21 22. Longitudinally, this group showed deterioration
on the memory factor, which is in line with other longitudinal studies on cognition
in manifest HD15 23. When we controlled for motor functioning all factors ceased
to show deterioration for this group. That in our fully adjusted model the deterio-
ration on all cognitive factors did not differ from that of the control group seems
counterintuitive, due to the neurodegenerative nature and the known cognitive
deficits in manifest HD24. The most likely explanation is the selective attrition
that takes place in longitudinal studies, where the subjects most vulnerable to
cognitive decline have a larger chance of becoming lost to follow-up. Indeed, in
our manifest HD group 14 out of the initial 19 were lost to follow-up, which likely
resulted in a pronounced underestimation of the cognitive decline in this group.
The cognitive course over time for the subjects who were premanifest at baseline
was most remarkable. Those who converted to manifest disease showed deteri-
oration on both the memory and the executive functioning factors, as compared
to controls. The decline on the executive factor was however most pronounced,
a decline that was even greater than that of the manifest subjects. These results
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are supported by the findings of Solomon et al.14 who also performed a ten-year
follow-up study. They used three cognitive tasks (i.e. subtests from the WAIS-
R) and six motor and psychomotor tasks and found that their converter group
showed greater rates of decline on the motor and psychomotor tasks compared
with non-converters. Similarly, Rupp et al.25 also reported faster deterioration for
their converter group, especially in tests of psychomotor abilities.
In contrast, the subjects in our study who remained premanifest over the ten year
follow-up showed no deterioration on any of the cognitive factors or the individual
cognitive tests. They even showed a slight improvement over time on the executive
functioning factor compared to controls, which was lessened to borderline signifi-
cant when we introduced the motor speed factor to the analysis. This result could
reflect a biphasic or non-linear pattern of progress of executive functioning, where
premanifest subjects are able to maintain test requirements to the same, or even
better, extent as controls, but where a rapid decline occurs close to or directly
after disease onset. Non-linear progression of premanifest test performance has
also been suggested by other authors. Snowden et al.12 and Paulsen et al.26 found
that decline on certain cognitive measures (i.c. memory and executive functioning)
seems to accelerate close clinical disease onset. Rupp and colleagues also observed
an improvement for their premanifest group, which was far from predicted disease
onset25. Rupp et al. attributed this to learning effects, however, this is a less likely
explanation for our premanifest group as no significant improvement was found on
the other factors. However, the influence of practice effects cannot be ruled out,
especially since alternative versions were only available and used for certain, but
not all, tests (i.c. SDMT and TMT). As Duff et al. have demonstrated27, the
influence of practice effects in repeated testing should be considered as a clarifica-
tion for our results. Another explanation could again be the selective drop-out of
subjects who are cognitively and functionally already impaired, even though only 4
of the original premanifest subjects were lost to follow-up. Overall, our results indi-
cate that tests of memory, and to a somewhat larger extent, executive functioning
are likely to be most sensitive to subtle deteriorations during the premanifest and
transition phases of HD.
Splitting the original premanifest group (including those who converted to mani-
fest HD over time) into ‘far’ (more than 15.2 years from predicted disease onset)
and close (15.2 or less years to onset) strengthened our hypothesis of non-linear
progression for the memory and executive functioning factors. We found worse
performance for the close group compared to the control group. This finding
implicates that cognitive decline, and more specifically executive dysfunctioning
and memory decline, is present and can be detected even before overt (motor-
symptomatic) disease onset, an assumption that is also shared by other authors28.
Our findings strengthen the idea proposed by Papp et al.11 amongst others, that
premanifest subjects should not be regarded as one group, but that at least two
different subgroups (i.e. close to and far from predicted disease onset) exist that in-
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deed demonstrate different cognitive profiles. Further analyses revealed that poorer
performance on the SDMT contributed most to executive dysfunction. This finding
corroborates other findings where the SDMT proved most sensitive to the earliest
cognitive change in premanifest HD23 29 30. Our results suggest that the SDMT
is a sensitive instrument to track disease progression over time, especially around
clinical onset.
Besides the progression of cognitive factors over a ten-year period we were also
interested in the effect that motor functioning has on cognition, especially in the
premanifest phase of HD. As for most cognitive tests some kind of motoric response
(e.g. writing, drawing, speaking) is required, and as subtle motor disturbances have
already been found in premanifest groups20 31, this effect is worth investigating.
We approached this by using the test that we hypothesized to be mainly motoric
and relatively free of cognitive effort; the simple reaction time (RT) test (i.e. re-
sponding as quickly as possible to a tone or a light in two separate conditions by
pushing a response button) as a covariate in our analyses. We found evidence
for substantial mediating effects of motor speed on all three cognitive factors.
When we adjusted for motor speed, results on particularly the global cognition and
memory factors ceased to be significant. Also, p-values became less significant.
That differences weaken and disappear with the introduction of a motor measure,
underlines the importance of taking this motor influence into account while inves-
tigating cognition in HD. Studies that do not take into account the influence of
motor function in the HD groups could potentially result in an overestimation of
the ‘pure’ cognitive effect.
This is one of the few cognitive studies where the effect of motor functioning on
cognitive test scores is quantitatively studied. However, we acknowledge that the
choice for motor speed was an arbitrary choice and that we did not a-priori in-
vestigate whether this variable indeed (only) measures motor speed. There is a
possibility that this variable also measures some kind of cognitive construct as our
memory results were also affected by the introduction of the motor speed variable.
Memory tasks are often less dependent on motor abilities than executive tasks, as
they often only require a verbal response. On the other hand, from our supple-
mentary data on the individual cognitive tests we can see that the WMS MQ is
especially affected by the introduction of the motor speed variable. One of the
sub-tests making up the WMS MQ is visual reproduction, where the patients is
required to draw from memory, and this element could be especially sensitive to
motor speed influence. The other memory tests, e.g. direct and long term recall
from the VLGT, seem to be less affected by the introduction of the motor vari-
able, strengthening our hypothesis that we are controlling for motor functioning.
Nonetheless, future research is needed to more thoroughly investigate the potential
influence of motor functioning on cognitive testing.
However, we feel that our attempt to quantify the influence of motor functioning on
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cognitive scores has provided some interesting insights on differential influences on
cognitive measures in HD, even though our results should be interpreted with cau-
tion. If our hypothesis that our motor factor measures pure motor speed is correct,
our results indicate that commonly used tests for global functioning and memory
used in HD are sensitive for the progressive motor disturbances characteristic for
HD, which reduces their ability to pick up cognitive decline. It is unlikely that
no decline on these measures occurs in the premanifest phase, as memory decline,
and to a lesser extent also global functioning decline, have consistently been found
in premanifest HD gene carriers24 32 33. Indeed, without the correction for motor
speed, both converters and subjects close to predicted disease onset also showed
deterioration compared to controls on the memory factor. Our findings suggest
however, that these results could have been mediated by motor functioning and
are likely to be smaller in extend. Nonetheless, tests of executive functioning, and
the SDMT in particular, do show sensitivity for motor disturbances, but remain
sensitive enough to pick up cognitive decline, which makes them best suited for
use in longitudinal follow-up studies and clinical trials.
Our study adds to the existing literature as one of the longest follow-up stud-
ies on cognition in both manifest and premanifest HD. The diverse battery of
cognitive tests is also a strong aspect of this study. Moreover, adjusting for the
influence of motor speed has provided insights about the negative impact of motor
functioning on cognition. However, some limitations have to be mentioned. Dur-
ing the study half of the initial participants were lost to follow-up, introducing a
potential attrition bias. Therefore, results of both manifest subjects and converters
should be interpreted with caution as the numbers in these groups were small and
variability in test scores is substantial. Additionally, the influence of medication
use (e.g. neuroleptics) was not investigated in this study, even though the effect
can be both beneficial and disadvantageous. To avoid overestimation of results,
future studies are advised to administer a motor task alongside cognitive tasks, to
be able to disentangle the influence of motor disturbances on cognitive functioning
in HD.
We conclude that both memory and executive functioning are sensitive in pick-
ing up premanifest decline in subjects close to their predicted disease onset. The
latter cognitive domain is specifically sensitive, with the SDMT proven to be the
most sensitive individual test. Our results imply that the course of executive func-
tioning in the premanifest stage is not uniform and that in subjects furthest away
from disease onset changes are difficult to detect. Additionally, we have found
evidence for influence of motor speed on cognitive outcome measures.
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MMSE 29 (28;29) 28 (28;29) 29 (28;29) 28 (27;29) 29 (28;30) 29 (28;30) 29 (28;30) 28 (27;28)
SDMT 52 (9) 50 (10) 51 (17) 42 (12) 52 (8) 52 (7) 48 (10) 38 (16)
Verbal fluency 32 (11) 34 (10) 33 (14) 32 (9) 36 (12) 41 (14) 35 (7) 26 (12)
Stroop colour 76 (12) 75 (9) 76 (15) 67 (15) 79 (12) 79 (11) 64 (25) 66 (18)
Stroop word 100 (16) 99 (14) 93 (9) 94 (22) 103 (15) 102 (11) 76 (22) 86 (23)
Stroop interf. 44 (8) 43 (9) 46 (10) 39 (13) 46 (10) 47 (9) 41 (10) 38 (14)
TMT A (sec.) 32 (10) 38 (13) 35 (21) 48 (21) 27 (8) 26 (8) 38 (23) 44 (18)
TMT B (sec.) 54 (19) 57 (21) 54 (25) 87 (42) 49 (18) 51 (27) 69 (48) 84 (43)
VLGT list A 58 (9) 59 (9) 54 (7) 48 (11) 56 (13) 57 (12) 48 (18) 50 (12)
VLGT list B 7 (2) 7 (2) 9 (2) 7 (2) 6 (2) 7 (2) 6 (2) 5 (3)
VLGT ST recall 13 (12;15) 13 (11;15) 13 (9;14) 13 (11;13) 13 (10;15) 13 (10;14) 7 (5;7) 10 (9;10)
VLGT LT recall 13 (11;15) 14 (11;15) 12 (11;15) 10 (8;14) 14 (12;15) 14 (12;15) 8 (4;8) 11 (10;11)
VLGT LT recog. 15 (15;16) 16 (15;16) 15 (15;16) 15 (14;16) 16 (15;16) 16 (15;16) 15 (11;15) 13 (12;13)
Boston naming 27 (25;28) 27 (26;28) 29 (25;29) 26 (24;27) 27 (25;28) 26 (26;28) 29 (27;29) 28 (26;29)
WMS MQ 120 (13) 114 (17) 118 (13) 109 (18) 131 (12) 122 (18) 114 (23) 107 (12)
WAIS TIQ 104 (11) 101 (14) 104 (14) 95 (12) 114 (13) 110 (15) 109 (19) 101 (5)
WAIS PIQ 105 (11) 104 (13) 101 (12) 94 (14) 117 (14) 117 (12) 108 (18) 101 (13)
WAIS VIQ 103 (10) 99 (14) 106 (15) 96 (11) 110 (10) 104 (14) 109 (17) 98 (11)
Reaction time 418 (65) 432 (84) 435 (91) 473 (108) 450 (104) 488 (106) 457 (46) 432 (52)
Note. Data are standardized mean differences versus controls (standard errors). In all multilevel regression analyses a compound symmetry
covariance matrix (CS) was used. * p<0.05, ** <0.01, *** <0.001 indicate significant differences compared to the control group in post-hoc
tests. LT=long term, MMSE=mini mental state examination, PIQ=performal intelligence quotient, SDMT=symbol digit modalities test,
ST=short term, TIQ=total intelligence quotient, TMT=trail making test, VIQ=verbal intelligence quotient, VLGT=verbale leer- en geheugen
















Table 5: Supplementary table: Changes over ten-year follow-up on cognitive tests for premanifest HD and manifest












A. Adjusted - Age, gender, education B. Adjusted - Age, gender, education, motor speed
MMSE
Baseline diff. Ref. -0.18 (SE 0.16) -0.31 (SE 0.19) 0.19 -0.16 (SE 0.17) -0.25 (SE 0.19) 0.32
Slope diff. Ref. 0.02 (SE 0.23) -0.53 (SE 0.36) 0.33 0.09 (SE 0.24) -0.43 (SE 0.44) 0.54
SDMT
Baseline diff. Ref. -0.29 (SE 0.19) -0.85 (SE 0.20)***<0.001 -0.28 (SE 0.18) -0.82 (SE 0.20)***<0.001
Slope diff. Ref. 0.08 (SE 0.14) -0.23 (SE 0.22) 0.43 0.08 (SE 0.14) -0.13 (SE 0.27) 0.72
Verbal fluency
Baseline diff. Ref. 0.27 (SE 0.22) 0.03 (SE 0.24) 0.47 0.22 (SE 0.21) 0.05 (SE 0.24) 0.58
Slope diff. Ref. 0.02 (SE 0.15) -0.54 (SE 0.24) 0.08 0.08 (SE 0.16) -0.48 (SE 0.30) 0.19
Stroop colour
Baseline diff. Ref. -0.15 (SE 0.20) -0.68 (SE 0.22)** 0.01 -0.12 (SE 0.20) -0.60 (SE 0.22)** 0.02
Slope diff. Ref. -0.08 (SE 0.14) -0.18 (SE 0.24) 0.69 -0.02 (SE 0.15) -0.12 (SE 0.28) 0.91
Stroop word
Baseline diff. Ref. -0.31 (SE 0.23) -0.41 (SE 0.29) 0.20 -0.29 (SE 0.22) -0.35 (SE 0.28) 0.26
Slope diff. Ref. 0.19 (SE 0.14) -0.15 (SE 0.24) 0.28 0.25 (SE 0.15) -0.09 (SE 0.29) 0.22
Stroop interference
Baseline diff. Ref. -0.26 (SE 0.21) -0.51 (SE 0.26) 0.1 -0.22 (SE 0.20) -0.38 (SE 0.26) 0.24
Slope diff. Ref. -0.03 (SE 0.01) 0.16 (SE 0.16) 0.16 0.20 (SE 0.17) -0.44 (SE 0.32) 0.14
TMT A
Baseline diff. Ref. -0.25 (SE 0.13) -0.36 (SE 0.15)* 0.03 -0.25 (SE 0.13) -0.35 (SE 0.15)* 0.02
Slope diff. Ref. 0.10 (SE 0.15) -0.47 (SE 0.24) 0.09 0.22 (SE 0.16) -0.15 (SE 0.30) 0.30









Table 5: (Continued) Supplementary table: Changes over ten-year follow-up on cognitive tests for premanifest HD












A. Adjusted - Age, gender, education B. Adjusted - Age, gender, education, motor speed
TMT B
Baseline diff. Ref. -0.27 (SE 0.19) -0.77 (SE 0.20)*** 0.001 -0.26 (SE 0.18) -0.74 (SE 0.21)*** 0.002
Slope diff. Ref. 0.02 (SE 0.16) -0.33 (SE 0.27) 0.44 0.02 (SE 0.17) -0.13 (SE 0.32) 0.91
VLGT list A
Baseline diff. Ref. -0.17 (SE 0.19) -0.79 (SE 0.22)** 0.001 -0.19 (SE 0.20) -0.76 (SE 0.23)** 0.004
Slope diff. Ref. 0.07 (SE 0.22) 0.12 (SE 0.43) 0.92 0.19 (SE 0.23) 0.08 (SE 0.45) 0.70
VLGT list B
Baseline diff. Ref. -0.17 (SE 0.23) 0.00 (SE 0.41) 0.77 -0.16 (SE 0.23) -0.01 (SE 0.44) 0.78
Slope diff. Ref. 0.08 (SE 0.26) -0.98 (SE 0.57) 0.19 0.19 (SE 0.27) -0.96 (SE 0.58) 0.16
VLGT short term recall
Baseline diff. Ref. -0.37 (SE 0.23) -0.68 (SE 0.40) 0.10 -0.42 (SE 0.22) -1.08 (SE 0.41)** 0.01
Slope diff. Ref. -0.09 (SE 0.20) 0.26 (SE 0.43) 0.73 -0.03 (SE 0.20) 0.54 (SE 0.43) 0.44
VLGT long term recall
Baseline diff. Ref. -0.13 (SE 0.18) -0.69 (SE 0.20)** 0.004 -0.15 (SE 0.19) -0.76 (SE 0.21)*** 0.002
Slope diff. Ref. -0.07 (SE 0.19) -0.26 (SE 0.39) 0.78 0.03 (SE 0.20) -0.22 (SE 0.39) 0.83
VLGT long term recognition
Baseline diff. Ref. 0.03 (SE 0.17) -0.38 (SE 0.19) 0.11 0.02 (SE 0.17) -0.37 (SE 0.20) 0.15
Slope diff. Ref. -0.48 (SE 0.23)* -0.75 (SE 0.44) 0.043 -0.40 (SE 0.24) -0.82 (SE 0.45) 0.07
BNT
Baseline diff. Ref. 0.12 (SE 0.18) -0.43 (SE 0.21) 0.07 0.11 (SE 0.19) -0.40 (SE 0.21) 0.11
Slope diff. Ref. 0.05 (SE 0.18) 0.10 (SE 0.32) 0.92 0.03 (SE 0.18) -0.24 (SE 0.34) 0.75
















Table 5: (Continued) Supplementary table: Changes over ten-year follow-up on cognitive tests for premanifest HD












A. Adjusted - Age, gender, education B. Adjusted - Age, gender, education, motor speed
WMS MQ
Baseline diff. Ref. -0.26 (SE 0.18) -0.70 (SE 0.21)** 0.003 -0.34 (SE 0.18) -0.75 (SE 0.21)*** 0.001
Slope diff. Ref. -0.27 (SE 0.14) -0.70 (SE 0.23)** 0.004 -0.13 (SE 0.15) -0.50 (SE 0.28) 0.17
WAIS TIQ
Baseline diff. Ref. 0.02 (SE 0.18) -0.78 (SE 0.20)*** 0.001 -0.03 (SE 0.19) -0.76 (SE 0.20)*** 0.001
Slope diff. Ref. -0.09 (SE 0.13) -0.42 (SE 0.24) 0.18 0.06 (SE 0.13) -0.53 (SE 0.26) 0.09
WAIS PIQ
Baseline diff. Ref. -0.08 (SE 0.20) -0.84 (SE 0.22)*** 0.001 -0.13 (SE 0.20) -0.85 (SE 0.22)*** 0.001
Slope diff. Ref. 0.03 (SE 0.16) -0.74 (SE 0.29)* 0.043 0.12 (SE 0.17) -0.65 (SE 0.33) 0.09
WAIS VIQ
Baseline diff. Ref. 0.07 (SE 0.18) -0.62 (SE 0.19)** 0.004 0.04 (SE 0.18) -0.61 (SE 0.20)** 0.007
Slope diff. Ref. -0.09 (SE 0.12) -0.57 (SE 0.22)* 0.039 0.03 (SE 0.13) -0.76 (SE 0.25)** 0.007
Note. Data are standardized mean differences versus controls (standard errors). In all multilevel regression analyses a compound symmetry
covariance matrix (CS) was used. BNT = Boston naming task, MMSE = mini mental state examination, PIQ = performal intelligence
quotient, Ref. = Reference group, RT = reaction time. SDMT = symbol digit modalities test, TIQ = total intelligence quotient, TMT = trail
making test, VIQ = verbal intelligence quotient, VLGT = verbale leer- en geheugen test, WAIS = Wechsler adult intelligence scale,










Table 6: Supplementary table: Changes over ten-year follow-up on cognitive tests for continual premanifest HD and














A. Adjusted - Age, gender, education B. Adjusted - Age, gender, education, motor speed
MMSE
Baseline diff. Ref. -0.19 (SE 0.18) -0.22 (SE 0.32) 0.48 -0.19 (SE 0.18) -0.17 (SE 0.32) 0.53
Slope diff. Ref. 0.06 (SE 0.24) -0.15 (SE 0.45) 0.90 0.14 (SE 0.25) -0.26 (SE 0.32) 0.73
SDMT
Baseline diff. Ref. -0.30 (SE 0.20) -0.20 (SE 0.36) 0.30 -0.29 (SE 0.20) -0.23 (SE 0.35) 0.31
Slope diff. Ref. 0.27 (SE 0.14) -0.70 (SE 0.26)** 0.002 0.20 (SE 0.15) -0.64 (SE 0.30)* 0.03
Verbal fluency
Baseline diff. Ref. 0.38 (SE 0.24) 0.12 (SE 0.42) 0.28 0.33 (SE 0.23) 0.06 (SE 0.41) 0.36
Slope diff. Ref. 0.14 (SE 0.16) -0.47 (SE 0.30) 0.15 0.18 (SE 0.17) -0.45 (SE 0.35) 0.19
Stroop colour
Baseline diff. Ref. -0.17 (SE 0.22) -0.15 (SE 0.38) 0.71 -0.13 (SE 0.21) -0.22 (SE 0.38) 0.75
Slope diff. Ref. 0.11 (SE 0.15) -0.88 (SE 0.28)** 0.003 0.03 (SE 0.15) -0.33 (SE 0.32) 0.54
Stroop word
Baseline diff. Ref. -0.20 (SE 0.25) -0.51 (SE 0.42) 0.39 -0.18 (SE 0.24) -0.55 (SE 0.41) 0.36
Slope diff. Ref. 0.37 (SE 0.15)* -0.63 (SE 0.28)* 0.002 0.32 (SE 0.16) -0.24 (SE 0.33) 0.08
Stroop interference
Baseline diff. Ref. -0.26 (SE 0.23) -0.17 (SE 0.39) 0.51 -0.22 (SE 0.23) -0.17 (SE 0.39) 0.60
Slope diff. Ref. 0.30 (SE 0.17) -0.47 (SE 0.32) 0.047 0.27 (SE 0.18) -0.23 (SE 0.37) 0.23
TMT A
Baseline diff. Ref. -0.29 (SE 0.15) -0.07 (SE 0.26) 0.15 -0.28 (SE 0.14) -0.09 (SE 0.25) 0.15
Slope diff. Ref. 0.27 (SE 0.16) -0.62 (SE 0.30)* 0.02 0.33 (SE 0.17) -0.39 (SE 0.36) 0.07
















Table 6: (Continued) Supplementary table: Changes over ten-year follow-up on cognitive tests for continual pre-














A. Adjusted - Age, gender, education B. Adjusted - Age, gender, education, motor speed
TMT B
Baseline diff. Ref. -0.28 (SE 0.20) -0.09 (SE 0.36) 0.38 -0.27 (SE 0.20) -0.11 (SE 0.36) 0.43
Slope diff. Ref. 0.17 (SE 0.18) -0.61 (SE 0.33) 0.09 0.10 (SE 0.18) -0.47 (SE 0.38) 0.36
VLGT list A
Baseline diff. Ref. -0.22 (SE 0.21) -0.12 (SE 0.38) 0.56 -0.25 (SE 0.21) -0.21 (SE 0.38) 0.46
Slope diff. Ref. 0.11 (SE 0.23) -0.12 (SE 0.47) 0.89 0.14 (SE 0.24) 0.63 (SE 0.56) 0.48
VLGT list B
Baseline diff. Ref. -0.35 (SE 0.25) 0.57 (SE 0.42) 0.10 -0.36 (SE 0.25) 0.51 (SE 0.41) 0.11
Slope diff. Ref. 0.28 (SE 0.27) -0.88 (SE 0.55) 0.13 0.29 (SE 0.28) -0.18 (SE 0.64) 0.54
VLGT short term recall
Baseline diff. Ref. -0.43 (SE 0.25) -0.38 (SE 0.41) 0.19 -0.44 (SE 0.25) -0.45 (SE 0.41) 0.15
Slope diff. Ref. -0.01 (SE 0.21) -0.53 (SE 0.42) 0.46 -0.01 (SE 0.21) -0.11 (SE 0.49) 0.98
VLGT long term recall
Baseline diff. Ref. -0.21 (SE 0.20) -0.01 (SE 0.36) 0.57 -0.23 (SE 0.20) -0.13 (SE 0.36) 0.53
Slope diff. Ref. 0.05 (SE 0.20) -0.70 (SE 0.41) 0.22 0.04 (SE 0.20) -0.05 (SE 0.47) 0.98
VLGT long term recognition
Baseline diff. Ref. 0.02 (SE 0.17) -0.04 (SE 0.31) 0.99 0.00 (SE 0.17) -0.13 (SE 0.31) 0.92
Slope diff. Ref. -0.44 (SE 0.23) -0.70 (SE 0.47) 0.07 -0.45 (SE 0.23) -0.07 (SE 0.54) 0.16
BNT
Baseline diff. Ref. 0.09 (SE 0.20) 0.07 (SE 0.19) 0.63 0.11 (SE 0.20) 0.26 (SE 0.36) 0.70
Slope diff. Ref. 0.07 (SE 0.19) -0.00 (SE 0.35) 0.93 -0.00 (SE 0.19) 0.24 (SE 0.41) 0.84









Table 6: (Continued) Supplementary table: Changes over ten-year follow-up on cognitive tests for continual pre-














A. Adjusted - Age, gender, education B. Adjusted - Age, gender, education, motor speed
WMS MQ
Baseline diff. Ref. -0.33 (SE 0.19) -0.08 (SE 0.35) 0.23 -0.41 (SE 0.19) -0.17 (SE 0.35) 0.10
Slope diff. Ref. -0.13 (SE 0.15) -0.88 (SE 0.27)** 0.006 -0.06 (SE 0.15) -0.49 (SE 0.32) 0.30
WAIS TIQ
Baseline diff. Ref. 0.02 (SE 0.20) 0.10 (SE 0.35) 0.96 -0.02 (SE 0.20) -0.00 (SE 0.35) 0.99
Slope diff. Ref. -0.01 (SE 0.14) -0.41 (SE 0.24) 0.24 0.02 (SE 0.14) 0.30 (SE 0.32) 0.65
WAIS PIQ
Baseline diff. Ref. 0.05 (SE 0.21) -0.26 (SE 0.37) 0.74 -0.00 (SE 0.21) -0.36 (SE 0.37) 0.62
Slope diff. Ref. 0.09 (SE 0.17) -0.50 (SE 0.31) 0.20 0.12 (SE 0.18) 0.08 (SE 0.40) 0.79
WAIS VIQ
Baseline diff. Ref. -0.05 (SE 0.19) 0.42 (SE 0.35) 0.45 -0.08 (SE 0.20) 0.36 (SE 0.35) 0.52
Slope diff. Ref. 0.01 (SE 0.13) -0.51 (SE 0.23) 0.08 0.05 (SE 0.13) -0.11 (SE 0.30) 0.86
Note. Data are standardized mean differences versus controls (standard errors). In all multilevel regression analyses a compound symmetry
covariance matrix (CS) was used. BNT = Boston naming task, MMSE = mini mental state examination, PIQ = performal intelligence
quotient, Ref. = Reference group, RT = reaction time. SDMT = symbol digit modalities test, TIQ = total intelligence quotient, TMT = trail
making test, VIQ = verbal intelligence quotient, VLGT = verbale leer- en geheugen test, WAIS = Wechsler adult intelligence scale,

















Table 7: Supplementary table: Changes over ten-year follow-up on cognitive tests for premanifest HD subjects far













A. Adjusted - Age, gender, education B. Adjusted - Age, gender, education, motor speed
MMSE
Baseline diff. Ref. -0.14 (SE 0.21) -0.25 (SE 0.21) 0.45 -0.15 (SE 0.22)a -0.24 (SE 0.22)a 0.50
Slope diff. Ref. 0.10 (SE 0.28) -0.09 (SE 0.31) 0.87 0.10 (SE 0.32)a 0.03 (SE 0.37)a 0.95
SDMT
Baseline diff. Ref. 0.19 (SE 0.23) -0.77 (SE 0.23)** 0.001 0.16 (SE 0.22) -0.73 (SE 0.22)** 0.003
Slope diff. Ref. 0.12 (SE 0.17) 0.02 (SE 0.18) 0.78 0.13 (SE 0.17) -0.04 (SE 0.20) 0.69
Verbal fluency
Baseline diff. Ref. 0.41 (SE 0.28) 0.23 (SE 0.28) 0.31 0.33 (SE 0.28) 0.20 (SE 0.28) 0.45
Slope diff. Ref. -0.03 (SE 0.19) 0.09 (SE 0.20) 0.88 -0.03 (SE 0.19) 0.28 (SE 0.23) 0.45
Stroop colour
Baseline diff. Ref. 0.13 (SE 0.26) -0.47 (SE 0.25) 0.13 0.13 (SE 0.25) -0.44 (SE 0.25) 0.15
Slope diff. Ref. -0.16 (SE 0.18) 0.02 (SE 0.20) 0.63 -0.17 (SE 0.17) 0.22 (SE 0.21) 0.28
Stroop word
Baseline diff. Ref. -0.11 (SE 0.29) -0.46 (SE 0.30) 0.31 -0.10 (SE 0.29) -0.46 (SE 0.29) 0.30
Slope diff. Ref. 0.22 (SE 0.18) 0.14 (SE 0.20) 0.42 0.18 (SE 0.19) 0.34 (SE 0.22) 0.24
Stroop interference
Baseline diff. Ref. 0.02 (SE 0.27) -0.54 (SE 0.27) 0.14 0.02 (SE 0.27) -0.51 (SE 0.27) 0.16
Slope diff. Ref. -0.03 (SE 0.01) -0.08 (SE 0.20) 0.09 -0.09 (SE 0.20) 0.66 (SE 0.24)** 0.02
TMT A
Baseline diff. Ref. -0.07 (SE 0.17) -0.42 (SE 0.17) 0.06 -0.09 (SE 0.17) -0.42 (SE 0.17) 0.05
Slope diff. Ref. 0.14 (SE 0.19) 0.03 (SE 0.21) 0.76 0.15 (SE 0.19) 0.30 (SE 0.23) 0.38









Table 7: (Continued) Supplementary table: Changes over ten-year follow-up on cognitive tests for premanifest HD













A. Adjusted - Age, gender, education B. Adjusted - Age, gender, education, motor speed
TMT B
Baseline diff. Ref. 0.06 (SE 0.24) -0.55 (SE 0.24) 0.06 0.04 (SE 0.24) -0.53 (SE 0.24) 0.08
Slope diff. Ref. -0.00 (SE 0.21) 0.04 (SE 0.23) 0.99 -0.07 (SE 0.21) 0.13 (SE 0.25) 0.80
VLGT list A
Baseline diff. Ref. -0.19 (SE 0.25) -0.22 (SE 0.25) 0.58 -0.20 (SE 0.25) -0.27 (SE 0.26) 0.48
Slope diff. Ref. 0.17 (SE 0.27) -0.08 (SE 0.31) 0.75 0.18 (SE 0.27) 0.21 (SE 0.33) 0.71
VLGT list B
Baseline diff. Ref. -0.33 (SE 0.28) 0.03 (SE 0.30) 0.47 -0.31 (SE 0.27) 0.02 (SE 0.30) 0.50
Slope diff. Ref. 0.27 (SE 0.31) -0.18 (SE 0.37) 0.55 0.27 (SE 0.31) 0.09 (SE 0.39) 0.70
VLGT short term recall
Baseline diff. Ref. -0.39 (SE 0.27) -0.46 (SE 0.29) 0.18 -0.38 (SE 0.27) -0.51 (SE 0.29) 0.15
Slope diff. Ref. 0.03 (SE 0.24) -0.27 (SE 0.28) 0.58 0.03 (SE 0.24) -0.12 (SE 0.30) 0.91
VLGT long term recall
Baseline diff. Ref. -0.24 (SE 0.24) -0.11 (SE 0.24) 0.57 -0.25 (SE 0.24) -0.17 (SE 0.24) 0.53
Slope diff. Ref. 0.06 (SE 0.23) -0.25 (SE 0.27) 0.59 0.06 (SE 0.23) -0.04 (SE 0.28) 0.95
VLGT long term recognition
Baseline diff. Ref. 0.06 (SE 0.21) -0.06 (SE 0.21) 0.91 0.08 (SE 0.21) -0.13 (SE 0.21) 0.72
Slope diff. Ref. -0.60 (SE 0.27) -0.36 (SE 0.30) 0.07 -0.60 (SE 27) -0.08 (SE 0.32) 0.08
BNT
Baseline diff. Ref. 0.30 (SE 0.24) -0.02 (SE 0.24) 0.43 0.29 (SE 0.24) 0.00 (SE 0.24) 0.48
Slope diff. Ref. 0.00 (SE 0.22) 0.21 (SE 0.24) 0.88 0.02 (SE 0.22) 0.03 (SE 0.27) 0.99
















Table 7: (Continued) Supplementary table: Changes over ten-year follow-up on cognitive tests for premanifest HD













A. Adjusted - Age, gender, education B. Adjusted - Age, gender, education, motor speed
WMS MQ
Baseline diff. Ref. -0.29 (SE 0.24) -0.28 (SE 0.23) 0.28 -0.31 (SE 0.23) -0.41 (SE 0.23) 0.12
Slope diff. Ref. .00 (SE 0.18) -0.61 (SE 0.19)** 0.005 0.03 (SE 0.17) -0.40 (SE 0.21) 0.15
WAIS TIQ
Baseline diff. Ref. 0.03 (SE 0.24) 0.05 (SE 0.24) 0.98 -0.00 (SE 0.24) -0.01 (SE 0.24) 0.99
Slope diff. Ref. 0.17 (SE 0.16) -0.40 (SE 0.17)* 0.02 0.19 (SE 0.16) -0.16 (SE 0.19) 0.28
WAIS PIQ
•Baseline diff. Ref. 0.18 (SE 0.25) -0.21 (SE 0.25) 0.48 0.14 (SE 0.25) -0.28 (SE 0.25) 0.40
•Slope diff. Ref. 0.14 (SE 0.20) -0.24 (SE 0.22) 0.34 0.15 (SE 0.20) 0.04 (SE 0.24) 0.74
WAIS VIQ
•Baseline diff. Ref. -0.07 (SE 0.24) 0.16 (SE 0.23) 0.72 -0.08 (SE 0.24) 0.12 (SE 0.24) 0.81
•Slope diff. Ref. 0.18 (SE 0.15) -0.42 (SE 0.16)** 0.007 0.20 (SE 0.15) -0.26 (SE 0.18) 0.10
Note. Data are standardized mean differences versus controls (standard errors). In all multilevel regression analyses a compound symmetry
covariance matrix (CS) was used. BNT = Boston naming task, MMSE = mini mental state examination, PIQ = performal intelligence
quotient, Ref. = Reference group, RT = reaction time. SDMT = symbol digit modalities test, TIQ = total intelligence quotient, TMT = trail
making test, VIQ = verbal intelligence quotient, VLGT = verbale leer- en geheugen test, WAIS = Wechsler adult intelligence scale,
WMS MQ = Wechsler memory scale memory quotient. * p<0.05, ** p<0.01, *** p<0.001 indicate significant differences compared to controls
in post-hoc tests.
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Abstract
Understanding the relation between predominantly choreatic and hypokinetic-rigid
motor subtypes and cognitive and general functioning may contribute to knowl-
edge about different motor-phenotypes in Huntington‘s disease. In the European
Huntington‘s Disease Network Registry study, 1882 subjects were classified as being
predominantly choreatic (N=528) or hypokinetic-rigid (N=432), according to their
score on items of the total motor score a priori labelled as choreatic or hypokinetic-
rigid; the other 922 patients were of a mixed type. The relationship between motor
type and cognitive (verbal fluency, symbol digit modalities, Stroop colour, word
and interference tests) and functional (total functional capacity) capacity was in-
vestigated using multiple linear regression. Motor subtype contributed significantly
to the total functional capacity score (partial r2: 7.8%; p<0.001) and to the five
cognitive scores (partial r2 values ranging from 2.0-8.4%; all p-values <0.001),
patients with a predominantly choreatic motor phenotype performing better in all
areas than patients with a hypokinetic-rigid motor phenotype.
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INTRODUCTION
Huntington‘s disease (HD) is a progressive neurodegenerative disorder, caused by
an unstable expansion of a CAG trinucleotide repeat on chromosome 41. Although
motor disturbances often stand out, the clinical presentation is also determined by
behavioural problems and dementia2.
HD is generally categorized as a hyperkinetic disorder3. Hypokinesia, however,
also plays an important role in the motor presentation4 5. Clinically, three motor
subtypes can be distinguished: choreatic, hypokinetic-rigid and mixed-motor type.
It has been reported that the predominantly rigid type, typically seen in juvenile
HD6, is less common in adult-onset HD than chorea-predominant HD7. Never-
theless, some authors have stated that it is not chorea but hypokinesia-rigidity
that is the core movement disorder in HD8 9 10. Most probably hyperkinesia and
hypokinesia co-exist in HD, one of the two being predominant10 11.
Because of the progressive nature of HD, motor symptoms worsen. Clinical ob-
servation suggests that this process is not uniform and that patients who present
with predominantly choreatic or hypokinetic-rigid motor symptoms show different
cognitive and functional profiles, a notion already stated by Brandt12.
Several studies have investigated HD motor subtypes, but as the classification
methods are heterogeneous, no uniform conclusions about the relation between
motor type and clinical functioning can be drawn. Hyperkinesia in HD was found
to be both related13 and unrelated9 to cognitive functioning, whereas hypokinesia
was associated with cognitive9 14 and functional impairment4 5 8 15.
Investigating the cognitive and functional profiles of both motor types may add
to the existing knowledge about motor functioning in HD patients, and may have
implications for patient management.
We investigate the relationship between the predominant motor type and cognitive
and general functioning and hypothesize that patients with predominantly chore-
atic motor characteristics function better than hypokinetic-rigid patients on both
cognitive and general levels. We also examine the use of neuroleptics in both
groups16 17, and assess whether the motor phenotype is associated with disease
duration.
METHODS
We used on-site, monitored data from the first visit of subjects with a CAG of
≥36 and a Unified Huntington‘s Disease Rating Scale (UHDRS)18 total motor
score (TMS) of >5, as recorded in the European Huntington‘s Disease Network
Registry study. The number of subjects fulfilling these criteria was 1882. Variables
consisted of the motor, function and cognitive parts of the UHDRS, CAG repeat
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length, date-of-birth, gender, medication and educational level.
To enable classification into predominantly choreatic or hypokinetic-rigid motor
phenotypes, certain TMS items were selected: for the choreatic subtype the items
of the chorea scale, adding up to 28. For hypokinetic-rigidity finger taps, pronate-
supinate hands, bradykinesia, rigidity, items measuring speed of movement and
rigidity, again with a maximum of 28.
For subjects to be subdivided into predominantly choreatic or hypokinetic-rigid
types, the total scores for the two subtypes had to differ by at least one standard
deviation (i.e. 4 points). If the difference was smaller, it was considered to be
a mixed motor type. This resulted in 528 choreatic, 432 hypokinetic-rigid and
922 mixed subjects. As we were interested in differences between predominantly
choreatic and hypokinetic-rigid motor types, the mixed group was not included in
analyses. The use of neuroleptic medication was scored as ‘1 = present’ or ‘0 =
absent’.
SPSS 17.0 was used for data analysis, and independent sample t-tests for group
differences on demographic variables were performed, except for gender and neu-
roleptics (χ2-test) and total functional capacity (Mann-Whitney U-test). Multiple
linear regression models were constructed to evaluate the contribution of mo-
tor type to either cognition (verbal fluency, symbol digit modalities (SDMT) and
Stroop colour, word and interference tests) or global functioning (total functional
capacity; TFC). Age, gender, CAG repeat length, disease duration, TMS, and ed-
ucation were used as covariates and entered in one block. Motor type was entered
as a binary variable. Partial correlation coefficients were calculated to examine the
contribution of the separate covariates. To investigate whether the distribution of
motor types was constant overt the disease course, disease duration was divided
into quartiles and the distribution was examined with a χ2-test. Statistical signifi-
cance was set at p<0.05. For regression analysis the p-value was divided by six to
correct for multiple testing, resulting in p<0.008.
RESULTS
Demographic analysis showed that the choreatic group was older, more often male,
had been educated for longer (p<0.005), had a higher age at disease onset, shorter
disease duration and lower CAG repeat (all p-values <0.001) compared to the
hypokinetic-rigid group (Table 1). The choreatic group had a higher TFC and
lower TMS (p<0.001). In all cognitive tests, hypokinetic-rigid subjects had lower
scores than choreatic subjects (p<0.001). There was no difference between groups
with regard to the number of participants using neuroleptic drugs.
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Table 1: Demographics of whole group and of separate motor groups





N 1882 528 432
Age (yrs) 50.6 (11.6) 52.2 (11.0) 49.8 (12.5) <0.005
Gender f/m (%m)a 929/953 (51) 224/304 (58) 225/207 (48) <0.005
Neuroleptics yes/no
(%yes)a
1237/645 (66) 344/184 (65) 302/130 (70) 0.067
Years of education 11.2 (3.6) 11.4 (3.8) 10.8 (3.3) <0.005
Age at disease onset
(yrs)
43.6 (11.0) 45.2 (10.6) 41.7 (11.3) <0.001
Disease duration
(yrs)
7.0 (5.0) 6.9 (4.7) 8.1 (5.7) <0.001
CAG large 44.1 (3.3) 43.7 (3.0) 45.0 (3.5) <0.001
Total Functional
Capacityb
9.0 (5) 10.0 (5) 6.0 (7) <0.001
Total Motor Score 34.5 (18.4) 34.0 (16.4) 41.7 (19.8) <0.001
Verbal fluency total
score
17.7 (11.5) 19.4 (11.5) 13.7 (11.1) <0.001
SDMT total score 20.6 (12) 22.8 (11.2) 15.4 (11.7) <0.001
Stroop color total
score
40.8 (17.5) 44.4 (17.2) 33.0 (17.0) <0.001
Stroop word total
score
55.2 (22.7) 60.5 (22.2) 44.3 (21.9) <0.001
Stroop interference
total score
22.2 (12) 24.7 (12.0) 17.4 (11.5) <0.001
Note. Data are mean (standard deviation), expect for a (total number) and for b (median and
interquartile range). Analyses are independent samples t-test, except for a (χ2 test) and b
(Mann-Whitney U-test). SDMT = Symbol Digit Modalities Test.
Linear regression analyses on cognitive functioning, taking differences in age, sex,
education, disease duration, CAG and TMS into account (Table 2b-e), revealed
that motor subtype was a predictor of all cognitive tests (all p<0.001). Patients
in the hypokinetic-rigid group had significantly worse scores on all tests than those
in the choreatic group. As revealed by the squared partial correlation coefficients,
motor subtype was the second most contributing variable after TMS in all models
(p<0.001) except verbal fluency, where it was the third most contributing factor
(p<0.001).
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Table 2: a-d. Linear regression analyses on total functional and cognitive scores
B SE B Partial r2 P-value
2a. Total Functional Capacity Score
Constant 19.00 2.23 <0.001
Age (yrs) -0.03 0.01 .000 <0.005
Gender 0.29 0.16 .003 0.075
Education (yrs) 0.10 0.02 .018 <0.001
Disease duration (yrs) -0.14 0.02 .062 <0.001
CAG -0.09 0.04 .005 0.029
Total Motor Score -0.10 0.01 .297 <0.001
Motor subtype -1.50 0.17 .078 <0.001
2b. Total Verbal Fluency Score
Constant 48.08 8.71 <0.001
Age (yrs) -0.08 0.05 0.003 0.070
Gender -1.05 0.63 0.003 0.094
Education (yrs) 0.65 0.09 0.055 <0.001
Disease duration (yrs) -0.11 0.07 0.003 0.116
CAG -0.40 0.16 0.007 0.010
Total Motor Score -0.27 0.02 0.157 <0.001
Motor subtype -2.87 0.65 0.020 <0.001
2c. Symbol Digit Modalities Score
Constant 70.49 7.60 <0.001
Age (yrs) -0.26 0.04 0.045 <0.001
Gender -0.56 0.55 0.001 0.303
Education (yrs) 0.56 0.08 0.053 <0.001
Disease duration (yrs) -0.13 0.06 0.005 0.032
CAG -0.52 0.14 0.015 <0.001
Total Motor Score -0.33 0.02 0.278 <0.001
Motor subtype -4.67 0.57 0.059 <0.001
2d. Stroop Colour Test Score
Constant 84.96 12.07 <0.001
Age (yrs) -0.24 0.06 0.014 <0.001
Gender -0.93 0.87 0.000 0.286
Education (yrs) 0.53 0.12 0.020 <0.001
Disease duration (yrs) -0.12 0.10 0.002 0.196
CAG -0.16 0.22 0.001 0.454
Total Motor Score -0.52 0.03 0.267 <0.001
Motor subtype -7.39 0.90 0.066 <0.001
Table continues on next page.
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Table 2: (Continued) e-f. Linear regression analyses on total functional
and cognitive scores
B SE B Partial r2 P-value
2e. Stroop Word Test Score
Constant 119.48 15.30 <0.001
Age (yrs) -0.30 0.08 0.014 <0.001
Gender -1.56 1.10 0.021 0.159
Education (yrs) 0.80 0.15 0.028 <0.001
Disease duration (yrs) -0.37 0.12 0.096 <0.005
CAG -0.35 0.27 0.002 0.206
Total Motor Score -0.65 0.04 0.264 <0.001
Motor subtype -10.62 1.14 0.084 <0.001
2f. Stroop Interference Test Score
Constant 63.98 8.20 <0.001
Age (yrs) -0.28 0.04 0.042 <0.001
Gender -0.21 0.59 0.001 0.718
Education (yrs) 0.45 0.08 0.031 <0.001
Disease duration (yrs) -0.13 0.07 0.004 0.043
CAG -0.30 0.15 0.000 0.038
Total Motor Score -0.32 0.02 0.229 <0.001
Motor subtype -4.73 0.61 0.059 <0.001
Note. B=regression coefficient, SE B=standard error of B, r2=squared partial correlation coef-
ficients.
Motor subtype also contributed significantly to general functioning (TFC) (p<0.001)
when the covariates were taken into account (Table 2a), and was the second most
contributing variable after the TMS (partial r2=.078, p<0.001). Together, inde-
pendent variables explained 56% of the variance in TFC (p<0.001). Hypokinetic-
rigid subjects performed significantly worse on TFC than choreatic subjects.
A χ2-test revealed significant differences in the distribution of choreatic and hypokinetic-
rigid subjects across disease duration quartile groups (p= 0.008), and shifted from
slightly more choreatic than hypokinetic-rigid in the first three quartiles (I and
II: 59% versus 41%, III: 56% versus 44%) to slightly more hypokinetic-rigid than
choreatic in the last quartile (45% versus 55%).
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DISCUSSION
We investigated the differences in clinical and cognitive performance between pre-
dominantly choreatic and hypokinetic-rigid HD patients. We found motor subtype
defined by either predominantly chorea or hypokinesia-rigidity characteristics to be
an independent predictor of both cognitive and general functioning, with choreatic
patients functioning significantly better.
Investigating function and cognition in relation to predominantly choreatic or
hypokinetic-rigid HD has not previously been carried out in this way. Earlier stud-
ies did, however, find that higher hypokinesia-rigidity scores were related to poorer
cognitive and general functioning4 5 14. The lack of relation between choreatic
movements and cognitive and functional impairment found in previous studies9 13 15
seems to be in line with our finding that chorea in HD is characterized by better
performance in both areas.
Clinically different motor subtypes have also been identified in Parkinsons dis-
ease (PD): tremor-dominant subtype (characterized by mild disease progression),
akinetic-rigid subtype (where cognitive impairment is more severe), and postural
instability and gait difficulty subtype (associated with cognitive impairment and
severe disease progression)19 20. Comparable to our results, the hypokinetic PD
subtypes are associated with poorer functioning than the subtype related to more
hyperkinetic features.
The distribution of motor types across disease duration quartiles revealed a shift
from slightly more choreatic than hypokinetic-rigid subjects in the first three quar-
tiles to slightly more hypokinetic-rigid than choreatic subjects in the last quartile.
Although these findings are based on group comparisons and do not necessarily
reflect the probability that an individual patient follows the same course (i.e. the
distribution across motor types of patients in the highest quartile of disease dura-
tion may already have been present in these same patients earlier in the disease),
the alternative explanation that it does reflect the increasing probability that a
patient converts from a more choreatic to a more hypokinetic-rigid motor type
as disease duration lengthens is very well possible. This would support earlier
findings on motor phenotype progression7 21. However, even if patients have an
increased probability to convert to a more hypokinetic-rigid motor type with ad-
vancing disease, it does not account for our findings that the choreatic motor type
is associated with better global and cognitive functioning because differences in
disease duration were taken into account in the regression analyses. Furthermore,
the differences in profiles can also not be explained by the influence of neuroleptic
medication, as its use was comparable between groups.
Conclusions about our findings should be drawn with caution. The Registry
database, due to its international nature, does not provide sufficient nor uniform
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information about the dosages or indications for use of neuroleptics. Although
neuroleptic use did not differ between groups, we cannot exclude the possibility
that choreatic subjects are falsely assigned to the hypokinetic-rigid group due to
medication-induced hypokinesia. Also, longitudinal analyses are essential to inves-
tigate the progression of choreatic and hypokinetic-rigid motor symptoms during
the course of the disease. Replication of our results and further in-depth study of
medication usage and degree of motor impairment is needed to ensure that the
functional differences found can reliably be ascribed to different motor profiles.
To summarise, in a large cohort of patients with Huntington‘s disease, we found
that predominantly choreatic HD is characterized by better global and cognitive
functioning than hypokinetic-rigid HD, differences that could not be explained by
differences in age or disease duration. Further research is, however, necessary.
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Abstract
Objective Motor disturbances can be present in both manifest and premanifest
Huntington‘s disease (HD). We aimed to investigate the role of motor functioning
on executive functioning in order to understand the progression of actual cognitive
dysfunction in HD.
Methods Forty manifest HD (MHD), 21 premanifest HD (PMHD) and 28 control
subjects were tested twice, with a one-year interval. For the Symbol Digit Modal-
ities test (SDMT) and Figure Fluency test (FFT) extra conditions were designed
to measure motor involvement. Subtraction of this motor score from the original
test score resulted in isolation of the cognitive component. Groups were compared
on motor, cognitive and original test scores. Additionally, PMHD far from (‘far’)
and close to (‘close’) expected disease onset were investigated.
Results MHD showed lower baseline scores on the SDMT original (p=0.03) and
motor isolation (p=0.006) parts, and deterioration over one-year follow-up on the
original SDMT (p=0.001) compared to controls. PMHD showed lower baseline
scores on the SDMT motor part (p=0.008) and deterioration on the SDMT origi-
nal (p=0.001) and cognitive isolation (p=0.02) parts. Secondary analyses revealed
that the premanifest findings were the result of worse scores by the close to pre-
dicted onset group only.
Conclusions We found evidence for the presence of motor disturbances which
influence executive functioning in HD. Isolation of the cognitive component still
revealed cognitive deterioration in the premanifest group, caused by decline of
scores of premanifest subjects that are close to their predicted clinical disease on-
set. The SDMT proved most sensitive to premanifest decline, even over one-year
follow-up.
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INTRODUCTION
Huntington‘s disease (HD) is generally described as a hyperkinetic movement dis-
order, where unwanted movements are often the most characteristic signs of the
clinical profile1. Next to these motor abnormalities cognitive decline and psychi-
atric disturbances are also part of the triad of symptoms belonging to HD2. Due
to its autosomal dominant genetic nature, children with an HD parent are at 50%
risk of inheriting the gene. Since 1993 it is possible to be tested for the presence
of the HD gene, and individuals carrying the gene, but not yet displaying clinical
symptoms of the disease (so-called premanifest gene-carriers), can be identified3.
Much cognitive research has focused on executive dysfunctioning as it is one of
the main areas of dysfunctioning in manifest HD4 5. Impairments of planning,
organisation and problem solving (key executive functions) have been found in
HD patients, increasing with disease progression6 7 8. In premanifest HD subjects,
executive problems have also been identified9 10. As almost all commonly used
tests of executive functioning require a motor response, often by means of verbal
or written answers, it is important to investigate its possible confounding effect
on cognitive scores. Especially since subtle motor changes have been found in
premanifest HD gene-carriers years before overt clinical disease onset11 12.
We aim to measure actual cognition that is relatively free from motor disturbances
in premanifest and manifest HD. By estimating the motor component of two ex-
ecutive functioning tasks and subsequently subtracting this motor part from the
actual test score we strive to measure more pure cognitive scores. We hypothesize
to find worse scores on the original conditions of the executive tests used, for the
HD groups compared to controls. When the motor component is isolated from the
cognitive component we expect that both groups will show differences compared
to controls on the motor conditions, and that cognitive results remain, albeit less
strong. If premanifest results emerge we expect that the differences will be the
result of worse performance in the subjects close to predicted disease onset.
METHODS
Participants
Gene-positive subjects who visited the outpatient neurology department at the
Leiden University Medical Centre for their annual clinical evaluation were asked
to participate in this study. Gene-negative spouses and siblings were recruited to
participate as controls. Eighty-nine subjects agreed to participate, of which 61
were gene-positive and 28 controls.
Gene-positive subjects were grouped into either premanifest or manifest HD groups
at baseline, according to their total motor score (TMS) on the Unified Hunting-
ton‘s Disease Rating Scale (UHDRS)13. Scores of 5 or less are premanifest scores,
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6 or higher are manifest scores. This resulted in 40 manifest HD (MHD), and 21
premanifest HD (PMHD) participants. The premanifest group was further sub-
divided into those far from (‘far’, n=11) and close to (‘close’, n=10) predicted
disease onset by means of a median-split of the variable ‘predicted years to onset’
(median=10.2 years). Predicted years to disease onset were estimated using the
data provided by Langbehn et al14.
Of the initial 89 participants, 67 returned for follow-up assessment. Three PMHD
subjects converted to manifest HD after one year, based on their TMS. Fifteen
MHD subjects were not able to complete the study due to disease progression.
Consequently, 5 controls, which were partners of these MHD drop-outs, were not
willing to participate alone. One premanifest subject was not able to complete
follow-up because of personal reasons. As a result one extra control subject (part-
ner of PMHD drop-out) was also lost to follow-up.
Procedure
Participants were tested twice, with a one year interval. At both visits all par-
ticipants were assessed using the UHDRS for neurological functioning, the Mini
Mental State Examination (MMSE)15 as an indicator of global cognitive func-
tioning and the Becks Depression Inventory - BDI-II16 to detect the presence of
a depression. The following cognitive tests were performed: the Symbol Digit
Modalities test (SDMT)17 and the Figure Fluency test (FFT)18. To isolate the
cognitive component of these executive tasks we designed extra ‘high motor and
low cognition load’ conditions for the SDMT and FFT (for complete description
see ‘isolation cognitive components’ below). The study was approved by the local
ethics committee and all participants gave written informed consent.
Isolation cognitive components
For the traditional SDMT, participants have to match numbers to symbols, ac-
cording to a given key. They are instructed to match as many numbers to symbols
in subsequent order in 90 seconds. To isolate the cognitive part of the SDMT we
substituted the symbols with the numbers they represent in the original test, and
asked participants to copy the numbers below, in subsequent order, again for 90
seconds (removing the cognitive task of matching a symbol to a number). We
calculated time per stimulus on the SDMT by dividing the total time by the total
amount of correctly matched symbols (90/total correct SDMT). Next, we calcu-
lated motor time per stimulus by dividing the total time by the total amount of
numbers copied on the extra condition (90/total correct extra condition). The
cognitive time per stimulus was calculated by subtracting the motor time per stim-
ulus from the time per stimulus on the SDMT.
For the Figure Fluency test, subjects are instructed to generate as many unique
designs as possible by connecting two or more dots displayed in a fixed pattern,
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on a form with 35 of these dot patterns. Subjects have to generate as many dif-
ferent designs in one minute and avoid duplicating earlier ones. There are five
conditions (each with a one minute time-limit), where the dot patterns are dif-
ferent from the one before and additional distracting stimuli are added, such as
already drawn lines. Subjects are instructed to ignore these distracters. To isolate
the cognitive component (i.e. non-verbal fluency), we created an extra condition
where pre-drawn designs of different numbers of connected dots are presented and
subjects are asked to accurately trace as many designs as possible in one minute.
Designs range from two connected dots to complex designs of multiple connected
dots. We calculated time per stimulus on the FFT by dividing the total time of
the five conditions (300 seconds) by the total amount of correctly and uniquely
generated designs on all five conditions (300/total amount correct FFT). We also
calculated the motor time per stimulus by dividing the 60 seconds time-limit of the
extra condition by the total amount of correctly traced designs (60/total amount
correct extra condition). Cognitive time per stimulus was calculated by subtracting
the motor time per stimulus from the time per stimulus on the FFT.
Statistical analysis
Analyses were performed using IBM SPSS version 20. Continuous demographic
variables were analysed using ANOVA. Chi-square tests were used for gender and
education variables. The skewed score of the total functional capacity (TFC)
variable was analysed with the Kruskal-Wallis test. Multilevel regression analysis
(i.e. linear mixed models) with a compound symmetry covariance matrix was
performed to study group differences on SDMT and FFT scores. Both crude and
corrected models were constructed. Covariates comprised age, gender, education,
BDI-II score and TFC. The two-level structure consisted of the two time points
(i.e. lower level) and the subjects (i.e. higher level). The PMHD and MHD
groups were compared to controls for differences at baseline and differences in
the rate of decline (time*group interaction effects). To facilitate interpretation
of the differences, the raw test scores were converted into z-scores. Therefore,
beta-coefficients in tables can be interpreted as follows: for baseline differences it
refers to how many standard deviations an HD group differs from the controls at
baseline, and for the rate of decline it refers to how many standard deviations that
an HD group changes during the follow-up period as compared to the controls.
Positive values denote deterioration (i.e. during follow-up the reaction times on
the tests increased, so subjects became slower). Secondary analyses comprised the
premanifest group divided into ‘close’ and ‘far’ to predicted disease onset compared
to controls to investigate the influence of closeness to motor-manifest disease onset.
All tests were two-tailed with p<0.05 denoting statistical significance.
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RESULTS
Baseline demographics
Baseline demographics are presented in Table 1. The MHD group had lower TFC
compared to controls and PMHD subjects (p<0.001). They also showed higher
TMS scores compared to both PMHD and control subjects (p<0.001), and higher
depression scores compared to controls (p=0.02). Scores on the MMSE showed
that all groups were non-demented (i.e. MMSE<25 is indicative of cognitive
impairment).
SDMT baseline differences and rate of decline for the HD
groups compared to controls
In the analyses corrected for age, gender, education, depression and TFC scores
(Table 2A) the MHD group showed lower baseline scores of on average 0.53 SD (SE
0.24, p=0.03). Lower baseline scores for the MHD compared to the control group
were also found for SDMT motor isolation score (0.71 SD (SE 0.25), p=0.006).
Longitudinally, this group showed a deterioration over the one-year follow-up of
0.47 SD (SE 0.13, p=0.001) compared to controls on the original SDMT.








Age (yrs) 50 (8) 45 (9) 49 (10) 0.150
Gender (m/f) 13/15 8/13 13/27 0.508
Education (% high) 14 29 25 0.204
CAG 42 (2) 43 (3)
Total motor score 2 (2) 3 (1) 26 (16) <0.001
Total functional capacity score 13 (0) 13 (0) 11 (6) <0.001
BDI-II score 4 (5) 5 (5) 8 (7) <0.02
MMSE score 30 (2) 29 (1) 29 (3)
Disease burdena 282 (57) 366 (68)
Expected yrs to disease onsetb 10 (6)
Note. Data are Mean (SD), except for gender (number), education (percentage) and total
functional capacity, MMSE and expected years to disease onset (median and interquartile range).
ANOVA was used for age and TMS variables. χ2-test was used for gender and education variables.
Kruskal-Wallis test was used for total functional capacity score. PMHD = premanifest HD,
MHD = manifest HD, BDI-II = Becks Depression Inventory II, MMSE = Mini Mental State
Examination. aBased on formula ‘(CAG-35.5)*age)’ by Penney et al. (1997). bBased on survival
analysis formula by Langbehn et al. (2004).
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The PMHD group showed lower baseline scores of 0.67 SD (SE 0.25, p=0.008)
on the SDMT motor isolation score, as compared to controls. Longitudinally, this
group also showed a deterioration of 0.48 SD (SE 0.14, p=0.001) on the original
SDMT, again compared to controls. The same pattern was seen for the SDMT
cognition isolation score, where the PMHD group deteriorated with on average
0.52 SD (SE 0.21, p=0.02) compared to controls.
FFT baseline differences and rate of decline for the HD groups
compared to controls
For the FFT, group differences were only found for the motor isolation score (Table
2A). Here, both the MHD and the PMHD group showed lower baseline scores as
compared to controls. The MHD group had lower scores of on average 0.58 SD
(SE 0.24; p=0.02). The PMHD group scores were 0.63 SD (SE 0.24; p=0.01)
lower.
Comparison of premanifest subjects close to and far from their
predicted age at disease onset
Table 2B presents baseline differences and rate of decline on the SDMT and FFT
for the close and far groups compared to controls. The corrected analyses showed
significant deterioration over time for the close group on the original SDMT score
compared with controls. Over the one-year follow-up they deteriorated with on
average 0.65 SD (SE 0.18, p=0.001). The SDMT cognitive isolation analysis
showed that the close group deteriorated with 0.59 SD (SE 0.27, p=0.03) com-
pared to controls. Considering the FFT, the close group showed lower baseline



























2A. Premanifest and manifest HD subjects
compared to controls
2B. Premanifest HD subjects close to and far from
predicted disease onset compared to controls
SDMT original
Baseline diff. Ref. -0.22 (SE 0.26) 0.85 (SE 0.22)***<0.001 Ref. 0.04 (SE 0.29) -0.52 (SE 0.30) 0.19
Rate of decline Ref. 0.49 (SE 0.14)**0.41 (SE 0.14)** 0.001 Ref. 0.66 (SE 0.18)**0.35 (SE 0.18) 0.003
SDMT motor isolation
Baseline diff. Ref. 0.58 (SE 0.26)* 1.12 (SE 0.23)***<0.001 Ref. 0.65 (SE 0.30) 0.50 (SE 0.31) 0.06
Rate of decline Ref. 0.01 (SE 0.18) -0.12 (SE 0.17) 0.71 Ref. 0.12 (SE 0.18) -0.14 (SE 0.18) 0.46
SDMT cognition isolation
Baseline diff. Ref. -0.54 (SE 0.27)*0.51 (SE 0.23)* <0.001 Ref. -0.30 (SE 0.29) -0.81 (SE 0.30)** 0.03
Rate of decline Ref. 0.55 (SE 0.21)* 0.31 (SE 0.20) 0.04 Ref. 0.59 (SE 0.26)* 0.53 (SE 0.26)* 0.04
FFT original
Baseline diff. Ref. 0.05 (SE 0.27) 0.86 (SE 0.24)***<0.001 Ref. 0.09 (SE 0.30) -0.01 (SE 0.31) 0.95
Rate of decline Ref. 0.09 (SE 0.15) 0.17 (SE 0.21) 0.71 Ref. 0.25 (SE 0.28) -0.02 (SE 0.28) 0.63
FFT motor isolation
Baseline diff. Ref. 0.48 (SE 0.27) 0.94 (SE 0.24)*** 0.001 Ref. 0.58 (SE 0.28) 0.36 (SE 0.29) 0.10
Rate of decline Ref. -0.05 (SE 0.16) 0.00 (SE 0.15) 0.94 Ref. -0.06 (SE 0.21) 0.01 (SE 0.21) 0.95
FFT cognition isolation
Baseline diff. Ref. -0.18 (SE 0.27) 0.63 (SE 0.24)** 0.003 Ref. -0.15 (SE 0.30) -0.22 (SE 0.31) 0.74
Rate of decline Ref. 0.04 (SE 0.27) 0.22 (SE 0.25) 0.65 Ref. 0.34 (SE 0.34) -0.21 (SE 0.34) 0.40

























Table 2: (Continued) Differences at baseline and change over time for PMHD and MHD and for PMHD close and
















2A. Premanifest and manifest HD subjects
compared to controls
2B. Premanifest HD subjects close to and far from
predicted disease onset compared to controls
SDMT original
Baseline diff. Ref. -0.04 (SE 0.24) 0.53 (SE 0.24)* 0.04 Ref. -0.02 (SE 0.32) -0.19 (SE 0.36) 0.87
Rate of decline Ref. 0.48 (SE 0.14)**0.47 (SE 0.13)** 0.001 Ref. 0.65 (SE 0.18)**0.33 (SE 0.18) 0.003
SDMT motor isolation
Baseline diff. Ref. 0.67 (SE 0.25)**(0.71 (SE 0.25)** 0.008 Ref. 0.60 (SE 0.32) 0.72 (SE 0.36) 0.06
Rate of decline Ref. 0.00 (SE 0.19) -0.04 (SE 0.18) 0.97 Ref. 0.12 (SE 0.19) -0.15 (SE 0.19) 0.47
SDMT cognition isolation
Baseline diff. Ref. -0.42 (SE 0.26) 0.24 (SE 0.26) 0.045 Ref. -0.25 (SE 0.31) -0.51 (SE 0.35) 0.32
Rate of decline Ref. 0.52 (SE 0.21)* 0.38 (SE 0.20) 0.038 Ref. 0.59 (SE 0.27)* 0.54 (SE 0.27) 0.04
FFT original
Baseline diff. Ref. 0.20 (SE 0.25) 0.52 (SE 0.25) 0.12 Ref. 0.10 (SE 0.31) 0.34 (SE 0.35) 0.62
Rate of decline Ref. 0.08 (SE 0.22) 0.26 (SE 0.20) 0.43 Ref. 0.25 (SE 0.29) -0.01 (SE 0.29) 0.65
FFT motor isolation
Baseline diff. Ref. 0.63 (SE 0.24)**0.58 (SE 0.24)* 0.018 Ref. 0.66 (SE 0.29)* 0.66 (SE 0.32) 0.03
Rate of decline Ref. -0.06 (SE 0.16) 0.06 (SE 0.15) 0.77 Ref. -0.07 (SE 0.20) 0.03 (SE 0.21) 0.92
FFT cognition isolation
Baseline diff. Ref. -0.07 (SE 0.26) 0.30 (SE 0.27) 0.35 Ref. -0.19 (SE 0.31) 0.12 (SE 0.34) 0.72
Rate of decline Ref. 0.01 (SE 0.27) 0.32 (SE 0.25) 0.35 Ref. 0.34 (SE 0.35) -0.20 (SE 0.35) 0.43
Note. Data are standardized mean differences versus controls (standard errors). In all multilevel regression analyses a compound symmetry
covariance matrix (CS) was used. * p<0.05, ** p<0.01, *** p<0.001 indicate significant differences compared to the control group in post-
hoc tests. SDMT = Symbol Digit Modalities test, FFT = Figure Fluency test, BDI-II = Becks Depression Inventory, Ref. = Reference
group, TFC = Total Functional Capacity.
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DISCUSSION
In this study we showed that there is a significant influence of motor disturbances
on the SDMT for both manifest and premanifest subjects. Additionally, isolation of
the cognitive component of this test showed a deterioration of executive function-
ing over the one-year follow-up for the premanifest group only. Secondary analyses
revealed that the subjects closest to predicted clinical disease onset showed rapid
decline while those further away from diagnosis performed similar to healthy con-
trols.
To our knowledge, O‘Rourke et al. have been the first in HD literature to investi-
gate the cognitive domain of executive functioning, while minimizing the influence
of non-cognitive factors of the test19. They used the Trail Making Test (TMT),
which consists of two parts. Part A is hypothesized to rely on visuoperceptual
abilities and visual search, and part B additionally relies on executive functioning
abilities20. Amongst other derived scores, they subtracted the score on part A
from that of part B to isolate the executive functioning components of the test.
Contrary to our results, they concluded that the TMT primarily measures cognition
in premanifest HD, and is not significantly affected by motor or psychiatric distur-
bances. One explanation that they offered is that motor deficits in the premanifest
phase are too subtle to influence cognitive test outcome.
However, our study showed that isolation of the motor component of both the
SDMT and the FFT resulted in motor scores that were significantly slower com-
pared to controls for both manifest and premanifest participants. Even premanifest
subjects proved to be more than 0.5 SD slower than controls, indicative of the pres-
ence of motor abnormalities in our premanifest group. No differences were found
for the rate of decline of the motor components of both the SDMT and the FFT,
which implies that motor dysfunctioning is stable over a one-year period. Moreover,
we found that these motor abnormalities have an influential effect on the overall
test score: when the motor component was subtracted from the original SDMT
score to isolate the actual cognitive component of the test, no significant results
remained for our manifest subjects. However, the premanifest group did show a
decline of the cognitive component score over the one-year follow-up. Thus, even
when the motor influence was taken into account, premanifest subjects deterio-
rated on their performance of the SDMT over one year.
No cognitive differences or deterioration in the manifest group was observed. This
could mean that most rapid decline has already taken place preceding disease on-
set, and that deterioration of executive functioning stabilizes to a rate similar to
that of controls in the manifest phase of the disease. Another explanation could
be that the motor disturbances associated with manifest HD have become thus
pronounced that they prevent from any cognitive effect to be measured. Indeed,
we did find lower baseline scores for the manifest group on both the original SDMT
score and on the motor isolation part. And, when the cognitive part was isolated by
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subtracting the motor part from the original SDMT score, no significant differences
remained. Therefore, it seems that motor functioning is the main contributor to
the overall score on the SDMT in manifest HD.
So, on the one hand, we have found that motor disturbances are already present in
the premanifest phase of the disease, revealed by slower motor component scores
for the premanifest group compared to the control group. That subtle motor ab-
normalities are present in premanifest subjects was also observed by Biglan et al21,
in their study on data from the PREDICT-HD study. On the other hand, executive
functioning deterioration also already occurs in this phase of HD, even when the
influence of motor functioning is minimized. To date, cognitive HD literature has
not yet reached consensus about the nature and extent of premanifest cognitive
changes. Our study adds to the discussion with proof that executive functioning
is one of the cognitive domains most sensitive to premanifest changes.
Secondary analyses revealed that the premanifest differences were the result of
worse performance of the premanifest subjects that were predicted to be close to
disease onset. This group showed a deterioration on the original condition of the
SDMT, but also on the cognitive part of this test. Subjects further away from
predicted onset performed at the same level as controls on all components of the
executive functioning tests. Here, either no change takes place, or changes in
executive functioning are too subtle to pick up with the tests used in this study.
Altogether, our results point in the direction of a biphasic deterioration of ex-
ecutive functioning, with performance that is comparable to healthy controls in
premanifest subjects more than 10 years from predicted disease onset, and a rapid
deterioration close to clinical (motor-manifest) disease onset. Furthermore, decline
is rapid as it is measurable over a one-year interval.
This is an assumption that is shared by other authors that have investigated cog-
nition in the premanifest phase. They found that deterioration of several cognitive
domains (e.g. executive functioning, memory) is most pronounced and rapid just
before clinical disease onset, and is often the result of the performance decline of
premanifest subjects who are about to convert to manifest HD22 23.
Another important finding is that, using the SDMT, we were able to detect pre-
manifest change on its original and isolated cognitive parts over a follow-up period
of only one year. The SDMT is a test of executive functioning that has con-
sistently been found to be impaired in both manifest and premanifest HD24 25.
Cross-sectional as well as longitudinal24 26 27 studies have reported poorer scores
on the SDMT for premanifest gene-carriers. Outcome measures that are sensitive
to change over short periods of time are of vital importance in the design and
implementation of future clinical trials. Ideally, the effect of disease modifying
or even slowing agents are to be measured over time periods as short as possi-
ble considering study costs and patient well-being. Our study indicates that the
SDMT is a candidate cognitive outcome measure sensitive to premanifest change
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in executive functioning.
Apart from differences on the motor part of this test, the FFT did not reveal
any results for the HD groups on both the original and the cognitive conditions.
One possible explanation could be that the FFT measures an executive construct
different from that of the SDMT, and results are therefore not comparable. Indeed,
a fundamental difference between the two tests is that the SDMT has a key with
the correct answers that is provided alongside the test and which participants can
refer to while completing the task. For the FFT, on the other hand, self-directed
planning and organisation is needed to generate as many unique figures as possible.
Additionally, due to its self-directed instead of key-directed component, the FFT
seems to rely on more complex executive functioning abilities that even healthy
controls find difficult to complete. As a result, the FFT seems not well suited to
differentiate between healthy subjects and HD gene carriers.
With this study we have provided evidence that motor functioning contributes
to performance on the SDMT. Consequently, cognitive findings in HD could be
overestimated when this negative influence is not taken into account. Our findings
implicate that the results of previous studies that have used the SDMT and have
not controlled for the influence of motor functioning should be interpreted with
caution. Also, in the design of future studies incorporating executive tasks with a
high motor load, ways of minimizing motor influence should be considered to be
better able to unravel actual cognitive performance. The extra motor conditions
are of an experimental design. To isolate the motor component of the executive
tasks used in this study we designed an extra ‘low cognition - high motor’ load
conditions that mimic the motor requirements of the original task. However, no
validation of these extra conditions were performed. Considering our findings,
investigation of possible other ways of minimizing or controlling for motor contri-
bution on cognitive tests deserves recommendation.
Concluding, we have found evidence for the presence of motor disturbances which
are of influence on the score of the SDMT. These motor disturbances are stable
over a one-year period. With isolation of the cognitive component of the SDMT
we revealed cognitive deterioration in the premanifest group only, caused by de-
teriorating scores of premanifest subjects that are close to their predicted clinical
disease onset. Lack of deterioration in subjects more than 10 years from onset
suggests a biphasic course of progression for executive dysfunctioning. The FFT
was not found to be able to pick up premanifest cognitive change.
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Chapter 8
General discussion and future
perspectives
Understanding the course of cognitive decline is of great importance in the study of
HD, to gain knowledge to improve specialized care for HD patients and to aid the
design of future clinical trials. Research in the premanifest phase of the disease is
of particular importance as many pathophysiological mechanisms remain unclear.
Furthermore, investigation of the influence that HD motor disturbances have on
cognitive test results will help to entangle the actual cognitive effect from other
influential factors.
Course of cognitive functioning
Impaired cognitive abilities such as mnestic deficits and executive dysfunctioning
have consistently been found in manifest HD1. However, the results in the pre-
manifest phase are not that clear-cut. Several longitudinal studies on cognition
show cognitive deficits in premanifest gene carriers even decades before estimated
age at disease onset2, while others do not detect differences between their preman-
ifest and control groups3 4. With the ever growing understanding of HD genetics
we move closer to clinical intervention studies to investigate agents with possible
disease modifying or disease slowing effects. Increasing the knowledge about phe-
notypical progression of symptoms remains however important as there is not yet
a uniform agreement, especially in the areas of cognition and psychiatry.
Executive functioning most sensitive to premanifest change
In our cognitive studies we have found strong evidence that the cognitive domain
of executive functioning is most sensitive to premanifest cognitive deterioration.
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Ten-year follow-up of cognition (chapter 5) showed that the executive functioning
factor was the only factor to show results in the premanifest group. Interestingly,
when studying the premanifest group as a whole, results were not different from
that of controls. Only when the subjects who converted to manifest disease over
the ten-year follow-up were analysed separately from the subjects who remained
premanifest during the study, informative differences emerged. The converters
showed a significant deterioration over time compared with the control subjects,
while the scores of the continual premanifest subjects were comparable to control
scores. Likewise, when we divided the premanifest group into those subjects who
at baseline were far from expected disease onset and those who were close to onset,
only the subjects close to expected onset showed lower baseline scores compared
to controls, on the executive functioning factor only.
Further analyses revealed that the above findings were the result of poorer perfor-
mance of the converter and close to onset groups on the Symbol Digit Modalities
test (SDMT). Large premanifest effects on the SDMT were also found in our
one-year follow-up study where we tested possible decline on both the SDMT and
the Figure Fluency test (chapter 7). Even when we controlled for the influence
of motor functioning, only the SDMT proved sensitive to premanifest change in
the close to predicted onset group. The SDMT is a widely used test of executive
functioning, and has often been found to be sensitive to change in the premanifest
phase of HD. Our results support other findings that the SDMT is a well suited
cognitive instrument to catch early cognitive decline in HD.
The above results lead us to hypothesize that progression of executive functioning
in the premanifest phase evolves in a non-linear manner. Subjects that are further
away from disease onset are able to maintain test requirements to the level of
controls, while subjects close to disease onset show a rapid decline in performance.
Additionally, the lack of deterioration over time for the manifest group suggests
that most rapid deterioration of executive functioning abilities occurs around dis-
ease onset. Furthermore, in our study on cognition over a seven-year follow-up
period (chapter 4) we found additional evidence for non-linear decline of mem-
ory functioning. Here, the observed memory decline over time in the premanifest
group could be fully attributed to the gene carriers who converted to manifest dis-
ease over the follow-up time. Premanifest subjects who remained without clinical
motor symptoms did not show memory deficits compared to controls, they only
showed lower scores on a sub-test supposed to measure concentration abilities.
That progression of cognitive symptoms does not evolve in a linear manner has
also been reported by other authors. Snowden et al.5 and Paulsen et al.2 have both
observed a more rapid decline of memory and executive functioning, respectively,
in subjects approaching motor symptomatic disease onset, as compared to gene
carriers further away from disease onset. Furthermore, Rupp et al. have reported
on a longitudinal study where those closest to onset showed the largest rates of
decline on cognitive measures6.
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Evidence for compensatory mechanisms
In this thesis we provide evidence for possible cognitive compensatory mechanisms
in HD. In the cross-sectional study on the SART and simultaneous P300 registra-
tion (chapter 2) we observed a pronounced post-error slowing of reaction time for
the manifest HD group, which could be indicative of a compensatory strategy to
prevent the occurrence of errors. This so-called ‘speed accuracy trade-off’, where
a slowing in reaction time raises the amount of correct responses, could be an ex-
planation for our findings. The slowing indeed seems to prevent the manifest HD
group from making more No-go errors compared to both premanifest gene carriers
and controls. The post-error slowing that we observed could not be ascribed to
mere motor slowing. Indeed, the manifest group was slower to react to the appear-
ance of stimuli overall. For the reaction time pattern of trials surrounding correctly
responded No-go trials a significantly slower but similar pattern of reaction was
observed for the manifest group compared to the premanifest gene carriers and the
controls. However, when studying the pattern around incorrectly responded No-go
trials, the responses were not only slower, but a different pattern also emerged.
The difference in reaction time patterns surrounding correct No-go trials and No-
go trials where an error has been made, leads us to hypothesize that the observed
post-error slowing can indeed be caused by a compensatory mechanism such as
speed accuracy trade-off.
In the longitudinal study on the SART and P300 (chapter 3) we no longer found
evidence for compensation in the manifest group. Manifest subjects showed slower
responses compared to premanifest gene carriers and controls, and also slowed
more over time compared to both other groups. As there was no observed benefit
from the slowing (i.e. less errors), we assumed that in this group of patients the
neurodegenerative damage has become too large to effectively apply compensatory
strategies. In contrast, we did find evidence for compensation taking place in our
premanifest group. Only on specific trials we found a slowing over time in this
group, and as there was no increase in errors over time, we hypothesized that this
could reflect the implementation of the compensatory speed accuracy trade-off
strategy.
That compensatory mechanism are at work in HD, and especially in the preman-
ifest phase of the disease, is an idea that is receiving growing evidence. Using
functional MRI, both cognitive7 and motoric8 compensation has been reported,
as well as cognitive compensation using event related potentials9. In other neu-
rodegenerative diseases such as Parkinson‘s and Alzheimer‘s disease compensatory
mechanisms have also been found, sometimes referred to as the ”cognitive reserve
hypothesis”. Furthermore, the unexpected lack of functional changes in preman-
ifest gene carriers in the TRACK-HD study has resulted in the TRACK-ON HD
study, especially designed to investigate possible compensatory mechanisms in the
premanifest phase of HD.
128 | Chapter 8
Influence of motor functioning on cognition
HD is primarily known as a movement disorder, and clinical disease onset is in most
cases based on the appearance of motor symptoms characteristic for the disorder.
However, subtle disturbances in motor functioning have also already been found
in premanifest subjects10. And as almost all cognitive tests require some kind of
motoric response, often by means of verbal or written answers, investigating the
influence of motor changes on cognitive functioning could provide important infor-
mation on cognitive functioning.
Evidence for negative effect of motor on cognition
In our ten year longitudinal study on the course of cognition in HD (chapter 5) we
investigated the influence of motor speed on cognition by adding this variable as a
covariate in the cognitive statistical model. We found that the significant cognitive
results diminished by 20% when motor speed was taken into account, opposed to
the model without this motor measure. Here, several results that ceased to be sig-
nificant, while those who remained significant lessened in strength. We concluded
that motor speed has a substantial influence on cognitive test results, accounting
for up to 20% of the significance of cognitive results when not statistically ac-
counted for.
In another study we created additional conditions for existing cognitive tests of
executive functioning, the SDMT and the Figure Fluency test (FFT) (chapter
7). These extra conditions were designed in such a way that the cognitive load
was minimal while the motor demands were relatively similar to the original test.
By subtracting this motor condition from the original test score we expected to
measure a more ‘pure’ cognitive score. Our results showed there was a substantial
(negative) influence of motor functioning on cognition, especially in the manifest
HD group. When the actual cognitive component was isolated by subtraction
of the motor component, no cognitive results remained for this group. For the
premanifest group the influence of motor disturbances could also be detected,
however, cognitive differences could still be measured. From these two studies we
can conclude that the influence of motor functioning in HD has a negative effect
on cognitive outcomes. Even in premanifest subjects, where motor disturbances
are very subtle, cognitive outcomes are impacted by these abnormalities. Even
though the motoric effect is substantial, we have also always measured a cognitive
effect in premanifest subjects in both studies.
Two motor phenotypes with different clinical profiles
There is not only an influence of motor functioning on cognition, we have also
found evidence for the existence of different motor subtypes of HD, with different
cognitive profiles (chapter 6). When we divided a large group of manifest HD
subjects into either choreatic or hypokinetic-rigid HD according to the motor signs
that were predominant in these subjects, we found that the hypokinetic-rigid group
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performed significantly worse on tests of global and cognitive functioning, com-
pared with the choreatic group. Furthermore, we established that these differences
were not caused by differences in age, disease duration and use of neuroleptic drugs,
which strengthened our hypothesis that fundamental different clinical profiles exist
between predominant choreatic and predominant hypokinetic-rigid HD.
Future perspectives
To date, many clinical trials investigating the efficacy of agents designed to enhance
functioning in HD subjects are implemented in different stages of manifest disease.
If we however want to move forward to disease modification or even prevention,
inclusion of subjects in the premanifest phase is vital. Already a small number
of clinical trials is aimed at preventative therapies in the premanifest phase (e.g.
Pre-QUEST and PREQUEL [http://clinicaltrials.gov/ct2/home]), and the expec-
tation is that this number will rise in the coming years. From our studies we can
conclude that early changes in executive functioning are already visible in subjects
nearing clinical onset, and that decline is rapid. Clinical trials investigating agents
designed to improve cognitive functioning in HD should therefore make use of
tests of executive functioning, preferably including the SDMT, to be best able to
capture drug induced change.
Furthermore, our results prove that subjects close to their predicted disease on-
set are most suitable as key research group in future clinical trials. Firstly, as
they show the most rapid decline in executive functioning opposed to premanifest
subjects further from onset and subjects further into the manifest phase of HD,
drug-induced disease modifying effects may potentially be measured over relatively
short periods of follow-up time. Secondly, as they are the group to deteriorate most
rapidly they are also the group that would probably show maximum benefit from
drug intervention, especially when disease slowing agents will become available.
Parallel to drug development projects, observational studies such as Track(-On)
HD and Predict-HD are searching for the optimum time point in the course of HD
to first introduce drug treatment. Our results on the course of cognition add to
the knowledge from these multicentre studies.
To avoid overestimation of cognitive results we advocate that to control for a quan-
titative measure of motor functioning, such as reaction time, in cognitive studies,
to be able to entangle the influence of motor influence on cognition in HD. Our
findings also implicate that the results of previous cognitive studies which have
not included some measure of motor functioning have to be interpreted with some
caution. As a substantial part of the cognitive effect in these studies is possibly
the result of (subtle) motor disturbances, the findings should not be regarded as
‘pure’ cognitive effects.
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The existence of two different motor subtypes with different clinical profiles has
implications for both care and scientific research. Concerning clinical care for HD
patients, hypokinetic-rigid patients need more specialized care as they have been
proven to be both generally and cognitively worse. Because a patient with predom-
inant hypokinetic-rigid motor symptoms is more likely to have cognitive deficits,
this patient is also more likely to benefit from repeated instructions, or cognitive
training, to maintain a relatively good quality of life for a longer period of time.
Instead, patients with predominant choreatic symptoms may need less cognitive
care, even though they are often times motorically very affected.
The knowledge about different clinical profiles for patients with different predomi-
nant motor symptoms is also of importance for the design of future clinical trials.
Studies using cognitive or global functional (e.g. total functional capacity scale)
outcome measures which have mostly included patients with predominant chore-
atic HD motor symptoms will show different results from when mostly predominant
hypokinetic-rigid HD patients or even a mix of the two groups are included.
Limitations
One general point of caution has to be noted. In all of the studies included in this
thesis we have made the division of premanifest or manifest according to a cut-off
point of the score on the total motor score (TMS), the subscale of the Unified
Huntington‘s Disease Rating Scale measuring motor functioning. It may well have
been that certain subjects already experienced a non-motor clinical onset, such
as severe cognitive impairment or behavioral disturbances. Indeed, Orth et al.11
investigated age at onset in the REGISTRY study and found that out of the 423
subjects studied 28% (120) had a non-motor onset of disease. The motor-based
division that we have used could have introduced a selection bias, where subjects
who may have been manifest based on cognitive or psychiatric criteria, but were
nonetheless included in the (motor)premanifest group, possibly confounding study
results. We question if the TMS should continue to be used as golden standard for
group division in HD. Studies using broader criteria to make a distinction between
manifest and premanifest may maximize both study and treatment outcomes.
Furthermore, it should be mentioned that the studies reported in this manuscript
show some overlap in participants. A group of subjects (n=26) who participated
in the longitudinal study on P300 and SART performance also participated in the
seven and ten year cognitive follow-up study. Also, for the one-year follow-up study
on executive functioning in both premanifest and manifest HD 15 subjects already
also already participated in the seven and ten year follow-up study. This raises the
question of practice effects, a well-known challenge in HD research. Due to the
relative rarity of the disease HD subjects are often recruited for multiple studies
using identical tests. This also makes that the results from the mentioned studies
are not fully independent, which potentially limits generalizability.
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Summary
Huntingtons disease (HD) is an autosomal neurodegenerative disorder caused by
the expansion of the huntingtin gene located on chromosome 4. The clinical pic-
ture is characterized by a triad of symptoms: motor disturbances, behavioural
changes and cognitive decline. Disease manifestation occurs in mid-life, having a
devastating effect on an individuals work, family and personal life. To date, no
means of curing or even slowing the disease are available and inheriting the gene
inevitable leads to disease and a premature death. With the chromosomal map-
ping of the disease in 1983 and the discovery of the huntingtin gene in 1993, it
became possible to be tested for the presence of the gene. When tested positive,
and without overt signs and symptoms of the disease, an individual is called a pre-
manifest gene carrier. In these premanifest gene carriers subtle changes in motor,
behavioural and cognitive functioning have been found, along with early changes
in structure and function of the brain.
Even though almost all cognitive tests require some form of motor response, often
by means of written or verbal answers, there is little attention for the influence
of motor functioning on cognitive test outcome in HD. Furthermore, because it is
known that subtle motor deficits can occur in the premanifest phase of HD, under-
standing the possible negative effect of motor on cognitive functioning is necessary
when trying to understand the progression of cognitive decline in all stages of HD.
In this thesis we have studied cognitive functioning in both patients and preman-
ifest gene carriers, making use of several different techniques. Furthermore, we
have investigated the influence of the known (subtle) motor deficits on cognitive
scores by controlling for several measures of motor functioning.
The event related potential (ERP) P300, a positive peak visible on the EEG ap-
proximately 300 milliseconds following the presentation of a stimulus, is thought
to be a neurophysiologic measure of attentional processing. The peak latency
is hypothesized to be linked to speed of stimulus evaluation, or more generally,
to speed of attentional processing, and its amplitude to the amount of attention
allocated to the stimulus. A key feature of the P300 is that it is a measure of
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attentional processing that is independent of motor influences. We have registered
the P300 simultaneous to a test of attention, the Sustained Attention to Response
task (SART) (chapter 2). Seventeen patients, 12 premanifest gene carriers and 15
controls were assessed. We found attentional control to be deficient in patients, as
demonstrated by more errors being made by this group. Further investigation re-
vealed post-error slowing in case of a certain type of error, which could be induced
by a cognitive compensatory strategy called speed-accuracy trade-off. Furthermore,
the observed attentional control deficits during the SART were corroborated by a
reduced P300 amplitude and prolonged P300 latency, indicative of lowered atten-
tional capacities.
The findings on the SART with simultaneous P300 registration were further studied
in a longitudinal pilot-study (chapter 3). A subset of participants (five patients,
nine premanifest gene carriers and 12 controls) from the cross-sectional study was
also tested over a three year interval to investigate the progression of attentional
control in HD. Patients showed heightened error rates and prolonged reaction times
compared to the other two groups. There was however, no evidence for compen-
sation in the form of speed-accuracy trade-off, as proposed in our cross-sectional
study, because the slowing in reaction time did not prevent the occurrence of er-
rors. One explanation that we offered was that due to disease progression the
employment of the compensation strategy has reached a maximum in the patient
group and is no longer effective in reducing error rates. On the other hand we
observed slowing of reaction time on the trials just before having prevented an
error in the premanifest gene carriers. As no slowing was found on other trials, and
the slowing was not accompanied by elevated error rates, we hypothesized that
compensatory mechanisms may be at work here.
The progression of cognitive functioning in the premanifest phase of HD was stud-
ied in a longitudinal study (chapter 4). The 29 premanifest gene carriers and 43
control participants who completed the seven-year follow-up were analyzed in this
study. They were tested four times, using an extensive battery of tests covering
most areas of cognitive functioning such as memory and executive functioning. We
found that the premanifest gene carriers deteriorated on the domains of memory
and concentration. These changes could primarily be ascribed to the carriers who
converted to manifest disease over the study period. When these subjects were
excluded from the analyses only the concentration sub test of the Wechsler Mem-
ory Scale was found to deteriorate over time for the premanifest gene carriers. We
concluded that most cognitive change probably takes place in the phase close to
disease onset.
Further study of this cohort resulted in an additional ten-year follow-up of pa-
tients and premanifest gene carriers (chapter 5). The tests used in this study were
combined into four factors by means of factor analyses: three cognitive (global cog-
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nition, executive functioning and memory) and one motor factor (motor speed).
The progression of premanifest gene carriers (n=26), patients (n=19) and control
subjects (n=87) over ten-years on the four factors was studied using multilevel
regression analyses. The patients showed lower baseline scores compared with
controls on all cognitive factors. When the converters were analyzed separately
from the participants who remained premanifest during the whole follow-up, we
found that only the converters deteriorated over time as compared with controls on
the executive functioning + memory factors. Furthermore, when the premanifest
group was divided in those close to and those far from expected disease onset, we
observed a deterioration on the executive functioning factor for the subjects close
to disease onset. We concluded that the executive functioning factor is most sensi-
tive to premanifest cognitive progression, especially around disease onset. Another
important outcome of this study was that the influence of motor functioning on
cognitive test scores is substantial and should be taken into account in cognitive
research in HD.
We also investigated the different cognitive and functional profiles between two mo-
tor subtypes of HD: predominantly choreatic HD and predominantly hypokinetic-
rigid HD (chapter 6). We divided the subjects from the REGISTRY study database
into the two motor types, which resulted in 528 choreatic and 432 hypokinetic-
rigid subjects. Using regression analyses we found that the hypokinetic-rigid group
performed worse on a measure of global functioning, as well as on several mea-
sures of cognitive functioning. As the analyses were controlled for age and disease
duration, and because both groups were comparable considering use of neurolep-
tics, we concluded that different profiles exist between the two motor types of HD.
Here, predominantly choreatic HD subjects are functionally and cognitively better
than predominantly hypokinetic-rigid HD subjects, which could have implications
for both scientific research and clinical care.
To investigate the influence of motor functioning on cognitive functioning we de-
signed an extra condition that measures motor functioning for two tests of executive
functioning (the symbol digit modalities test [SDMT] and the figure fluency test
[FFT]) (chapter 7). Subsequently we subtracted the motor condition from the
original test score, which we hypothesized would result in a more pure cognitive
score. Forty patients and 21 premanifest gene carriers were compared to 28 con-
trol subjects. We found a substantial negative influence of motor functioning on
executive task performance, especially in patients. However, even in the preman-
ifest group there motor disturbances were measurable. With the isolation of the
actual cognitive component we found deterioration on the SDMT only, caused by
deteriorating scores of subjects that were close to their predicted age at disease
onset.
A general discussion and future perspectives are discussed (chapter 8). In sum-
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mary, we advocate that the domain of executive functioning is best targeted in fu-
ture clinical trials as this cognitive domain is most sensitive to premanifest change.
The SDMT is recommended as a suitable executive test to serve as outcome mea-
sure. As most rapid deterioration of executive functioning is found in subjects
approaching their clinical disease onset, this group is put forward as key research
group in clinical trials. Following our findings of substantial negative effects of mo-
tor functioning on cognition, we advise future cognitive studies to always control
for motor functioning in cognitive testing, to be able to entangle the influence of
motor disturbances on cognition in HD. Lastly, the existence of two different HD
motor phenotypes, namely predominant choreatic and predominant hypokinetic-
rigid HD, with different clinical profiles brings about implications for both clinical
care and scientific research.
Samenvatting
De ziekte van Huntington (ZvH) is een autosomale dominante neurodegeneratieve
aandoening die wordt veroorzaakt door een abnormale expansie van het hunting-
tine gen, dat zich bevindt op chromosoom 4. Het klinisch beeld wordt getypeerd
door een trias van symptomen: bewegingsstoornissen, gedragsveranderingen en
cognitieve achteruitgang. De ziekte uit zich doorgaans ongeveer tussen de 30 en
50 jaar. In deze belangrijke periode van het leven heeft de ziekte dan ook een zeer
ingrijpend effect op het werk, gezins- en persoonlijke leven van een persoon. Tot
op heden is er geen genezing mogelijk en is er geen manier om de progressie van
de ziekte te vertragen of veranderen. Het erven van het gen leidt dan ook onher-
roepelijk tot ziekte en een vroegtijdig overlijden. Met de chromosomale lokalisatie
van de ziekte in 1983, en de ontdekking van het gen in 1993, is het mogelijk
geworden om op de aanwezigheid van het gen te worden getest. Wanneer iemand
het gen heeft, maar nog geen uiterlijke symptomen van de ziekte vertoont, noemen
wij iemand een premanifeste gendrager. Eerder onderzoek heeft aangetoond dat
bij deze premanifeste gendragers subtiele veranderingen op motorisch, gedrags- en
cognitief gebied al aanwezig kunnen zijn, en dat deze samengaan met vroege ve-
randeringen in zowel structuur en functie van het brein.
Hoewel bijna alle cognitieve testen enige vorm van motorische respons vergen,
vaak door verbaal of schriftelijk antwoord te moeten geven, is er weinig aandacht
voor de invloed van motoriek op cognitieve testscores bij de ZvH. Bovendien is het
bekend dat subtiele motorische afwijkingen al in de premanifeste fase van de ziekte
aanwezig kunnen zijn. Dit maakt dat het onderzoeken en daarmee begrijpen van
de mogelijk negatieve invloed van motoriek op cognitief functioneren noodzakelijk
is wanneer we de progressie van cognitieve achteruitgang in alle stadia van de ZvH
in kaart willen brengen.
Dit proefschrift beschrijft het onderzoek dat wij hebben uitgevoerd naar cognitief
functioneren in zowel de premanifeste als de manifeste fase van de ZvH, waarbij
we gebruik hebben gemaakt van diverse meettechnieken. Bovendien hebben wij
de invloed van de (subtiele) stoornissen in de motoriek op cognitieve scores on-




De P300 is een ‘event related potential’, dat wil zeggen een potentiaal dat is
gerelateerd aan een gebeurtenis, en kan worden afgeleid uit het EEG. Het is een
positieve piek die ongeveer 300 milliseconden na de presentatie van een stimulus
kan worden gezien op het EEG. Er wordt verondersteld dat het een neurofysiol-
ogische maat is voor diverse aandachtsprocessen. De latentie waarmee de piek
zijn hoogste punt bereikt wordt gekoppeld aan de snelheid waarmee een stimu-
lus wordt gevalueerd, of anders gezegd, aan de snelheid van aandachtsverwerking.
De P300 amplitude wordt daarentegen gekoppeld aan de hoeveelheid aandacht
die aan een stimulus wordt besteed. Een belangrijke eigenschap van de P300 is
dat het een maat voor aandachtsprocessen is die onafhankelijk is van de invloed
van motoriek. Wij hebben de P300 geregistreerd tijdens een aandachtstest, de
Sustained Attention to Response test (SART), waarbij zeventien patiënten, 12
premanifeste gendragers en 15 controle personen werden onderzocht (hoofdstuk
2). Wij vonden dat de aandachtscontrole was aangedaan bij de patiënten, hetgeen
bleek uit het hoge aantal fouten dat deze groep maakte. Uit verder onderzoek bleek
dat er sprake was van een vertraging in reactietijd direct na het maken van een
specifiek type fout. Dit kan het gevolg zijn van een bepaalde cognitieve compen-
satiestrategie genaamd ‘speed-accurracy trade-off’. Bovendien ging dit gebrek aan
aandachtscontrole gepaard met een verlaagde P300 amplitude en een vertraagde
latentie, wat verder bewijs is voor verlaagde aandachtscapaciteiten.
In een longitudinale pilot-studie hebben wij de cross-sectionele resultaten van de
SART met gelijktijdige P300 registratie verder onderzocht (hoofdstuk 3). Een
deel van de deelnemers aan de cross-sectionele studie (vijf patiënten, negen pre-
manifeste gendragers en 12 controles) werden na drie jaar nogmaals getest om
de progressie van aandachtscontrole bij ZvH te onderzoeken. Nu maakten de
patiënten wederom meer fouten en waren zij langzamer vergeleken met de andere
twee groepen. Aanwijzingen voor compensatie strategieën in de vorm van speed-
accurracy trade-off, zoals verondersteld in onze eerdere studie, werden nu echter
niet gevonden. De vertraagde snelheid waarmee de patiënten reageerden voork-
wam niet dat er fouten werden gemaakt. Een verklaring hiervoor kan zijn dat het
gebruik van de strategie maximaal profijt heeft bereikt en geen voordelen meer
oplevert vanwege de progressie van de ziekte in de groep patiënten. Aan de andere
kant vonden we bij de premanifeste gendragers ook vertraging, en wel specifiek
vlak voordat het maken van een fout werd vermeden. Omdat er verder geen ver-
traging in reactietijd werd gevonden, en omdat de geobserveerde vertraging niet
samenging met het maken van meer fouten, concludeerden wij dat hier wel sprake
kan zijn van een compensatiemechanisme.
De progressie van cognitief functioneren in de premanifeste fase van de ZvH hebben
we onderzocht in een longitudinale studie (hoofdstuk 4). De analyses betreffen de
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29 premanifeste gendragers en 43 controle deelnemers die de zeven jaar follow-up
afmaakten. Zij werden vier keer getest met een uitgebreide batterij van cogni-
tieve testen die bijna alle gebieden van het cognitief functioneren, zoals bijvoor-
beeld geheugen en executief functioneren, omvatten. Wij vonden dat de premani-
feste gendragers op de domeinen van geheugen en concentratie verslechterden over
tijd. Deze verslechtering werd echter vooral veroorzaakt door de deelnemers die
gedurende de studie manifest werden. Wanneer de analyses werden herhaald zon-
der deze zogenaamde ‘converters’ bleek dat de premanifeste gendragers over tijd
alleen verslechterden op de concentratie sub-test van de Wechsler Memory Scale.
Hieruit concludeerden wij dat de meeste cognitieve verandering waarschijnlijk vlak
voor het begin van de ziekte plaatsvindt.
Verdere studie van dit cohort resulteerde in een tienjarige follow-up van patiënten
en premanifeste gendragers (hoofdstuk 5). De testen die werden gebruikt in deze
studie werden door middel van factor analyse samengebracht in vier factoren: drie
cognitieve (globale cognitie, executief functioneren en geheugen) en een motor
factor (motor snelheid). De progressie van de premanifeste gendragers (n=26),
patiënten (n=19) en controle personen (n=87) op deze vier factoren over tien
jaar werd onderzocht met behulp van multilevel regressie analyse. De patiënten
lieten lagere baseline scores zien op alle cognitieve factoren. Toen de converters
apart werden geanalyseerd van de deelnemers die premanifest bleven gedurende de
studieperiode, bleek dat alleen de converters verslechterden over tijd op de executief
functioneren factor, vergeleken met controles. Bovendien, toen de premanifeste
groep werd verdeeld in deelnemers dichtbij en veraf van hun verwachte leeftijd
waarop de ziekte zal beginnen, bleek dat er alleen een verslechtering op het gebied
van executief functioneren werd gevonden voor de deelnemers dicht bij verwacht
ziektebegin. Wij concludeerden dat executief functioneren het cognitieve domein
is dat het meest sensitief is voor cognitieve veranderingen in de premanifeste fase,
vooral rondom het begin van de ziekte. Een andere belangrijke bevinding van deze
studie was dat er een substantiële invloed van motoriek op cognitieve test scores
is en dat er rekening gehouden dient te worden met deze negatieve invloed bij het
doen van cognitief onderzoek bij de ZvH.
Ook onderzochten wij de verschillen in de profielen met betrekking tot globaal en
cognitief functioneren tussen twee motorische subgroepen in de ZvH: predominant
choreatisch en predominant hypokinetisch-rigide (hoofdstuk 6). Wij verdeelden
de deelnemers van de Europese REGISTRY studie in deze twee typen: dit resul-
teerde in 528 choreatische en 432 hypokinetisch-rigide deelnemers. Met behulp
van regressie analyse vonden wij dat de hypokinetisch-rigide groep slechtere scores
had op de maten voor globaal functioneren en op alle testen voor het cognitief
functioneren. In de analyses werd gecontroleerd voor onder andere leeftijd en
ziekteduur, en omdat het gebruik van neuroleptica in beide groepen gelijk was,
concludeerden wij dat de twee motorische subtypen verschillen laten zien in cogni-
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tief en globaal functioneren. Predominant choreatische patiënten zijn functioneel
en cognitief beter dan de patiënten met het predominante hypokinetisch-rigide
type. Dit verschil in klinisch profiel kan gevolgen hebben voor zowel de zorg als
het wetenschappelijk onderzoek bij de ZvH.
Om de invloed van motoriek op cognitief functioneren te onderzoeken hebben
wij voor twee testen van het executief functioneren (Symbol Digit Modalities test
[SDMT] en Figure Fluency test [FFT]) een extra conditie ontwikkeld die hoofdzake-
lijk motoriek meet (hoofdstuk 7). Vervolgens hebben wij deze motorische conditie
afgetrokken van de test score van de originele test, om een meer pure cognitieve
score te meten. De scores van veertig patiënten en 21 premanifeste gendragers
werden vergeleken met de scores van 28 controle deelnemers. Wij vonden een
flinke negatieve invloed van motoriek op cognitie, vooral bij de patiënten. Maar
ook in de premanifeste groep waren motorische stoornissen meetbaar. Isolatie van
de cognitieve score resulteerde in een verslechtering voor alleen de SDMT, welke
werd veroorzaakt door slechtere scores van de personen die dicht bij de leeftijd
waren waarop voorspeld was dat de ziekte klinisch zou beginnen.
Tot slot worden de algemene discussie en toekomstperspectieven besproken
(hoofdstuk 8). Samengevat pleiten wij ervoor dat toekomstig medicijn onder-
zoek zich het beste kan richten op executief functioneren, omdat dit het meest
gevoelige domein is voor premanifeste cognitieve veranderingen. De SDMT wordt
aangeraden als meest geschikte uitkomstmaat voor executief functioneren. Om-
dat de meest snelle premanifeste achteruitgang wordt gemeten in personen die
dicht bij klinisch begin van de ziekte zitten, lijkt deze groep het best geschikt als
onderzoeksgroep in medicatie onderzoek. Naar aanleiding van onze bevindingen
dat er een substantiële negatieve invloed van motoriek op cognitie is, adviseren
wij om altijd te controleren voor motorisch functioneren bij cognitief onderzoek,
om beter in staat te zijn om de ‘echte’ cognitieve effecten te scheiden van andere
invloedrijke factoren. Tot slot brengt het bestaan van twee verschillende motor
fenotypen, namelijk predominant choreatisch en predominant hypokinetisch-rigide
HD, met verschillende klinische profielen consequenties voor zowel zorg als weten-
schappelijk onderzoek met zich mee.
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Coleman, Ellen Hart, Alexandra Dürr, Blair R. Leavitt, Raymund A. C. Roos, Doug
R. Langbehn, Sarah J. Tabrizi and Chris Frost. Evaluation of longitudinal 12- and
24-month cognitive outcomes in premanifest and early Huntington‘s disease (2012)
Journal of Neurology, Neurosurgery and Psychiatry, 83(7), 687-694
143
144
Eve Dumas, Maarten Versluis, Simon van den Bogaard, Matthias van Osch, Ellen
Hart, Willeke van Roon-Mom, Mark van Buchem, Andrew Webb, Jeroen van der
Grond and Raymund Roos. Elevated brain iron is independent from atrophy in
Huntington‘s Disease (2012) Neuroimage, 61(3), 558-564
Izelle Labuschagne, Rebecca Jones, Jenny Callaghan, Daisy Whitehead, Eve M.
Dumas, Miranda J. Say, Ellen P. Hart, Damian Justo, Allison Coleman, Rachelle
C. Dar Santos, Chris Frost, David I. Craufurd, Sarah J. Tabrizi, Julie C. Stout and
the TRACK-HD Investigators. Emotional face recognition deficits in pre-manifest
through stage-II Huntington‘s disease (2012) Psychiatry Research, 207(1-2), 118-
126
C.K. Jurgens, E.P. Hart, M-N. Witjes-Ané, H.A.M. Middelkoop and R.A.C. Roos.
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